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1 ABSTRACT 
 
To this day, glioblastoma (GBM) remains a brain tumor impossible to cure. Among its tumor 
properties are rapid proliferation and aggressive migration, two hallmarks investigated in this 
study. GBM's rapid recurrence after treatment is attributed to tumor cells exhibiting stem cell 
properties, the so called brain tumor initiating cells (BTICs). These are targeted by the anti-
diabetic drug metformin which has demonstrated its anti-glioma potential in previous studies. 
However, metformin's mechanisms and especially its links to transforming growth factor beta 
2 (TGF-β2) are not yet fully understood. Therefore, this study explored the effects of different 
doses of metformin and a single dose of TGF-β2 on proliferation and migration of proneural 
and mesenchymal BTICs and their differentiated counterparts (TCs) as well as possible 
functional interactions. Proliferation and migration of 5 BTIC and 5 TC lines were assessed in 
cell counts, CyQuant assays, spheroid migration assays and scratch migration assays.  
The functional investigation showed that 10 mM metformin reliably reduced proliferation and 
migration of primary GBM cell lines and also demonstrated that low doses of metformin may 
inhibit proliferation of proneural BTICs. Proneural cells were more susceptible to metformin 
than mesenchymal cells and BTICs were more susceptible than TCs providing possible 
predictors for successful metformin treatment. The low-dose effects of metformin also seem 
attainable in brain tissue of human cancer patients. Hence, this study sets the rationale to 
explore higher doses of metformin in patients who may profit from metformin treatment, 
especially since proneural cells respond less to standard temozolomide (TMZ) treatment.  
The effects of TGF-β2, a cytokine held responsible for GBM's proliferation, invasion, 
angiogenesis and immunosuppression, were also assessed. Unexpectedly, TGF-β2 had 
either no effects or it decreased proliferation and migration. Generally, mesenchymal cells 
showed an increased sensitivity.  
As TGF-β2 has been described to increase proliferation and migration while metformin may 
lower both, this study investigated whether their functional effects were opposite. This was 
not the case. The effects of the combination of TGF-β2 and metformin were anti-proliferative 
and anti-migratory. They were either as strong as those of the single agents or stronger 
indicating that there is no functional opposition of the two but rather uniform effects possibly 
potentiating each other. Thus, this study suggests that metformin and TGF-β2 exert their 
functional effects independently of each other.  
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2 ZUSAMMENFASSUNG 
 
Das Glioblastom (GBM) ist ein bis heute nicht heilbarer Hirntumor. Diese Studie untersuchte 
zwei der wichtigsten Tumoreigenschaften des Glioblastoms, seine rasche Proliferation und 
seine Migration. Die hohe Rezidivrate bei Glioblastompatienten wird einer Zellpopulation mit 
Stammzelleigenschaften zugeschrieben, den sogenannten Hirntumor-initiierenden Zellen 
(BTICs). Bisherige Studien zeigten, dass die Vermehrung und die Wanderung von GBM 
Zellen im Allgemeinen und von BTICs im Speziellen mithilfe von Metformin reduziert werden 
können. Allerdings sind die Wirkmechanismen von Metformin und insbesondere seine 
potentiellen Interaktionen mit dem Wachstumsfaktor transforming growth factor beta 2 (TGF-
β2) bisher nicht vollständig verstanden. Darum untersuchte diese Studie die Wirkung 
verschiedener Dosen Metformin und einer Dosis TGF-β2 auf die Proliferation und Migration 
von proneuralen und mesenchymalen BTICs und den jeweiligen differenzierten Tumorzellen 
(TCs) sowie mögliche Interaktionen. Proliferation und Migration von 5 BTIC- und 5 TC-Linien 
wurden mittels Zellzählungen, CyQuant Assays, Spheroid-Migrationsassays und Scratch-
Migrationsassays untersucht.  
Dabei zeigte sich, dass 10 mM Metformin zuverlässig Proliferation und Migration der GBM 
Zelllinien senkte und dass niedrige Dosen die Proliferation von proneuralen BTICs hemmten. 
Proneurale Zelllinien sprachen insgesamt besser auf Metformin an als mesenchymale und 
BTICs sprachen besser an als ausdifferenzierte Zellen. Damit kann die Einteilung von GBM 
in proneurale und mesenchymale Tumore weiter als Prediktor für das Ansprechen auf eine 
Behandlung mit Metformin erforscht werden um in der Zukunft möglicherweise klinische 
Anwendung finden. Da niedrige Metforminkonzentrationen realistischerweise im Hirngewebe 
erreicht werden können und proneurale Tumore schlecht auf die Standardbehandlung mit 
Temozolomid (TMZ) ansprechen, sollten klinische Studien mit Metforminbehandlung 
insbesondere bei Patienten mit proneuralen GBM durchgeführt werden. 
Außerdem wurde die Wirkung von TGF-β2, einem Wachstumsfaktor, der bei GBM 
Proliferation, Migration, Invasion und Angiogenese fördert und das Immunsystem 
supprimiert, untersucht. Im untersuchten zellulären Modell zeigte TGF-β2 entweder keine 
Effekte oder senkte Proliferation und Migration. Hierbei wiesen mesenchymale Zelllinien eine 
höhere Sensitivität auf als proneurale.  
Da TGF-β2 als Proliferations- und Migrations-fördernd beschrieben worden ist, Metformin 
beides zu senken vermag und zudem als Antagonist von TGF-β2 in anderen Tumormodellen 
beschrieben worden ist, untersuchte diese Arbeit des Weiteren, ob die Wirkungen von 
TGF-β2 und Metformin einander entgegenstehen. Dies war nicht der Fall: Die 
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Kombinationsbehandlung war, wenn es Effekte gab, anti-proliferativer oder anti-
migratorischer Natur. Dabei war die Wirkung entweder mindestens genauso stark wie bei 
Einzelbehandlung oder stärker. Insgesamt kann also nicht von einer entgegengesetzten 
Wirkung von Metformin und TGF-β2 auf Proliferation und Migration von GBM Zellen 
ausgegangen werden. Vielmehr scheinen die funktionalen Effekte von Metformin und TGF-β2 
unabhängig voneinander zu sein. 
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3 INTRODUCTION 
 
3.1 Glioblastoma 
Although a rare tumor entity, glioblastoma (GBM) is one of the deadliest. In the US, 3.19 per 
100,000 inhabitants acquire GBM per year and only 14% survive for more than two years. 
Five years after diagnosis, as few as 5% of the GBM patients are still alive making the 
diagnosis of GBM an almost certain death sentence (Stupp et al. 2009, Ostrom et al. 2014, 
Weller et al. Glioma guideline 2014). 
Men are 1.6 times more likely to develop GMB than women (Dubrow et al., 2011). Also, age 
presents one of the main risk factors with probability to develop GBM increasing 
exponentially to the 4th power of age (Dubrow et al., 2011). However, GBM can affect any 
age group (Dubrow et al., 2011, SEER Cancer Statistics Factsheets 2016). Although the 
exact mechanisms of tumor genesis remain elusive, several other GBM risk factors have 
been established including ionizing radiation, syndromes such as Li-Fraumeni, 
neurofibromatosis 1 and 2, retinoblastoma, Turcot’s, tuberous sclerosis and multiple 
hamartoma (Houben et al. 2005, Schwartzbaum et al. 2006, Ostrom et al. 2014) and 
Caucasian ethnicity (Dubrow et al. 2011, Maile et al. 2016).  
Patients suffering from GBM may present with a variety of symptoms. Twenty to 40% present 
with first time seizures (Glantz et al. 2000). Focal signs such as hemiparesis, 
hemihypaesthesia or aphasia, may be due to GBM (Omuro et al. 2013). Headaches, 
especially combined with nausea, vomiting, and those worsening when bending over, might 
also present the first symptom of a brain tumor (Forsyth et al. 1993). However, it is difficult to 
aptly diagnose GBM from generic symptoms such as headaches, ataxia, blurred vision, or 
dizziness (Urbánska et al 2014). Consequently, magnetic resonance imaging (MRI) is used 
to diagnose brain tumors. The combination of MRI and FET-PET (O-(2-[18F]fluoroethyl)-l-
tyrosine positron emission tomography) increases specificity in glioma detection (Pauleit et 
al. 2005). However, only biopsy or primary resection with subsequent histological analysis 
can determine whether or not a brain tumor belongs to the group of GBM (Weller et al. 
Glioma guideline 2014). 
Until 2016, Glioma was classified solely according to histological criteria defined by the 4th 
Edition of the WHO Classification of Tumors of the Central Nervous System (Louis et al. 
2007). Proliferation rate, infiltration of surrounding tissue, mitotic rate and atypical mitosis, 
cell and nuclear atypia, microvascular proliferation, endothelial proliferation, and necrosis, 
are evaluated to determine the WHO grade (I-IV) of a central nervous system (CNS) tumor 
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(Louis et al. 2007). GBM is a WHO grade IV brain tumor entity which belongs to the 
astrocytic tumor group and is characterized by: 
 high proliferation rates 
 high number of atypical mitosis 
 increased necrosis 
 microvascular proliferation 
The update on the 4th Edition of WHO Classification of Tumours of the Central Nervous 
System from 2016 (Louis et al. 2016) also accounts for genetic markers. Thus, mutations in 
the isocitrate dehydrogenase (idh) gene, defining whether a GBM is primary (idh-wildtype) or 
secondary (idh-mutant) are represented. Overall, GBM is now classified as a grade IV tumor 
within the group of diffuse astrocytic and oligodendroglial tumours according to mutational 
status (Louis et al. 2016): 
 GBM, IDH-wildtype 
o Giant cell GBM 
o Gliosarcoma 
o Epithelioid GBM 
 GBM, IDH-mutant. 
Idh-mutational status, histological criteria as well as molecular and genetic markers are also 
considered to plan treatment and predict outcome (Riemenschneider et al. 2010, Weller et al. 
2014). First, idh mutations can be helpful not only to differentiate between primary and 
secondary GBM, but also to differentiate between grade II or III glioma from grade IV glioma, 
because idh-1 and -2 mutations are found in approximately 80% of patients suffering from 
grade II or III glioma, but in only 5 to 10% of patients suffering from grade IV glioma (Weller 
et al. Glioma guideline 2014). The enzyme IDH catalyzes the oxidative decarboxylation of 
isocitrate, which is converted into α-ketoglutarate under production of NADPH (Olar et al. 
2014). However, if an idh-mutation is present, isocitrate is converted to the oncometabolite 
2-hydroxyglutarate (Olar et al. 2014). Due to its correlation with low grade tumors, but also 
due to other mechanisms, the presence of idh-mutations usually implies a better outcome 
(Olar et al. 2014). Additionally, assessing mgmt-methylation is useful for planning therapeutic 
procedures and for predicting the outcome. O6-methyguinine-DNA-methyltransferase 
(MGMT) is an enzyme involved in DNA repair. If the promoter region of mgmt is methylated, 
its transcription is inhibited resulting in lower enzyme levels and consequently reduced ability 
of tumor cells to repair their DNA. Thus, treatment with TMZ, a DNA alkylating agent (Stupp 
et al. 2005), is more effective in patients suffering from mgmt-methylation positive GBM 
(Weller et al. Glioma guideline 2014).  
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In general, gliomas are treated according to their WHO grade. For GBM, standard treatment 
includes complete macroscopic resection of the tumor if possible and subsequent radio-
chemotherapy (Stupp et al. 2005, Weller et al. Glioma guideline 2014). Surgery aims at 
cytoreduction of > 98% (Adamson et al. 2009). During surgery, the tumor can be stained with 
5-aminolevulinic acid to enable surgeons to distinguish cancer tissue from healthy brain 
tissue (Stummer et al. 2006). Alternatively, sodium fluorescein is used as it seems to have 
less side effects and may be helpful in detecting metastases (Schebesch et al. 2012). 
Following partial or total resection, patients are treated with TMZ and focal radiation (Stupp 
et al. 2005). For older patients with a positive mgmt methylation status, radiation is 
renounced in favor of chemotherapy (Weller et al. Glioma guideline 2014). Apart from this 
standard regime, there are two approaches approved for treatment of recurrent glioma in the 
US (Swanson et al. 2016): bevacizumab and tumor treating fields (TTF). Bevacizumab is a 
vascular endothelial growth factor (VEGF) antibody designed to lower neo-vascularisation, 
which largely contributes to the malignancy of brain tumors (Würth et al. 2014). TTF are 
alternating electrical fields which impede mitosis and lead to reduced cell proliferation. Thus, 
the combination of TTF and TMZ prolongs OS from 15.6 months (TMZ treatment only) to 
20.5 months (Stupp et al. 2015). The immune checkpoint inhibitors, ipilimumab, 
pembrolizumab, and nivolumab, are currently being evaluated in clinical trials (Theeler and 
Gilbert 2015). While ipilimumab is a humanized IgG1 monoclonal antibody against cytotoxic 
T lymphocyte antigen (CTLA-4), pembrolizumab and nivolumab are humanized monoclonal 
antibodies against programmed cell death 1 (PD-1) (Theeler and Gilbert 2015).  
However, despite extensive research on and continuous improvement of GBM treatment, 
prognosis remains poor. The mean survival time after diagnosis equals approximately 
15 months (Stupp et al 2005). However, prognosis of individual patients varies. Longer 
survival and higher quality of life are being reported for patients with (Louis et al. 2007, 
Adamson 2009, Verhaak et al 2010): 
 lower age 
 high Karnofsky index (indicating how well patients can perform everyday life tasks 
without external help) 
 complete macroscopic primary resection (>98%) 
 positive idh mutation status 
 positive mgmt methylation status. 
The poor prognosis of GBM is, among other factors, due to rapid recurrence after initial 
treatment. To explain rapid recurrence, it has been proposed that a small population of brain 
tumor initiating cells (BTICs) remains in the brain tissue after resection of the primary tumor 
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(Vescovi et al. 2006; Esparza et al. 2015). In 2006, Vescovi et al. proposed that these BTICs 
possess characteristic functional abilities: 
 self-renewal 
 formation of tumors in xenografts (e.g. mice) 
 potency to form different subtypes of cells including non-tumerogenic end cells 
 loss of proper differentiation 
 genetic mutations. 
In order to define brain tumor initiating cells, CD133 is widely used as a marker (Beier et al. 
2011). However, this concept has been challenged by Chen et al. reporting in 2010 that 
CD133- brain tumor cells are also capable of forming new tumors in nude mice. These 
inconsistencies within the tumor stem-cell model led to alternative explanations for 
differences among tumor cell subpopulations such as genetic heterogeneity and micro-
environment dependent plasticity (Meacham and Morrison 2013). While the tumor stem-cell 
model proposes a hierarchy of tumorigenic cells which can produce tumorigenic and non-
tumorigenic spouses, the concept of micro-environment dependent plasticity argues that cell 
fates largely depend on cues from the surrounding tissue rather than on different hierarchies 
of tumor cells (Meacham and Morrison 2013). This study was based on the tumor stem cell 
model. CD133 was utilized to define stemness of BTICs along with transcription factor Sex 
determining region of Y (Sox2), the intermediate filament Nestin, which is highly expressed in 
developing neural cells, and Oligodendrocyte transcription factor 2 (Olig2) (Würth et al. 
2014).  
Tumors mostly develop de novo, so only approximately 10% of GBM are secondary deriving 
from lower grade lesions (Urbánska et al. 2014). Primary and secondary GBM differ in their 
genetic mutations indicating that there might be different mechanisms of tumor genesis. 
While primary glioma are distinctly characterized by over-expression of epidermal growth 
factor receptors (EGFR) and phosphatase and tensin homolog (pten) mutations, they do not 
exhibit idh1 mutations. Secondary glioma, on the contrary, show idh1 mutations and p53 
mutations, but lack EGFR amplification (Riemenschneider et al. 2010). Examining primary 
glioma's specific patterns of genetic mutations, they prove to be substantially more varied 
than those of secondary gliomas, including alterations in Transforming growth factor beta 
signaling (TGF-β1) (Tso et al. 2006). Genetic mutations and variant gene products present 
potential therapeutic targets. As over 50% of all GBM exhibit EGFR mutations, most 
commonly EGFR variant III (EGFRvIII), anti-EGFR therapeutic approaches are being 
evaluated (Francis et al. 2014, Furnari et al. 2015, Hicks et al. 2016). Also, compounds to 
inhibit TGF-β receptors and signaling have been explored (Hau et al. 2007, Bogdahn et al. 
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2011) and continue to be a focus of research (Nana et al. 2015, Herbertz et al. 2015, Gallo-
Oller et al. 2016, clinical trials using the TGFR inhibitor galunisertib listed on 
www.clinicaltrials.gov: NCT02423343, NCT01220271, NCT01582269; Nov. 2016). 
The heterogeneous group of GBM cells can be clustered into subgroups according to marker 
expression and genetic aberrations (Verhaak et al. 2010, Van Meir et al. 2010). In 2010, 
Verhaak et al. were able to distinguish the four subgroups of neural, proneural, classical and 
mesenchymal GBM cells. As experiments of the present work were conducted using 
proneural and mesenchymal cell lines, these are described in more detail in Table 1.   
Table 1: Molecular and genetic characteristics of proneural and mesenchymal GBM cells (Verhaak 2010) 
Abbreviations: CHI3LI = Chitinase 3 like protein 1; MET = HGFR hepatic growth factor receptor; CD44 = cluster of 
differentiation 44; MERTK = C-Mer proto-oncogene tyrosine kinase; PDGFRA = platelet derived growth factor 
receptor A; IDH = isocitrate dehydrogenase; NF1 = neuro fibromatosis 1; TP53 = tumor protein 53; LOH = loss of 
heterozygosity;  PI3KCA = phosphoinositide 3 kinase catalytic subunit alpha; PI3KR1 = phosphoinositide 3 kinase 
receptor 1; TRADD = gene encoding for tumor necrosis factor receptor type 1-associated DEATH domain protein; 
RELB = V-Rel avian reticulo-endotheliosis viral oncogene homolog B; TNFRSF1A = tumor necrosis factor 
receptor superfamily member 1A. 
Clustering GBM cells into subgroups is helpful to predict response to treatment and survival 
rates, because they are different for each subgroup. While aggressive chemotherapy 
prolongs survival of patients with mesenchymal GBM, it does not affect survival of patients 
with proneural GBM (Verhaak et al. 2010). However, radiation treatment targets proneural 
cells to a greater extent than mesenchymal cells (Bhat et al. 2013, Nakano 2015). 
Importantly, different GBM subtypes are present within the same tumor (Patel et al. 2014). 
As different subtypes respond differently to treatments, intratumoral heterogeneity needs to 
be considered when designing new treatment approaches (Patel et al. 2014).  
Additionally, it is important to note the altered metabolism of tumor cells. Instead of 
channeling all incoming glucose into the citric acid cycle, many tumor cells rely heavily on 
Subgroup Marker expression Characteristic mutations Further 
frequent 
mutations 
proneural  PDGFRA alteration, IDH-
mutation 
p53, LOH, 
PIK3CA/PI3KR1 
mesenchymal CHI3LI, MET, CD44, 
MERTK 
NF1 deletion High expression 
of TRADD, 
RELB, 
TNFRSF1A 
INTRODUCTION 
9 
 
glycolysis, a mechanism termed "aerobic glycolysis" or "Warburg effect" (Warburg 1956, 
Vander Heiden et al. 2009). In GBM cell lines, 70 to 80% of cellular adenosine 
5'-triphosphate (ATP) stems from glycolysis (Sesen et al. 2015). Marcus et al. (2010) 
demonstrated, that the tumor environment differs significantly from healthy brain regions in 
the same patient regarding glucose and lactate levels, but also growth factors and proteases. 
While glucose levels in a healthy brain are between 2 and 5 mM, only 0 to 3 mM are found in 
brain tumor tissue (Marcus et al. 2010). Lactate levels are normally below 25 mM, but 
increase to 50 - 250 mM in brain tumor tissue (Marcus et al. 2010). These findings underline 
that GBM cells exhibit high metabolic activity and increased glycolysis. Thus, glycolysis 
seems to be a preferred mechanism to generate ATP in GBM cells. However, glycolysis only 
yields 2 molecules of ATP instead of 36 molecules of ATP obtainable in the citric acid cycle 
(Vander Heiden et al. 2009). This apparent waste of resources raises the question of the 
utility of aerobic glycolysis in the presence of oxygen. One explanation is that the needs of 
rapidly dividing cells exceed the mere need for ATP. Prior to cell division, lipids, amino-acids 
and nucleotides have to be generated which requires acetyl-coenzyme A (Acetyl-CoA) and 
nicotinamide adenine dinucleotide phosphate hydrogen (NAD(P)H) on top of ATP (Vander 
Heiden et al. 2009). Glycolysis results in a stable NADH production enabling proliferation. 
This may be one of the reasons why GBM cells engage mostly in aerobic glycolysis 
(DeBerardinis et al. 2007). Another reason might be that brain tumors are very well supplied 
with nutrients, thus not being at a selective advantage when producing ATP most efficiently 
(by channeling glucose towards the citric acid cycle), but rather when multiplying most 
efficiently (by building bio mass) (Vander Heiden et al. 2009). Due to increased lactate 
production, the extracellular compartment acidifies. This acidification promotes migration and 
invasion of tumor cells (Stock et al. 2009). Thus, an altered tumor cell metabolism may 
sustain invasiveness through creating a more acidic extracellular environment. Glucose 
withdrawal, on the other hand, resembles growth factor withdrawal as both result in 
increased apoptosis (Vander Heiden et al. 2001). While 70 to 80% of GBM cells' ATP stems 
from glycolysis (Sesen et al. 2015), BTICs rely more on oxidative phosphorylation for ATP 
production indicating that BTICs differ not only genetically and functionally, but also 
metabolically (Janiszewska et al. 2012). Thus, GBM metabolism needs to be targeted in 
more than one way (Kim et al. 2016, Sesen et al. 2015).  
Lastly, growth factor signaling and enzyme levels in the tumor environment are crucial 
factors for proliferation and invasion of GBM cells. Marcus et al. (2010) investigated the 
levels of growth factors and certain enzymes such as proteases in brain tissue immediately 
after resection of GBM in human patients. They found interleukin 8 (IL-8), a pro-angiogenic 
cytokine, to be significantly elevated, hinting at the important role of angiogenesis in GBM 
progression. Additionally, the metalloproteinase 2 (MMP2) to tissue inhibitor of 
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metalloproteinase 1 (TIMP-1) ratio was found to be elevated. Thus, MMP2's net activity, 
enabling tumor cells to migrate through the extracellular matrix, was increased. Overall, a 
great variety of growth factors, enzymes and metabolic changes seems to be responsible for 
GBM's aggressive proliferation, migration, angiogenesis and recurrence. Many researchers 
have described elevated levels of TGF-β2 in GBM (Bruna et al. 2007, Aigner and Bogdahn 
2008, Hau et al. 2011, Frei et al. 2015). Therefore, the present work will focus on the effects 
of metformin and TGF-β2 on two key properties of GBM cells, proliferation and migration.  
 
3.2 The role of metformin in diabetes and glioblastoma 
One of the agents influencing metabolism in general and tumor cell metabolism in particular 
is the anti-diabetic drug metformin. Metformin (N',N'-dimethylbiguanide), is the most 
commonly prescribed oral anti-diabetic drug to treat type 2 diabetes (T2D) (Kourelis and 
Siegel 2011). As metformin effectively lowers blood glucose levels and additionally 
diminishes vascular complications and mortality, it is considered first line medication for 
treatment of obese T2D patients in Germany (German National Guideline on treatment of 
T2D 2013). Side effects such as weight gain or hypoglycemia are only rarely observed. 
However, low glomerular filtration rates increase the risk for lactate acidosis (German 
National Guideline on treatment of T2D 2013).  
At a pH of 7.4, as usually found in intra- and extracellular compartments, metformin exists in 
its cationic form that is unable to penetrate membranes. Thus, its cellular uptake depends on 
the presence of organic cation transporters, namely OCT1, 2 and 3 (Shu et al. 2007). If 
OCTs are absent in a certain tissue or morphologically different due to polymorphisms or 
genetic aberrations, metformin's action is impeded (Shu et al. 2007). In hepatocytes, 
metformin's blood glucose reducing action is ascribed to its anti-gluconeogenic effects. 
Viollet et al. (2012) propose that metformin decreases gluconeogenesis by impairing 
complex I of the mitochondrial respiratory chain. Subsequently, two different signaling 
pathways result in lowered gluconeogenesis. Firstly, diminished ATP levels inhibit key 
gluconeogenic enzymes such as fructose-1,6-bisphosphatase. Secondly, decreased ATP 
and increased AMP levels activate AMP-activated protein kinase (AMPK). When AMP binds 
to the γ-catalytic subunit of AMPK, its activator, liver kinase B1 (LKB1) can bind more easily 
and activate AMPK (Hardie 2006). AMPK-activation inhibits transcription of various genes 
leading to lower levels of gluconeogenic and lipogenic enzymes. Hence, hepatocytes 
conserve energy when AMPK is activated and less glucose and fatty acids are being 
released into the blood stream preventing microvascular damage (Viollet et al. 2012).  
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Apart from metformin's beneficial effects on blood glucose levels and blood vessels, 
epidemiological studies suggest that patients who are being treated with metformin are at a 
lower risk of developing cancer (Evans et al. 2005). These findings sparked an 
unprecedented interest in metformin as an anti-cancer drug. An epidemiological study on 
type 2 diabetes and GBM reveals that patients suffering from type 2 diabetes and GBM have 
a better outcome when taking metformin compared to all other anti-diabetic medications 
(Welch and Grommes 2013, Elmaci and Altinoz 2016), a result supported by Adeberg et al. 
(2015) who also found that metformin treatment prolongs survival of diabetic GBM patients. 
In vitro studies have been performed including breast, lung, pancreatic, colorectal, ovarian 
and brain tumors and they have shown that metformin is able to lower tumor cell 
proliferation; either when being administered as a single agent or in combination with other 
cytoreductive agents (Würth et al. 2014). As metformin penetrates the blood-brain-barrier 
(Labuzek et al. 2010), it may unfold anti-tumerogenic action in glioma. Studies investigating 
the functional effects of metformin on glioma are outlined in Table 2.  
Table 2: Functional effects of metformin on glioma cells  
Study Cell 
lines 
Media Effects of metformin 
Beckner 
et al. 
2005 
U87MG 
LN229 
MEM eagle / 
α-MEM + 
10% FCS 
 
 inhibits migration in cells in which mitochondria were 
blocked with NaN3 
Isakovic 
et al. 
2007 
C6 (rat); 
U251 (h) 
Hepes (20 
mM)-
buffered 
RPMI1640 + 
5% FCS + 
10 mM glc. 
 no proliferation inhibition in primary astrocytes 
 4 mM induces morphological changes either to more 
spindle like shape or to granular shape 
 cell cycle arrest in non-confluent cells 
 4 mM reduces viability through caspase-mediated 
apoptosis in confluent cells 
Sato et 
al. 2012 
dnf dnf  1 mM reduces sphere formation 
 1 mM induces differentiation (astrocyte marker GFAP 
and neural marker βIII-tubulin) 
 500 mg/kg/day i.p. for 5 days delays tumor formation in 
transplanted mice 
Ferla et 
al. 2012 
LN18, 
LN229 
Low-glc. 
DMEM + 5% 
FCS 
 2-16 mM reduce proliferation in a dose-dependent 
manner 
 2-16 mM decrease migration  
Würth GBM   DMEM-  no effects on human stem cells from the umbilical chord 
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et al. 
2013 
1-4 F12/Neurob
asal (1:1) + 
10 ng/ml 
bFGF + 
20 ng/ml 
EGF 
 effects on TICs > differentiated cells 
 5-50 mM decrease viability, proliferation, and sphere 
formation 
Gao et 
al. 2013 
U251 DMEM + 
10% FCS 
 10 and 30mM decrease viability 
 0.3-3 mM inhibit migration in a dose-dependent manner 
Liu et 
al. 2014 
T98G, 
A172, 
U87 
DMEM + 
10% FCS 
 10 mM reduces proliferation (cytostatic effect) 
Sesen 
et al. 
2015 
U87, 
LN18, 
U251, 
SF767 
DMEM + 
10% FCS 
 10 mM decreases proliferation 
 in PTEN wildtype cells, proliferation decreases after 48 h, 
in PTEN mutated cells after 96 h 
 Timeline of death: cell cycle arrest --> death --> 
autophagy 
o 12 h:  earliest time point for cell cycle arrest in G1 
and transition into G0-phase 
o 24 h: beginning cell death as a consequence of 
cell cycle arrest 
o 48 h: consistent observation of cell death --> 
autophagy 
 300 mg/kg/day for 30 days reduces tumor volume and 
tumor weight in transplanted mice 
Kim et 
al. 2016 
TS1320
TS1588
TS0903
GSC11
U87 
DMEM/ F-12 
+ 10% FCS 
 5 mM metformin reduces proliferation in 1/5, enhances 
proliferation in 1/5 and leaves proliferation unaffected in 
3/5 cell lines. 
 15 mM inhibits sphere formation, a key factor of 
stemness 
 decreases stemness markers to some degree in 3/5 lines 
 5 mM / 15 mM metformin do not decrease migration  
Abbreviations: MEM = Minimal essential media; FCS = Fetal calf serum; RPMI1640 = cell media developed at the 
Roswell Park Memorial Institute (USA); TIC = tumor initiating cell; dnf = data not found; GFAP = glial fibrillary 
acidic protein (astrocyte marker); glc. = glucose; i.p. = intraperitoneal administration; DMEM = Dulbecco’s 
modified Eagle’s medium; bFGF = basic fibroblast growth factor; EGF = epidermal growth factor; PTEN = 
Phosphatase and tensin homolog. 
Much research has been undertaken to investigate the mechanisms of metformin's actions 
on non-tumor and on tumor cells. The most important pathways, which have been identified 
in various tumor tissues, are displayed in Figure 1. 
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Figure 1: Potential mechanisms and sites of metformin’s action in cancer cells (Republished from 
Kasznicki et al. 2014: "Metformin in cancer prevention and therapy." The Annals of translational medicine 
2014, 2 (6): 57, © 2014. Republished with author's permission and permission of the editor of The Annals 
of Translational Medicine, Sept. 2016) Abbreviations: PI3K= phosphoinositide 3-kinase; Akt= refers to a mouse 
named "Ak", expressing spontaneous lymphomas and thymoma and Akt= PKB= protein kinase B; TSC2= 
tuberous sclerosis complex protein 2; mTORC1= mammalian target of rapamycin complex 1; raptor= regulatory 
associated protein of mTOR; GβL= G protein beta subunit-like; deptor= DEP domain-containing mTOR-interacting 
protein; REDD1=  regulated in development and DNA damage responses 1; RAG GTPase= Ras-related GTPase; 
AMP= adenosine monophosphate; AMPK= AMP-activated protein kinase; LKB1= liver kinase 1; p53= protein 53; 
p70S6K= ribosomal protein S6 kinase; Atg13= autophy-related protein 13; eIF4E= eukaryotic translation initiation 
factor 4E; 4EBP1= eIF4E binding ptotein. 
Some of the functional effects of metformin that are listed in Table 2, such as decreased 
proliferation via cell cycle arrest, apoptosis and viability reduction can be explained on a 
molecular level. To begin with, some effects of metformin on cancer cells seem similar to 
those on hepatocytes. Hence, AMPK is activated through the inhibition of complex I of the 
mitochondrial respiratory chain (Viollet et al. 2012). Generally, AMPK activation returns a cell 
to energy safe mode, thus impairing the energy consuming process of self-replication. In 
order to self-replicate, cancer cells need to produce amongst others fatty acids, proteins and 
nucleotides. AMPK mediates these biosynthetic processes via several pathways. On the one 
hand, AMPK inhibits acetyl-CoA carboxylase (ACC), an enzyme involved in fatty acid 
synthesis, thus reducing lipid production (Viollet et al. 2012). On the other hand, it has been 
proposed by several authors that p53 and Cyclin D1 are mediated by AMPK and result in cell 
cycle arrest and apoptosis (Kasznicki et al. 2014, Würth et al 2014). In addition, metformin 
inhibits mammalian target of rapamycin (mTOR) signaling that regulates cell growth and 
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proliferation. According to Viollet et al. (2012) and Kasznicki et al. (2014), four pathways lead 
to the inhibition of mTOR by metformin. To begin with, AMPK phosphorylates tuberous 
sclerosis 2 (TSC2) which then inhibits mTOR. Secondly, AMPK impairs the association of 
mTOR and its regulatory associated protein (raptor) by phosphorylating raptor. Thirdly, 
AMPK-independent mechanisms of mTOR inhibition have been proposed such as 
metformin's potential to modulate a Ras-related GTPase (RAG GTPase), which 
subsequently leads to the inhibition of mTOR or, independently, metformin’s ability to 
activate “regulated in development and DNA damage responses 1” (Redd1) which also 
entails mTOR inhibition. Last but not least, metformin can modulate the PI3K/Akt axis. 
Normally, insulin, insulin-like growth factor (IGF) and other growth factors bind to 
corresponding receptors and trigger a signal transduction cascade. Phosphoinositide 
3-kinase (PI3K) catalyzes the reaction from phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 binds to Akt and facilitates its activation 
by kinases such as the mTOR complex 2. Once activated, Akt inhibits tuberous sclerosis 
complex 2 (TSC2) thus enabling the activation of mTOR. mTOR in turn up-regulates 
lipogenesis, glucose uptake, protein synthesis and inhibits autophagy (Schultze et al. 2012). 
This cascade is impaired by metformin at different levels. First and foremost, metformin 
lowers circulating insulin levels and consequently, IGF-levels also. As these substrates bind 
to their receptors less frequently, mTOR activation is being reduced. On the other hand, 
metformin can activate TSC2 via the AMPK-pathway resulting in mTOR inhibition. As mTOR 
regulates proliferation, inhibiting mTOR has an anti-proliferative effect, which constitutes of 
several aspects (Kasznicki et al. 2014, Würth et al. 2014). Cell growth is impaired, because 
p70S6K, normally in charge of phosphorylating the ribosome protein S6K, is not activated 
anymore. Autophagy is induced due to lack of p70S6K activation and lack of inhibition of 
autophagy-related protein 13 (Atg13). Protein synthesis is decreased as mRNA translation is 
diminished by decreased inhibition of eukaryotic translation initiation factor 4E (eIF4E) and 
by decreased activation of eIF4E-binding protein 1 (4E-BP1). The mechanisms of 
metformin's anti-cancer properties mentioned above have been elucidated using different 
tissues derived from breast, colon and prostate cancer, et cetera.  
Regarding metformin's molecular mechanisms on glioma, researchers mostly agree that 
either by Akt inhibition or AMPK activation, mTOR signaling is being inhibited which leads to 
decreased proliferation (Isakovic et al. 2007, Ferla et al. 2012, Sato et al. 2012, Würth et al. 
2013, Sesen et al. 2015, Yu et al. 2015). Metformin partially inhibits complex I of the 
respiratory chain in mitochondria thus leading to AMPK activation or Redd 1 / DDIT4 
activation (DNA damage-inducible transcript 4 protein) and thus mTOR inhibition (Sesen et 
al. 2015). AMPK activation through metformin may also activate c-Jun N-terminal kinase 
(JNK) and lead to production of reactive oxygen species (ROS) (Isakovic et al. 2007) or 
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cause STAT3 downregulation and Akt inhibition (Ferla et al. 2012). Also, both Akt inhibition 
and AMPK activation can lead to FOXO3 activation, a trigger for differentiation of BTICs 
(Sato et al. 2012). Metformin may as well decrease migration through fibulin-3 
downregulation and consequent MMP2 downregulation (Gao et al. 2013). These common 
notions are challenged by Würth et al. (2013) who state that Akt inhibition rather than AMPK 
activation leads to mTOR inhibition and by Liu et al. (2014) who report that no AMPK 
signaling is needed for mTOR inhibition but rather an association of PRAS40 and RAPTOR 
(Proline-rich Akt substrate of 40 kDa; Regulatory-associated protein of mTOR). Kim et al. 
(2016) observe neither AMPK activation nor mTOR inhibition while Gritti and Würth et al. 
(2014) report a completely independent mechanism of metformin's action: it blocks a chloride 
ion channel (CLIC1) in its open state thus trapping cells in G1 phase and lowering 
proliferation. Even though metformin's molecular mechanisms seem manifold, its main 
signaling axis seems to be AMPK activiation or Akt inhibition leading to mTOR inhibition. 
Metformin seems to selectively affect brain tumor initiating cells more than differentiated 
tumor cells and this to a greater extent than astrocytes or human stem cells (Isakovic et al. 
2007; Würth et al. 2013, Gritti et al. 2014). Accordingly, Würth et al. (2013) demonstrated 
that metformin's anti-proliferative effects are more pronounced in CD133+ cells, making 
metformin an ideal drug to target cancer initiating cells, which are claimed to be responsible 
for GBM recurrence.  
Several studies exist exploring the in vitro possibilities of metformin as a combination partner 
for other anti-glioma treatments. While Aldea et al. (2014) found metformin by itself unable to 
reduce glioma proliferation, its combination with sorafenib, a RAF inhibitor, attains high 
apoptotic rates. Kim et al. (2016) propose targeting more than one metabolic pathway by 
blocking oxidative phosphorylation (OXPHOS) using metformin and glycolysis using 
2-desoxy-glucose (2DG). This combination is able to reduce cell viability, sphere formation, 
expression of stemness makers and invasion in vitro and prolongs survival in tumor bearing 
mice. Sesen et al. (2015) investigated the effects of combining metformin with TMZ and / or 
irradiation and found the combination of the three most effective in inducing cell death. 
Soritau et al. (2011) and Yu et al. (2015) also found that the combination of TMZ and 
metformin is more effective in reducing GBM proliferation in vitro (Soritau et al.) and in tumor 
bearing mice (Yu et al.) than each agent by itself. 
According to Würth et al. (2013), the IC50 for metformin, indicating a 50% proliferation 
inhibition in vitro, is at 10 mM. Below 10 mM, metformin's action is cytostatic, because cell 
growth recovers after metformin withdrawal. At concentrations higher than 10 mM, however, 
metformin's effects are cytotoxic and at 50 mM, cells do not recover growth after removal of 
the drug (Isakovic et al. 2007; Würth et al. 2013). Therefore, 10 mM metformin was used as 
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highest dose for this study. Yet, clinically observed concentrations are lower than those used 
in vitro. Generally, concentrations of metformin can be discussed as plasma concentration 
and tissue concentration. Plasma concentrations in diabetic patients with oral treatment 
usually range from 8 to 31 µM and even at maximum oral treatment dosage rarely exceed 
39 µM (Menendez et al. 2014). In acute overdosing, concentrations as high as 300-800 µM 
were observed and doses between 600-1500 µM were considered fatalities; however, lethal 
doses have not been clearly defined (Menendez et al. 2014).  
At present, clinical trials mainly investigate the oral route of metformin application. There are 
two studies on metformin use in glioblastoma patients (NCT01430351, NCT02780024 on 
www.clinicaltrials.gov; Nov. 2016). In the first study, 1000 mg metformin twice a day and 
150 m/m2 TMZ are combined for post-radiation treatment. The other study investigates the 
effects of re-irradiation, metformin and a low carbon diet on recurrent GBM but does not 
provide information on metformin doses. Two other studies also include lower-grade glioma 
patients (NCT02149459, NCT02496741 on www.clinicaltrials.gov; Nov. 2016). One study 
(NCT02149459) combines temozolomide and metformin as treatment before and after 
radiation therapy for grade 2-4 glioma and the other study (NCT02496741) is a dose-finding 
study for metformin and chloroquin to treat IDH1/2-mutated solid tumors. 
Taking into account current research on metformin's role in GBM, several aspects have not 
been investigated so far. Firstly, the concentrations of metformin used in GBM experiments 
were higher than what seems achievable in the human brain tissue raising the question 
whether lower doses of metformin are effective in lowering proliferation and migration of 
GBM cells as well. Secondly, the effects of metformin on GBM were mainly explored in one 
to five cell lines (see Table 2), possibly resulting in bias due to a low case number. And 
thirdly, the exact molecular mechanisms of metformin's action in GBM are not fully 
understood to this date especially concerning possible interactions with growth factors such 
as TGF-β2.  
 
3.3 The role of TGF-β2 in glioblastoma 
Transforming growth factor beta 2 (TGF-β2) is a cytokine involved in complex regulations of 
proliferation, differentiation and the immune response. In healthy tissues, TGF-β controls 
proliferation; in cancer however, this control is lost and TGF-β becomes oncogenic (Bruna et 
al. 2007). This phenomenon is called the TGF-β paradox and has been explored in different 
cancerous tissues (Tian et al. 2009). In GBM, TGF-β promotes cell growth, migration, 
invasion, angiogenesis and immunosuppression (Platten et al. 2001, Hau et al. 2006, Joseph 
et al. 2014).  
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TGF-β belongs to the TGF-β superfamily which also encompasses other proteins such as 
bone morphogenic protein (BMP), nodal, activin and inhibin (Aigner and Bogdahn 2008). 
Three isoforms of TGF-β exist in humans: TGF-β1, TGF-β2, and TGF-β3. All of them are 
found in GBM, but levels vary. Some researchers have found TGF-β2 levels to be the highest 
in glioma (Bodmer et al. 1989, Kjellman et al. 2000, Leitlein et al. 2001), while Frei et al. 
(2015) found mRNA of TGF-β1 to be highest. Nonetheless, researchers agree that TGF-β2 
plays an important role in GBM (Bruna et al. 2007, Aigner and Bogdahn 2008, Hau et al. 
2011, Frei et al. 2015).  
 
Figure 2: Smad-dependent TGF-β signaling (Aigner and Bogdahn 2008. Republished with author's 
permission and permission from Springer from "TGF-beta in neural stem cells and in tumors of the central 
nervous system." Cell and tissue research 2008 (1): 225–241, © 2008. Permission conveyed through 
Copyright Clearance Center, Sept. 2016). Abbreviations: TGF-beta = transforming growth factor beta; TGFRI 
and II = TGF- receptor type I and II; R-Smad = regulatory small body size mother of decapentaplegic; ATP = 
adenosine triphosphate; ADP = adenosine diphoshate; Co-smad = smad4; DNA = deoxyribonucleic acid.  
TGF-β proteins are homodimers of 12.5 kD that bind to specific receptor serine/threonine 
kinases, the TGF-β receptors type I and type II (TGFR-I and II). Seven isoforms have been 
identified for receptor type I and five for receptor type II (Aigner and Bogdahn 2008, 
Massagué 2008). After binding the ligand, two TGFR-II units associate with two TGFR-I units 
to form a complex. A third receptor type, also known as betaglycan, increases the affinity of 
TGFR-II for TGF-β2 in GBM (Aigner and Bogdahn 2008). Other membrane proteins such as 
EMP3 (epithelial membrane protein 3) may increase TGF-β signaling in CD44+ mesenchymal 
GBM cells (Jun et al. 2016). In the receptor complex, TGFR-II activates TGFR-I by 
phosphorylation and TGFR-I subsequently phosphorylates Smad2 and 3 (small body size 
mothers against decapentaplegic) (Massagué 2000, Massagué 2008, Dong et al. 2015). 
Smad2 and 3 are receptor substrate smads (Rsmads). Upon activation, they associate with 
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co-smads (Smad4) and translocate into the nucleus. There, several other DNA-binding 
cofactors associate with the complex before it binds to specific gene regions. Depending on 
the type of cell and its environment, different cofactors are present which determine genes 
and groups of genes targeted by TGF-β signaling. Thus, TGF-β's effects are highly context-
dependent and promote or inhibit the expression of a great variety of genes (Massagué 
2008). In GBM, several Smads have been identified to play a leading role, namely Smad2 
and Smad3. However, there is no clear evidence to date, which one is more important in 
GBM. In 2007, Bruna et al. found mRNA of smad2 to be highly expressed in GBM while 
Kjellman et al. (2000) found mRNA of smad2, smad3 and smad4 decreased in GBM 
specimens.  
 
Figure 3: Signaling pathways diverging from and converging on TGF-β signaling (Aigner and Bogdahn 
2008. Republished with author's permission and permission from Springer from " TGF-beta in neural stem 
cells and in tumors of the central nervous system." Cell and tissue research 2008 (1): 225–241, © 2008. 
Permission conveyed through Copyright Clearance Center, Sept. 2016). Abbreviations: TGF-beta = 
transforming growth factor beta; TGFRI and II = TGF-receptor type I and II; EGF = epidermal growth factor; IFN-
gamma = interferon gamma; TNF-alpha = tumor necrosis factor alpha; Wht = data not found; MAPK = mitogen-
activated kinase also known as Ras-Raf-MEK-ERK pathway; JAK1 = Janus kinase 1; NF-kappaB = nuclear factor 
kappa-light-chain-enhancer of activated B cells; JNK = c-Jun N-terminal kinase; STAT1 = Signal transducer and 
activator of transcription 1; c-Jun = p39 = Jun Proto-Oncogene; Ras, Rho, RhoA = small GTPaseses of the Ras 
superfamiliy; TAK1 = TGF-β activated kinase 1; PP2A = protein phosphatase 2; Smad = small body size mother 
of decapentaplegic; ERK = extracellular signal-regulated kinase = nowadays known as MAPK; MAPK = mitogen-
activated kinase also known as Ras-Raf-MEK-ERK pathway; JNK = c-Jun N-terminal kinase; p160ROCK = a 
serine/threonine protein kinase; S6K = Ribosomal protein S6 kinase; DNA = deoxyribonucleic acid.  
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Apart from "classic" TGF-β/Smad2/3 signaling, several signaling pathways diverge from and 
converge to TGF-β signaling in different tissues. For example does TGF-β signaling diverge 
on: 
 the MAPK pathway, either mediated by TAK1 (Massagué 2000, Aigner and Bogdahn 
2008) or through Smad2-dependent activation (Moustakas and Heldin 2005)  
 the C-Jun-N-terminal kinases (JNK) which are activated by TGF-β in a Smad-
independent way (Aigner and Bogdahn 2008)  
 p38 signaling (Massagué 2000) 
 protein kinase A (PKA) signaling which is activated by Smad3 (Moustakas and Heldin 
2005) 
 the PI3K / Akt pathway (Aigner and Bogdahn 2008).  
The following pathways converge on TGF-β signaling: 
 MAPK may activate Smad signaling (Massagué 2000).  
 activation of Ras–MEK–ERK may lead to phosphorylation and thus inhibition of 
smad1, smad2 and smad3 (Massagué 2000, Moustakas and Heldin 2005).  
TGF-β signaling is thus embedded in a large network of cell signaling cascades, which is not 
understood in every aspect today. 
There exist several molecules to inhibit TGF-β signaling. In this study, we used SD-208, a 
TGF-β receptor I kinase inhibitor that has been shown to inhibit TGF-β signaling in glioma 
tissue in vitro and in vivo (Uhl et al. 2004).  
Glioma cells' responses to TGF-β are manifold, heterogeneous and they differ from healthy 
cells' responses in the sense that TGF-β may act as a tumor suppressor in healthy tissues 
but as a tumor promoter in glioma. Massagué (2008) proposed that cancer cells evade 
TGF-β's tumor control either due to mutations in TGF-β's core signaling pathway or because 
the suppressive arm of the signaling cascade is altered. In glioma, both mechanisms have 
been found. On the one hand, TGF-β receptor type II may become deficient leading to TGF-β 
immunity; on the other hand, TGF-β may lose its cytostatic control because of PI3K 
hyperactivation, loss of p15INK4b (Cyclin-dependent kinase 4 inhibitor B also known as 
multiple tumor suppressor 2) or mutational inactivation of RB (retinoablastoma protein) 
(Massagué 2008). Additionally, p53 mutations in both alleles may lead to enhanced 
proliferation under TGF-β stimulation in glioma (Kumar et al. 2015). But not only does TGF-β 
produce oncogenic responses in glioma cells, TGF-β production also sustains itself through 
an autocrine loop (Massagué 2008, Ikushima et al. 2009). TGF-β signaling stimulates cAMP 
responsive element binding protein 1 (CREB1) and Smad3 to induce transcription of TGF-β2. 
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This autocrine loop leads to high TGF-β2 levels in GBM tissue and promotes tumor 
progression (Rodon et al. 2014). 
The autocrine loop of TGF-β production has also been shown to conserve stem cell 
properties of GBM cells. In 2009, Ikushima et al. proposed that TGF-β directly alters 
transcription of sex determining region Y-box 4 (sox4) in the nucleus which increases 
expression of Sox2, a neural marker of stemness. In the same year, Peñuelas et al. reported 
that TGF-β directly induces leukemia inhibitory factor (LIF) and thus sustains self-renewal 
and prevents differentiation of brain tumor initiating cells. Narushima et al. (2016) identified 
TGFR-II as an important player for GBM cells to retain stemness. Thus, TGF-β inhibits 
differentiation and helps BTICs to remain tumor initiating cells possessing stem cell 
properties.  
Rapid proliferation and lack of proliferative control is one of GBM BTICs' characteristics and 
has been partly attributed to TGF-β. However, TGF-β effects on GBM in vitro and in vivo are 
heterogeneous. TGF-β may stimulate or attenuate proliferation or leave it unaltered (Rich et 
al. 1999, Piek et al. 1999, Bruna et al. 2007, Beier et al. 2012). Thus, the exact effects of 
TGF-β seem difficult to predict. Some of the differences might be due to differing receptor 
set-ups of proneural and mesenchymal cells. In vitro, proliferation of proneural BTICs does 
not increase under stimulation with TGF-β due to TGF-β receptor type II deficiency and 
consequent failure of Smad-mediated signal transduction (Beier et al. 2012). Another 
predictor might be the methylation status of the platelet derived growth factor gene B 
(pdgf-b). In glioma cells with a non-methylated pdgf-b gene, TGF-β induces pdgf-b 
expression and thus augments proliferation (Bruna et al. 2007).  
Phenotype and invasiveness of GBM cells depend on the tumor environment, especially its 
oxygen content and lactate levels. Hypoxia in tumoric tissues attracts myeloid cells. These 
release numerous growth factors, especially TGF-β, PDGF, FGF and EGF. In addition to 
myeloid cells, GBM cells neighboring necrotic areas may produce TGF-β as well. Due to 
these stimuli, tumor cells can undergo epithelial-mesenchymal transition (EMT), a process in 
which they acquire a mesenchymal and thus stem cell like phenotype (Iwadate 2016). This 
type of EMT is called EMT type 3 (Iwadate 2016). In the process, GBM cells lose cell-cell 
adhesions, because TGF-β represses E-cadherin and cells migrate to invade the 
surrounding tissue (Odenthal et al. 2016). EMT type 3 also plays a role in tumor recurrence: 
GBM cells evading radiation undergo EMT under TGF-β stimulation and become highly 
invasive mesenchymal cells leading to an aggressive tumor recurrence (Joseph et al. 2014, 
Iwadate 2016, Iwadate et al. 2016). Acidification and elevated lactate levels in the tumor 
environment may also enhance migration of GBM cells. Tumor cells express lactate 
dehydrogenase A (LDH-A) catalyzing lactate production. Lactate in turn activates TGF-β2 in a 
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thrombospondin 1 (THBS-1)-mediated manner, which then activates MMP2 and MMP9, two 
matrix enzymes necessary for migration. Also, TGF-β2 causes the integration of integrin αVβ3 
into the membrane. Taken together, these processes enhance migration of GBM cells (Wild-
Bode et al. 2001, Baumann et al. 2009, Seliger et al. 2013).  
Furthermore, TGF-β induces angiogenesis. As TGF-β leads to release of vascular 
endothelial growth factor (VEGF) by stroma and glioma cells, high TGF-β levels are 
associated with high vascularity (Aigner and Bogdahn 2008). Some researchers have 
proposed that the pro-angiogenic effect of TGF-β is more pronounced under hypoxia 
(Krishnan et al. 2015), others have found no such correlation (Seystahl et al. 2015). In 
clinical trials, bevacizumab, a VEGF antibody, showed its potential to improve survival and is 
hence the only approved molecular therapy for recurrent GBM treatment in the US (Würth et 
al. 2014).  
Originally, TGF-β2 was named GBM cell-derived T cell suppressor factor due to its ability to 
suppress T cells (Bodmer et al. 1989). This fact hints at another very important effect of 
TGF-β: immunosuppression. TGF-β secretion of GBM leads to downregulation of NKG2D 
receptors on infiltrating CD8+ T-lymphocytes and CD8+ natural killer (NK)-cells and thus 
inhibits their proliferation, differentiation and immune infiltration (Friese et al. 2004, Aigner 
and Bogdahn 2008, Crane et al. 2010, Beier et al. 2012). Thus, GBM escapes the 
surveillance of the immune system. While mesenchymal tumors do exhibit infiltration with 
immune cells at the tumor site, very few immune cells are found in proneural GBM tissue, 
because proneural BTICs impair CD8+ T- and NK-cells through TGF-β secretion (Beier et al. 
2012). Also, TGF-β downregulates the transcription of important cytolytic genes such as 
perforin, granzyme A, granzyme B, Fas ligand and interferon γ in CD8+ T-lymphocytes thus 
hampering their tumor control (Thomas and Massagué 2005).  
Clinically, high TGF-β2 levels in the tumor tissue are correlated with a shorter progression 
free and overall survival and thus a poorer prognosis (Bruna et al. 2007, Hau et al. 2011, Frei 
et al. 2015). Furthermore, high TGF-β2 levels correlate with high pSmad2 activity, which is 
also associated with poorer prognosis (Bruna et al. 2007); however, TGF-β serum levels are 
no valid predictor for survival of GBM patients (Chiorean et al. 2014). As high levels of 
CAMP-responsive element binding protein 1 (CREB1) are correlated with high levels of 
TGF-β2, CREB1 might be valuable as a biomarker to predict tumor sensitivity to anti-TGF-β 
treatment (Rodon et al. 2014).  
Reviewing the research that has been conducted on the role of TGF-β2 in GBM, contradictory 
reports exist concerning proliferation and migration under TGF-β2 stimulation and inhibition 
using SD-208. As TGF-β has been proposed to induce proliferation and migration, but 
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contrary effects have been reported for metformin, the following section will focus on possible 
links between the two.     
 
3.4 Possible links between metformin and TGF-β2 
Even though the role of TGF-β2 in GBM proliferation and migration remains controversial, 
some of the functional effects of TGF-β seem opposed to those of metformin raising the 
question of whether the effects of TGF-β and metformin are connected or even antagonistic. 
Numerous studies have investigated direct links of TGF-β and metformin in tissues other 
than GBM. Taken together with molecular findings of signaling outlined in previous chapters, 
the following connections may be postulated.  
Possible links between TGF-β and metformin include:  
1. functionally opposed effects such as proliferation increase or decrease 
2. metformin directly influencing core signaling pathways of TGF-β, especially Smad 
signaling 
3. TGF-β directly influencing core signaling pathways of metformin, namely Akt inhibition 
or AMPK activation leading to mTOR inhibition 
4. metformin changing the tumor environment in a way that TGF-β signaling is impacted 
5. metformin and TGF-β converging on the same signaling pathways. 
Firstly, functionally opposed effects have been described in GBM as TGF-β2 has been 
reported to increase proliferation and migration in numerous cases (view chapter 1.3) while 
metformin has been found to inhibit these exact processes (view chapter 1.2). In breast 
cancer tissue, metformin has been found to directly antagonize TGF-β induced EMT (Cufí et 
al. 2010, Vazquez-Martin et al. 2010) and TGF-β induced formation of mammospheres 
(Oliveras-Ferraros et al. 2011) indicating a functional antagonism of TGF-β and metformin in 
this case. Metformin also blocks TGF-β induced EMT in renal tubular epithelial cells (Lee et 
al. 2013). Therefore, a functional antagonism of metformin and TGF-β may be postulated, 
mostly for non-glioma tissues.  
Secondly, metformin has proven to directly impact TGF-β protein levels and Smad signaling. 
In breast cancer cells, metformin lowers TGF-β levels thus reducing EMT (Vazquez-Martin et 
al. 2010). Similarly, metformin inhibits secretion of TGF-β1 in cardiomyocytes (Wang et al. 
2011) and reduces TGF-β1 levels and vascularization after sponge implantation in mice 
(Xavier et al. 2010). In ovarian and uterine tissue, metformin is also able to reduce TGF-β1 
levels and prevent fibrosis (Zhang et al. 2013). In adipocytes, metformin activates Smad7, an 
inhibitory Smad, thus decreasing TGF-β signaling (Kim et al. 2015). In renal fibroblasts, 
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metformin inhibits Smad3 hence lowering TGF-β-induced collagen I production (Lu et al. 
2015). Lastly, in nasal polyp-derived fibroblasts, metformin directly inhibits Smad2/3 
phosphorylation (Park et al. 2014). Hence, metformin is able to lower TGF-β levels or inhibit 
Smad signaling in different tissues, but no research exists concerning glioma.  
Thirdly, direct inhibition of metformin signaling through TGF-β has been described. In renal 
fibroblasts, TGF-β1 directly counteracts metformin's signaling via AMPK inhibition thus 
causing fibrosis (Thakur et al. 2015). Again, no data exists for GBM.  
Fourthly, metformin lowers glucose levels thus decreasing TGF-β release. Gu et al. (2014) 
found that the glucose content in the culture medium has an effect on TGF-β secretion: the 
higher the glucose content the higher the TGF-β levels. The glucose induced TGF-β 
production of renal mesangium cells is impaired by metformin. Similarly, metformin can 
antagonize diabetes induced increase in TGF-β levels in renal tissue of diabetic rats 
(Maheshwari et al. 2014). On the other hand, impairment of complex I of the respiratory 
chain may increase lactate levels and lactate has been described as an activator of TGF-β 
signaling in GBM cells (Baumann and Leukel et al. 2009, Seliger et al. 2013). Thus, 
metformin may indirectly activate or inhibit TGF-β depending on cellular context. 
Fifthly, metformin and TGF-β are part of complex signaling networks which overlap at certain 
points. Metformin and TGF-β signaling may converge on FoxO signaling (Moustakas 2005, 
Sato et al. 2012), on JNK signaling (Moustakas and Heldin 2005, Isakovic et al. 2007), on 
Akt signaling (Moustakas and Heldin 2005, Sato et al. 2012) or on Sox expression (Ikushima 
et al. 2009, Zhang et al. 2014, Kim et al. 2016). These links have not been established for 
identical tissues, but may outline what a great variety of interactions between metformin and 
TGF-β is conceivable.  
The individual effects of metformin and TGF-β2 have been explored in GBM indicating that 
their effects might be opposed, but possibly also difficult to predict. Yet, no research exists 
reviewing functional and molecular effects of both, metformin and TGF-β2, on glioma cells.   
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3.5 Research aim 
The laboratory group of Molecular NeuroOncology Regensburg investigates brain tumor 
metabolism, tumor cell invasion, TGF-β-signaling and possible clinical applications for new 
anti-glioma treatments. This study was designed as a comprehensive approach to analyze 
the functional responses of proneural and mesenchymal BTICs and TCs to metformin, 
TGF-β2 and / or SD-208 treatment.   
So far, the effects of metformin on GBM have mainly been explored using concentrations 
higher than what seems achievable in human brain tissue and have shown various results. 
These have been attributed to different genetic and metabolic setups of different glioma cells. 
The reports about TGF-β2's influence on proliferation and migration of glioma are 
heterogeneous and again, have been attributed to genetic differences. Lastly, there exists no 
systematic research reviewing functional effects of both, metformin and TGF-β2, on GBM 
cells.   
Therefore, this study focused on three main topics:  
1. How do different subtypes of GBM cells react to different metformin concentrations? 
May low concentrations decrease cell proliferation and / or migration? Are there 
differences in susceptibility? 
2. How do TGF-β2 and SD-208 influence proliferation and migration of different GBM 
cell lines? Are there differences in susceptibility? 
3. Are there any links between the functional effects of metformin and TGF-β2 on 
GBM? 
In functional assays, changes in proliferation and migration under treatment with different 
doses of metformin, TGF-β2, SD-208 and combinations thereof, were examined. Proliferation 
was mainly assessed in cell counts and exemplarily tested in crystal violet stainings, and 
migration was mainly assessed in spheroid migration assays and exemplarily explored in 
scratch migration assays. To investigate whether different susceptibilities to metformin and 
TGF-β can be predicted based on cell differentiation status or subtype, five BTIC cell lines 
were maintained at serum-free conditions and compared to their differentiated counterparts 
(TCs), cultured with serum. BTIC and TC lines were composed of three mesenchymal and 
two proneural cell lines each. 
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4 MATERIAL AND METHODS 
 
4.1 Material 
4.1.1 Consumables and supplies 
Table 3: List of consumable and supplies 
Product Company 
6- and 96-well plates TPP; Trasadingen, Switzerland 
96-well plate, round bottom Costar; Corning, NY, USA 
Culture Inserts (Wound-healing-assay) Ibidi; Martinsried, Germany 
Flasks for cell culture (T25 and T75) TPP; Trasadingen, Switzerland 
Neubauer’s Hemocytometer Assistent; Sondheim/Rhön, Germany 
Hemocytometer cover glasses                 
(20 x 26 x 0.4 mm) 
Hartenstein; Würzburg, Germany 
Cell scraper 28 cm Greiner; Frickenhausen, Germany 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf, Hamburg; Falcon BD, 
Heidelberg, Germany 
Cryo tubes (1.6 and 1.8 ml) Sarstedt; Nürnbrecht, Germany 
Falcon tubes (15 and 50 ml) Sarstedt; Nürnbrecht, Germany 
Pipettes (2, 10, 20, 100, 200, 1000 µl) Gilson; Middleton, WI, USA 
Pipette tips (10, 200, 1000 µl) Sarstedt; Nürnbrecht, Germany 
Step pipette Eppendorf; Hamburg, Germany 
Step pipette tip (5 ml) Eppendorf; Hamburg, Germany 
Transferpette (0-200 µl) Brand; Wertheim, Germany 
Glas pipettes (5, 10, 20 ml) Brand; Wertheim, Germany 
Glas Pasteur pipette  Brand; Wertheim, Germany 
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4.1.2 Glioblatoma cell lines 
All brain tumor initiating cells (BTICs) used for the experiments were obtained during brain 
tumor surgery at the university hospital Regensburg (UKR) and isolated in the laboratory. 
After having grown the obtained cells for several passages, some were differentiated using 
Dulbecco’s modified Eagle Medium (DMEM with glucose 1000 mg/L) with 10% fetal calf 
serum (FCS). Thus, cells from each cell line existed as stem-like cells (BTIC) and as 
differentiated pair (TC). The following cells were used: 
Table 4: List of cell lines used 
Proneural cell lines BTIC passages  TC passages  
RAV19 P25 and P26 P23_3 and P26_6 
RAV57 P16 and P18 P17_2 and P20_3 
 
Mesenchymal cell lines BTIC passages  TC passages  
RAV21 P17, P19 and P24 P24_9 and P24_10 
RAV24 P12 and P14 P10_5 and P10_7 
RAV27 P16 and P20 P18_5 and P18_6 
 
For differentiated cell lines, Px_y denotes that cells were passaged x times as BTICs and y 
times as TCs, e.g. RAV19 P23_3 describes that RAV19 BTICs were passaged 23 times 
before being differentiated and passaged 6 times as TCs. Tumor cell properties for cells in 
primary tissue and in cell culture as well as patient characteristics are shown in Tables 5,6, 
and 7.  
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Table 5: Characteristics of the primary tumors 
 
Primary 
Tumors 
histology  grade MGMT-meth. IDH1 (wt/mut.) 
m
e
s
e
n
c
h
y
m
a
l 
 
RAV 21 GBM (prim.) IV meth. n.d. 
RAV 24 GS (prim.) IV meth. wt  
RAV 27 GBM (sec.) IV unmeth. p.R132H 
p
ro
n
e
u
ra
l 
 
RAV 19 GBM (prim.) IV unmeth. wt  
RAV 57 GBM (prim.) IV unmeth. wt  
Abbreviations: MGMT-meth. = methylation of the promotor region of the O
6
-methylguanine-DNA-
methyltransferase; IDH1 (wt/mut.) = isocitrate dehydrogenase wildtype or mutation; prim. = primary; sec. = 
secondary; meth. = methylated; unmeth. = unmethylated; n.d. = not determined 
 
Table 6: Tumor characteristics in cell culture 
 
Cell 
Culture 
growth MGMT                
-meth. 
IDH                      
(wt / mut.) 
CD133 
(%) 
Nestin Sox2 
m
e
s
e
n
c
h
y
m
a
l 
 
RAV 21 adherent meth. wt 1 pos. neg. 
RAV 24 adherent meth. wt 6 pos. pos. 
RAV 27 adherent meth. wt 62 pos. neg. 
p
ro
n
e
u
ra
l 
 
RAV 19 adherent unmeth. wt 3 pos. pos. 
RAV 57 adherent unmeth. wt 0 pos. pos. 
Abbreviations: MGMT-meth. = methylation of the promotor region of the O
6
-methylguanine-DNA-
methyltransferase; IDH1 (wt/mut.) = isocitrate dehydrogenase wildtype or mutation; CD133 = cluster of 
differentiation; Sox2 = SRY (sex determining region Y)-box 2; meth. = methylated; unmeth. = unmethylated; pos. 
= positive; neg. = negative 
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Table 7: Patient characteristics 
 
Patient 
data 
age  sex therapy OS (months) 
m
e
s
e
n
c
h
y
m
a
l 
 
RAV 21 46 m radio / chemo 18.75 
RAV 24 55 m radio / chemo 17.5 
RAV 27 42 m radio / chemo 8.5 
p
ro
n
e
u
ra
l 
 
RAV 19 52 f radio / chemo 4 
RAV 57 49 m radio / chemo 20.5 
Abbreviations: OS = overall survival; m = male; f = female 
 
Table 8: Endogenous TGF-β2 levels of BTICs 
 
Cell 
Culture 
TGF-β2 
(ng/ml) 
standard                  
deviation 
m
e
s
e
n
c
h
y
m
a
l 
 
RAV 21 0.2030 0.0250 
RAV 24 0.6655 0.0328 
RAV 27 1.6008 0.1179 
p
ro
n
e
u
ra
l 
 
RAV 19 0.0773 0.0347 
RAV 57 0.0385 0.0104 
Endogenous TGF-β2 levels were quantified using an ELISA.  
ELISA was performed with supernatants 48 hs after  
sowing out 400,000 cells of the respective cell line.  
 
4.1.3 Culture media and supplements 
Table 9: List of culture media and supplements 
Substance Company 
RHB-A Stem Cell Medium Stem Cell Technologies; Köln, Germany 
Epidermal Growth Factor (EGF) Miltenyi-Biotec; Bergisch-Gladbach, Germany 
Fibroblast Growth Factor (FGF) Miltenyi-Biotec; Bergisch-Gladbach, Germany 
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Dulbecco’s modified Eagle Medium 
(DMEM) Low Glucose (1000 mg/l) 
Sigma-Aldrich; München, Germany 
Fetal Calf Serum (FCS) Biochrom; Berlin, Germany 
Penicillin and Streptomycin (P/S) Sigma-Aldrich; München, Germany 
MEM Non essential amino acids 
(neAA) 
Sigma-Aldrich; München, Germany 
MEM - Vitamins Sigma-Aldrich; München, Germany 
Glutamine Sigma-Aldrich; München, Germany 
Cell Dissociation solution Sigma-Aldrich; München, Germany 
Trypsin-EDTA Sigma-Aldrich; München, Germany 
Phosphate Buffer Saline (PBS) Sigma-Aldrich; München, Germany 
Dimethylsulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Laminin Becton Dickinson; Heidelberg, Germany 
 
Table 10: Overview over  media ingredients 
Medium Ingredients 
RHB-A full medium 1% (v/v) Penicillin/Streptomycin 
20 ng/ml Epidermal Growth Factor (EGF) 
20 ng/ml Fibroblast Growth Factor (EGF) 
DMEM full medium 10% (v/v) Fetal Calf Serum (FCS) 
1% (v/v) Penicillin/Streptomycin 
1% (v/v) Non essential amino acids (neAA) 
1% (v/v) MEM-Vitamins 
1% (v/v) Glutamine 
Glucose content = 1000 mg/dl 
Cryo conservation medium RHB-A or DMEM full medium 
10% Dimethylsulfoxide (DMSO) 
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4.1.4 Additional substances and solutions 
Table 11: Additional substances used 
Substance Company 
Trypan blue stain Sigma-Aldrich; Taufkirchen, Germany 
Metformin Hydrochloride Fluka, Sigma-Aldrich; Steinheim, Germany 
Transforming growth factor beta 2 
mammalian (TGF-β2) 
Peprotech; Hamburg, Germany 
SD-208 (2-(5-Chloro-2-
fluorophenyl)-4-[(4-
pyridyl)amino]pteridine) 
Tocris; Bristol, UK 
Agarose Biozym; Oldendorf, Germany 
 
Table 12: Additional solutions used 
Solution Ingredients 
Crystal violet solution 0.5% crystal violet 
20% Methanol 
Sodium citrate 0.1 M Sodium citrate 
50% Ethanol 
Agarose 1% Agrose 
PBS 
 
4.1.5 Equipment 
Table 13: List of equipment 
Equipment Company 
Cell Culture Incubator HeraCell (Normoxia) Thermo Scientific, USA 
Cell Culture Hood HeraSafe Thermo Scientific, USA 
Water bath 1083 GFL; Burgwedel, Germany 
Light microscope Fluovert Type 090-123.012 Leitz; Wetzlar, Germany 
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Light microscope Type 090-135.001 Leica; Wetzlar, Germany 
Centrifuge Megafuge 10.R Thermo Scientific, USA 
Centrifuge 5417C Eppendorf; Hamburg, Germany 
Vortex-2-Genie Scientific Industries; Bohemia, NY, 
USA 
Varioscan Thermo Scientific, USA 
 
4.1.6 Software 
Table 14: List of computer software 
Programm Company 
Microsoft Excel Microsoft; Redmond, USA 
ProgRes CapturePro 2.6, JENOPTIK Laser Optik Systeme GmbH; Jena, Germany 
ImageJ NIH; Betheada, USA 
 
4.2 Methods 
4.2.1 Cell culture 
4.2.1.1 Origin of BTICs and differentiated GBM cells 
All brain tumor initiating cells (BTICs) used in the experiments were obtained during brain 
tumor surgery at the University Hospital Regensburg (UKR) and isolated in the laboratory. In 
the lab group, tumors were broken down physically by use of a scalpel and by being pipetted 
in PBS for several minutes. In addition, an erythrocyte lysis buffer was used to disintegrate 
any red blood cells that might still be left in the tumor tissue. After several further steps of 
washing with PBS and alternating centrifugation, the isolated brain tumor initiating cells were 
sowed out on 6-well plates for growth under three different conditions:  
 RHB-A full medium in a laminin coated well 
 RHB-A full medium in a laminin free well 
 DMEM + 10% FCS full medium in a laminin free well. 
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6-well plates were kept in normoxia, at 37°C and 5% CO2. The serum-free medium RHB-A 
was supplemented with epidermal growth factor (EGF) and fibroblast growth factor (FGF) to 
preserve BTICs' stem-like properties. For differentiation, BTICs were cultured in a DMEM 
(glucose 1000 mg/L) + 10% FCS full medium for at least 2-3 weeks and 1 or 2 passages 
preferably. After 2-3 weeks, morphological changes were confirmed under the microscope.  
4.2.1.2 Maintenance 
To culture BTICs and their differentiated pairs, cells were grown in ventilated T25 or T75 
flasks according to cell number. They were incubated at 38°C, 80% humidity, 20% oxygen 
(=normoxia) and 5% CO2.   
In order to preserve stem cell properties of BTICs, they were kept in RHB-A media. It was 
supplemented with 1 % Penicillin/Streptomycin to prevent bacterial infection as well as 1% 
EGF and 1% FGF. For differentiated cells, a low glucose DMEM medium (1000 mg 
glucose/l) with 10% FCS (fetal calf serum) was used. It was supplemented with 1% 
Penicillin/Streptomycin, 1% vitamins, 1% L-glutamine and 1% non-essential amino acids. 
10 ml of medium were used to keep cells in a T75 flask while 5 ml were used for T25 flasks. 
All media were changed under sterile conditions on a weekly basis. For adherent cells, half 
of the medium in the flask was taken out with a glass Pasteur pipette and refilled with fresh 
medium (e.g. 5 ml of medium were changed in a T75 flask). When adherent cells reached a 
confluence level between 80 to 90%, they were either split onto several flasks or stored away 
in a -80°C freezer. In order to split cells, the supernatant medium was taken out of one or 
several flasks containing the same cell line at the same passage number and put into a 50 ml 
flask to store. Then, 3ml of cell dissociation solution was added per flask before the flask was 
put into the incubator. After 5-10 minutes the flask was taken out and shaken moderately (if 
needed) to increase cell detachment. Next, the flask was rinsed once or twice using the cell 
dissociation solution already in the flask and then rinsed again once or twice using the stored 
medium. The resulting suspension was centrifuged at 1200 rpm and 20°C for 5 minutes. 
After the medium had been carefully taken out with a Pasteur pipette, the cell pellet was 
redissolved in a required amount of medium (e.g. 30 ml for 3 T75 flasks) and distributed onto 
the new flasks. Splitting cells in this way increased the passage number by one. After 
3 passages, old flasks were replaced.  
4.2.1.3 Cryo conservation 
In order to store cells, the cell pellet gained as described above was resuspended in a 10% 
DMSO and medium solution. The suspension was immediately put into a 2 ml cryo 
conservation cup, which was placed into a container filled with isopropanol for slow 
temperature reduction. This ensured that the temperature decreased by 1°C per minute 
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when the isopropanol container was stored in the –80°C freezer. In order to thaw cells, the 
cryo conservation cup was placed into a 37°C water bath for approximately 1 minute. Next, 
2 ml of fresh medium were added to dilute the toxic 10% DMSO solution for centrifugation. 
The suspension was transferred into a 15 ml falcon tube and centrifuged at 1200 rpm and 
20°C for 8 minutes. Afterwards, the supernatant was removed and the pellet was 
resuspended in 5 mL of fresh medium for transfer into a T25 flask.  
4.2.1.4 Cell count 
All cell counts were performed on Neubauer’s hemocytometers using trypan blue exclusion. 
Trypan blue is incorporated into the cell membranes of dead cells. Thus, dead cells will 
appear blue under a light microscope while living cells continue to appear white. To perform 
a cell count, 40 µl of cell suspension was mixed with 10 µl of trypan blue, resulting in a 
1:1.25 dilution. 10 µl of the stained cell suspension was then brought onto a hemocytometer 
and examined under the microscope at 10x magnification. Since each corner square has the 
dimensions 1mm x 1mm and a height of 0.1 mm, the resulting volume is 0.1 mm3 (= 0.1 µl). 
Therefore, the cell number in 1 ml of cell suspension can be calculated as follows: 
 
 
           
  
 
                                   
 
         
     
  
 
Eqn. 1 
 
y = number of corner squares counted 
1.25  = dilution factor 
10  = factor to account for the chamber volume of 0.1 µl 
 
4.2.2 Cell Proliferation Assays 
The aim of proliferation assays was to determine the effects of metformin, TGF-β2 and 
SD-208, a TGF-β2-I-receptor-kinase-inhibitor, on the proliferation of different GBM cell lines. 
Metformin was used in different concentrations up to 10 mM, the reported EC50 for GBM 
(Würth et al. 2013). TGF-β2 was used at 10 ng/ml according to prior laboratory experience 
and 1 µM SD-208 was used, because the EC50 for GBM was found at at 0.1 µM (Uhl et al. 
2004). Counting and comparing the number of living cells to the initial cell number allowed for 
an estimation of cytostatic effects while the number of dead cells was used as a measure of 
cytotoxic effects. A proliferation assay was performed over five days. On the first day, cells 
were sowed out, on the third day, they were treated, on the fourth day, they were retreated 
and on the fifth day, they were harvested, counted and cell pellets were stored away.  
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4.2.2.1 Preparation of 6-well plates 
For optimum coverage, 150,000 cells were sowed per well on a 6-well plate. Therefore, an 
average of 3 T75 flasks covered in cells was needed. The flasks were treated with cell 
dissociation solution and a pellet was gained as described in 2.2.1.2. The pellet was 
redissolved in approximately 5-10 ml of medium depending on its size. Spheroids of RAV19 
P25 and P26 had to be disintegrated by repeated pipetting. Then, 40 µl were taken out for 
cell counting. After the number of cells had been calculated using Equation 1, a 
predetermined volume of cell solution required to obtain 5x106 cells was put into a 50 ml 
falcon tube. Medium was then added to obtain a total volume of 50 ml. Following this, five 
6-well-plates were filled with 1.5 ml of cell suspension per well, before being incubated to 
allow cells to settle and adhere to the well. 
4.2.2.2 Treatment 
After approximately 48 hs, wells were treated to produce 10 different conditions in replicates 
of 3. In order to prepare the treatments, the following pipetting scheme was used: 
Table 15: Treatments for proliferation assays 
condition end volume medium substance 
control 7 ml 7 ml - 
DMSO control 1:10,000 7 ml 7 ml 0.7 µl DMSO 
0.01 mM metformin 11 ml 9.9 ml  1.1 ml from 0.1 mM metformin 
0.1 mM metformin 8 ml 8 ml  0.008 ml stock metformin 
1 mM metformin 6 ml 5.94 ml  0.06 ml stock metformin 
10 mM metformin 7 ml 6.3 ml  0.7 ml stock metformin 
SD-208 1 µM 7 ml 6.93 ml  0.07 ml stock SD-208 
TGF-β2 10 ng/ml 7 ml 6.986 ml  0.014 ml stock TGF-β2 
TGF-β2 10 ng/ml + 
0.01 mM metformin 
6 ml 5.388 ml  0.6 ml from 0.1 mM metformin + 
0.012 ml stock TGF-β2  
TGF-β2 10 ng/ml + 
10 mM metformin 
7 ml 6.286 ml 0.7 ml stock metformin +     
0.014 ml stock TGF-β2 
 
Stock solutions used were: 
 Metformin 100 mM in RHB-A or DMEM 
 SD208 100 µM in 1% DMSO in RHB-A or DMEM  
 TGF-β2 (mammalian) 5 nM in sterilized water, PBS and 0.1% BSA. 
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The following example illustrates how to calculate the necessary volume of TGF-β2 stock for 
an end volume (Vend) of 7 mL and an end concentration of 10 ng/ml: 
 
        
     
  
                
     
  
          
Eqn. 2 
 
            
 
    
                    
 
   
          
Eqn. 3 
                                                 Eqn. 4 
df  = dilution factor 
 
   
                 
                   
 
Eqn. 5 
 
       
        
          
       
Eqn. 6 
After all treatment solutions had been prepared, the supernatant medium was aspirated and 
1.5 ml of treatment solution was added per well. In case of spheroid cell growth (RAV19 P25 
and P26), only half the medium was taken out to avoid loss of spheres and treatments in 
double concentration were added.  
4.2.2.3 Re-treatment 
Starting after approximately 20 hs, cells growing under the conditions “0.01 mM metformin 
with 3 re-treatments" as well as “TGF-β2 + 0.01 mM metformin with 3 re-treatments” were 
retreated 3 times in approximate 4 h intervals. In order to add a minimal amount of fresh 
medium and still be able to pipette accurately, 15 µl were taken from the remaining volume of 
the 1 mM metformin solution from the previous day. Thus, each re-treatment added an 
identical amount of metformin to that used for initial treatment.  
4.2.2.4  Harvest and count 
48 hs after treatment, cells were harvested, counted and pellets were stored for Western 
Blotting. All of these procedures were performed under non-sterile conditions. Using a cell 
scraper, all cells were detached from the bottom of the well. As they tended to form large 
aggregates, a Pasteur pipette was used to disseminate cells by pipetting up and down 
10-20 times. Afterwards, each well was rinsed with the cell suspension and the entire 
contents were transferred into a 2 ml Eppendorf tube. After 8 minutes of centrifugation at 
2500 rpm and 20°C, supernatant medium was carefully transferred into another 2 ml tube for 
determination of lactate and glucose concentration. The remaining cell pellet was 
resuspended in 100 to 500 µl of PBS (phosphate-buffer-saline) by up-and-down-pipetting 
using a 200 µl (20 times) and a Pasteur pipette (10 times). Then, 40 µl were extracted for 
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counting while the remaining cell suspensions out of 3 wells were pooled. After centrifugation 
at 2500 rpm and 20°C for 8 minutes, the supernatant was removed and the pellets were 
stored in the -80°C freezer. Cells were counted according to the protocol in 2.2.1.4, while 
both dead and viable cells were noted down. In order to calculate the number of cells per 
well, a modified formula was used: 
            
  
 
                                   
 
             
Eqn. 7 
 
y = number of corner squares counted 
1.25  = dilution factor 
10  = factor to account for the chamber volume of 0.1 µl 
z  = number of ml used for resuspension of the cell pellet 
 
4.2.3 Crystal-Violet Staining 
Crystal violet assays provide an alternative way to determine cell number and thus 
proliferation. Crystal violet solutions stain all cells fixed to the well. Since in these 
experiments dead cells were drained with the supernatant, staining the remaining adherent 
cells within the well was used to determine only the number of viable cells. 
4.2.3.1 Preparation of a 96-well plate 
5000, 2500 and 1000 cells per well were distributed in 100 µl of medium on 96-well-plates. 
6 blank control were also used. 
4.2.3.2 Treatment 
To let cells adhere, they were kept in the incubator for 48 hs. Afterwards, each batch of cells 
was treated in replicates of 3 creating the conditions outlined in Table 15. When a 
proliferation assay was performed on the same day, one extra milliliter of each treatment 
solution was prepared and used. In order to treat the cells, the medium was carefully 
removed using a 100 µl pipette as the suction of a Pasteur pipette could potentially have 
damaged the integrity of the cell layer in the well. Six wells were thus drained at the same 
time to prevent the cells from drying out. Following this, 100 µl of treatment solution was 
carefully pipetted against the wall of the well to avoid cell detachment.  
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4.2.3.3 Re-treatment 
As with the proliferation assay, cells under the conditions “0.01 mM metformin with 3 re-
treatments” and “TGF-β2 + 0.01 mM metformin with 3 re-treatments” had to be retreated 
starting after 20 hs by adding the initial amount of metformin with every re-treatment. 
Therefore, 10 µl of left over 0.1 mM metformin solution was applied at time intervals of 4 hs.  
4.2.3.4 Staining and Measurements 
48 hs after the initial treatment, cells were stained using a 0.5% crystal violet solution in 20% 
methanol. At first, the supernatant was discarded. Next, 50 µl of crystal violet staining 
solution was pipetted into each well except for the 6 wells used as blank controls. After 
10 minutes of incubation at room temperature, the crystal violet staining solution was 
thoroughly shaken off. The plate was submerged in water 5 times and rinsed with tab water 
5 times to wash off any unspecific staining. In order to fully remove unspecific staining, it was 
very important to shake off the dye quickly and efficiently and to immediately rinse the plate 
with water. After the plate had dried for a minimum of 24 hs, 50 µl of 0.1 M sodium citrate in 
50% ethanol were added per well, redisssolving the dried crystal-violet dye. The resulting 
solution was then measured photometrically at a wavelength of 550 nm. The more stained 
cells there were per well, the higher the photometric value was, which was thus taken as a 
measure of proliferation. 
 
4.2.4 Spheroid Assay 
The aim of spheroid assays is to quantify migration using a light microscope in conjunction 
with a digital imaging device and ImageJ, a computer program to measure spheroid area in 
photographs. Spheroids form when cells are grown on agarose, which prevents cells from 
adhering to the bottom of the well. In these experiments, spheroid assays were performed to 
investigate the effects of metformin, SD-208 and TGF-β2 on GBM cell migration.  
4.2.4.1 Preparation of spheroids 
Analogous to the proliferation assay, spheroid assays were carried out on five consecutive 
days. Firstly, spheroids had to form on an agarose coated 96-well-plate. Agarose was used 
to prevent cells from adhering to the plate bottom. 1 g of GE LP Biozym Agarose was added 
to 100 ml of PBS and boiled in the microwave until fully dissolved. After letting the agarose 
cool for approximately 5 minutes, 100 µl were added per well using a step pipette. While the 
agarose coated plate cooled off, cells were harvested from flasks and prepared as described 
in 2.2.1.4 and 2.2.1.4. Following this, a cell suspension in fresh medium was prepared for 
65 wells, consisting of a total volume of 7 ml with a total cell number of 280,000 cells. Thus, 
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adding 100 µl of cell suspension per well resulted in a cell number of 4000 per well. The 
96-well-plate was subsequently incubated for approximately 48 h. 
4.2.4.2 Treatment 
The first step for spheroid treatment involved picking spheroids from their wells and 
transferring them into a U-bottom plate. In order to pick spheroids, 50 µl of the media were 
carefully taken out and discarded. Then, the remaining 50 µl were taken out. After checking 
for a spheroid in the pipette tip, it was carefully pipetted into the U-bottom-plate. Secondly, 
the treatment solutions had to be prepared. When performing a spheroid assay on the same 
day as a proliferation assay, the solutions mixed for the proliferation assay could be used as 
a basis. As each well already contained 50 µl of medium without treatment, the concentration 
of the 50 µl treatment solutions had to be twice as high as in the proliferation assay. In order 
to adjust for this fact, the pipetting scheme was modulated as shown below. 50 µL of these 
treatment solutions were added per well in replicates of 6. 
Table 16: Treatment for spheroid migration assays 
condition end 
volume 
from prolif. 
solution 
add 
control 0.5 ml 0.5 ml - 
DMSO control 1:10000 0.5 ml 0.5 ml 0.05 µl DMSO 
0.01 mM metformin 0.5 ml 0.5 ml 0.05 ml from 0.1 mM metformin 
1 mM metformin 0.5 ml 0.5 ml 0.005 ml stock metformin 
10 mM metformin 0.5 ml 0.5 ml 0.05 ml stock metformin 
SD-208 1 µM 0.5 ml 0.5 ml 0.005 ml stock SD-208 
TGF-β2 10 ng/ml 0.5 ml 0.5 ml 0.001 ml stock TGF-β2 
TGF-β2 10n g/ml + 
10 mM metformin 
0.5 ml 0.5 ml 0.05 ml stock metformin +    
0.001 ml stock TGF-β2 
TGF-β2 10 ng/ml +  
SD-208 1 µM 
0.5 ml 0.5 ml 0.002 ml stock TGF-β2 +  
0.01 ml stock SD-208 
 
4.2.4.3 Re-treatment 
Cells were retreated as described in section 2.2.3.3. 
4.2.4.4 Pictures 
In order to monitor spheroid migration, each spheroid was photographed at a set time point 
at 4x magnification. The time points were 0, 20 and 48 hs after treatment. For photography, a 
microscope with ProgRes C3B camera was used. The pictures were taken digitally using the 
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ProgRes Capture Pro2.6, JENOPTIK Laser, Optik Systeme GmbH software at 
2080x1542 pixels and an exposure time of 8.64 ms. Each picture was later analyzed using 
ImageJ. Firstly, the scale was set to 152 pixels/mm using a photograph of a Neubauer’s 
hemocytometer as a reference. This scale was applied to all pictures. Secondly, the area of 
the spheroid was quantified by drawing along the outer border of the spheroid with the 
freehand selection tool and then measuring its area. For the images taken after 20 and 
48 hs, the outer line of cells migrated furthest was used as spheroid border. Thus, the 
calculated area represents the entire area covered by cells after migration. The example 
below demonstrates how the same spheroid was measured after 0, 20 and 48 hs using the 
freehand selection tool and the measurement function of ImageJ. 
     
Figure 4: Measuring spheroid areas of RAV19 P23_6 control 1 after 0, 20 and 48 hs. 
 
4.2.5 Scratch Migration Assay 
The scratch migration assay was performed using special silicon culture inserts to produce a 
500 µm cell free gap. Over the course of 48 hs, migration of cells into the gap was 
documented photographically at different time points to investigate the gap closure time for 
different cell lines under different conditions. 
4.2.5.1 Preparation of 6-well plates 
3 culture inserts were glued into each of the six wells by gently pressing them onto the 
bottom with sterile tweezers. Perfect adhesion is required to form a cell free gap, as cells 
would otherwise migrate underneath the dividing wall. A solution of 12,500 cells per 70 µl 
was prepared. Then, they were carefully injected into each culture insert chamber resulting in 
triplets for the conditions control, 0.01 mM 3x, 0.01 mM, and 10 mM metformin as well as 
1 µM SD-208 and 10 ng/ml TGF-β2.  
4.2.5.2 Treatment and re-treatment 
After 24 hs of incubation, each well was treated with treatment solutions analogous to 
proliferation assays (see 2.2.2.2). After the culture inserts had been carefully removed from 
0.788 mm
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2
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the bottom of the well with sterile tweezers, 1.5 ml of treatment solution were pipetted into 
each well. Starting after 4 hs, the well of “0.01 mM metformin 3x” was retreated 3 times a day 
at 4 h intervals with 1.5 µl of left over 10 mM metformin solution.  
4.2.5.3 Measurements 
To monitor cell migration as well as gap closure time, gaps were photographed digitally 
under the light microscope at 4 h intervals. Pictures were taken at three points of each gap at 
10x magnification. In order to accurately reproduce the photo points at each given time point, 
they were chosen as follows: Firstly, the 'entrance' of the gap was photographed. The 
second photo was taken of the part directly underneath, avoiding overlap, while the third 
picture was taken of the 'exit' of the gap. Later, the area of each gap region was determined 
using the free hand selection tool of the photo program ImageJ and measured as described 
in 2.2.5.4.  
 
4.2.6 Analysis of data 
Data obtained in proliferation and migration assays was analyzed using Microsoft Excel. For 
proliferation assays, values were normalized to the medium control by dividing the number of 
viable cells per well by the average of viable cells per well in medium controls. Thus, relative 
proliferation rates were calculated. For migration data, a two-step normalization was 
performed. At first, values measured after 20 or 48 hs were divided by the initial spheroid 
size at 0 hs resulting in normalization to 0 hs. Then, these values were divided by the 
average of the medium control spheroid size at the given time point to obtain relative 
migration rates. In order to determine statistical significance, relative proliferation rates and 
relative migration rates under different conditions were compared to the medium control's 
proliferation/migration rate using a two-tailed heteroscedastic Student's T-Test. The only 
exemptions were any values obtained for cells treated with SD-208. As SD-208 is dissolved 
in a solution containing 1% DMSO, a DMSO 1:10,000 control was established to serve as a 
reference. The following symbols are used to indicate different levels of significance. 
Table 17: List of symbols indicating significance 
* p ≤ 0.05 compared to medium control # p ≤ 0.05 compared to DMSO-control 
** p ≤ 0.01 compared to medium control # # p ≤ 0.01 compared to DMSO-control 
*** p ≤ 0.001 compared to medium control # # #  p ≤ 0.001 compared to DMSO-control 
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5 RESULTS  
 
5.1 The functional effects of metformin on GBM cells 
This work investigated the effects of high and low doses of metformin on different types of 
GBM cell lines. In 2013, Würth et al. were able to show that metformin inhibits proliferation of 
GBM cells in a dose-dependent manner (Würth et al. 2013). Moreover, they calculated that 
the IC50 for metformin is at approximately 10 mM. These findings served as basis for 
proliferation and migration assays performed with 10 different GBM cells lines. Those cells 
were treated with 10 mM as well as lower concentrations of metformin. Another aim of the 
present study was to investigate whether 10 mM metformin reliantly reduces proliferation as 
well as migration. Concurrently, the susceptibility of certain cell lines towards lower dosages 
of metformin was of interest. 
 
5.1.1 Overall, high doses of metformin reliably reduced proliferation and 
migration 
As GBM's malignancy is largely due to its rapid proliferation and aggressive migration, these 
two characteristics were examined in different functional assays. To investigate proliferation, 
cell counts were carried out, and crystal-violet staining assays were performed to support 
data exemplarily. Similarly, spheroid migration assays were carried out to examine migration, 
while scratch migration assays supported the data in selected cases. Proliferation data was 
obtained in 20 experiments. Two proneural cell lines, RAV19 and RAV57, were used both in 
the form of brain-tumor-initiating cells (BTICs) and tumor cells (TCs); additionally, three 
mesenchymal cell lines, RAV21, 24 and 27 were used as BTICs and TCs. Cell counts for 
each condition were carried out in triplicates; furthermore, each cell count was repeated once 
with identical cell lines but different passage numbers (n = 6). 
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Figure 5: Relative proliferation rates of all cell lines after a 48 h treatment with different concentrations of 
metformin. 
Analysis of the combined proliferation data, demonstrated that only 10 mM metformin 
produced a significant decrease in proliferation to about 54% compared to the medium 
control (p < 0.001). Lower concentrations of metformin failed to reduce proliferation 
significantly. Yet, the large standard deviations indicate that different cell lines exhibit varying 
susceptibility to the anti-proliferative effects of metformin, especially in low doses.  
Proliferation and migration assays were performed with cells of the same passage number to 
ensure comparability. Spheroid migration assays were carried out in sets of 6 for each 
condition. Again, each experiment was repeated once to ensure a large database to draw 
from (n = 12). Migration was monitored atfter 20 and 48 hs in correlation to proliferation 
assays with 48 hs as end point. The measured values for spheroid area at each time point 
were normalized by division by the corresponding initial spheroid size at 0 hs. To compare 
the differing migratory rates of all cell lines each value was normalized to the average of the 
non-treated control. As a result, the migratory rate of each condition is shown as relative rate 
compared to the non-treated control. Figure 9 depicts the average effects of low and high 
doses of metformin on all cell lines after 20 and 48 hs.  
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Figure 6: Relative migratory rates of all cell lines after 20 and after 48 hs of treatment with increasing 
concentrations of metformin: Migration was normalized in two steps: Values of each time point were 
normalized to initial spheroid size, followed by normalization to the medium control. 
At both time points, low concentrations of metformin such as 0.01 mM in triple application 
showed small effects (migration increased by 5% and 1% respectively). However, 
intermediate and high concentrations of metformin inhibited migration. As opposed to 
proliferation assays where 1 mM metformin did not yield a significant reduction, 1 mM 
metformin reduced migration by 10% after 20 hs and 13% after 48 hs (p < 0.003 in both 
cases). Yet, 10 mM metformin was significantly more effective, decreasing migration by 34% 
after 20 hours and by 40% after 48 hours (p < 0.0001 in both cases).   
In summary, high doses of metformin reliably decreased proliferation and migration of GBM 
cells. Intermediate doses such as 1 mM metformin reduced migration significantly but 
revealed no consistent anti-proliferative effect. In contrast, low doses of metformin neither 
decreased proliferation nor migration significantly considering the overall data. Since 
susceptibility to metformin was heterogeneous, different groups of cells lines as well as 
individual cell lines were examined more closely as described in the following sections.  
 
5.1.2 Susceptibility to metformin's anti-proliferative and anti-migratory action 
varied among subgroups of cells  
According to cell characteristics and differentiation, cells were grouped into four categories: 
proneural BTICs, mesenchymal BTICs, proneural TCs, and mesenchymal TCs.  
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5.1.2.1 Low-dose metformin decreases proliferation of proneural BTICs effectively 
  
  
Figure 7: Cell counts after 48 hs of treatment with increasing concentrations of metformin: Absolute 
numbers of viable cells per well at every condition were divided by the average number of viable cells of the non-
treated control. 
The anti-proliferative power of even low dosages of metformin becomes evident when 
looking at different groups of cell lines, especially in proneural BTICs RAV19 and RAV57. 
Accordingly, triple re-treatment of cells with a very low dose of 0.01 mM metformin resulted in 
a marked decrease of proliferation (33% decrase) compared to the medium control 
(p < 0.003), see Figure 7 A. Triple re-treatment with 0.01 mM metformin led to a significantly 
more pronounced decrease in proliferation than single treatment with 0.01 mM metformin 
(p < 0.05). Treatment of proneural BTICs with 0.1 mM metformin decreased proliferation by 
31% compared to the medium control (p < 0.006). Therefore, treatment and re-treatment of 
proneural BTICs with low concentrations of metformin was effective to decrease proliferation. 
However, all other groups of cell lines did not exhibit significant responses to low doses of 
metformin as depicted in Figure 7 B-D.  
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As the magnitude of the anti-proliferative effect of metformin is most different between 
proneural and mesenchymal BTICs, their distinct susceptibilities to metformin are displayed 
in Figure 8.  
 
Figure 8: Comparing the different effect sizes of metformin’s anti-proliferative action between proneural 
and mesenchymal BTICs: Symbols of significance are put at a distance to indicate that proliferation rates of 
proneural cell lines RAV19 and 57 are compared to those of mesenchymal cell lines RAV21, 24 and 27 and not, 
as usually the case, to the medium control. 
For every concentration of metformin used, proneural BTICs' proliferation decreased more 
than mesenchymal BTICs'. The susceptibility profile can be described as follows: proneural 
BTICs RAV19 and 57 were highly responsive to metformin whereas mesenchymal BTICs 
RAV21, 24 and 27 were little responsive.  
Figure 7 also shows that susceptibility to anti-proliferative effects of high dose metformin 
differs considerably. Even though 10 mM metformin were able to reduce proliferation in all 
except proneural TCs, the comparison of reaction patterns, as detailed in Figure 9, reveals 
heterogeneous susceptibility to metformin. 
 
Figure 9: Comparing the effects of 10 mM metformin on different groups of cells.  
Mesenchymal TCs showed the strongest reaction to 10 mM metformin. Their proliferation 
rate was reduced to 0.24 compared to the non-treated control (p < 0.0001). Their proneural 
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counterparts were almost not affected as their relative proliferation decreased to 0.95 (non-
significant). These findings were reversed when comparing proneural to mesenchymal 
BTICs: Whereas 10 mM metformin led to a decrease to 0.68 in mesenchymal BTICs 
(p < 0.002), proliferation was lowered to 0.42 in proneural BTICs (p < 0.0001).  
5.1.2.2 High dose metformin impaired migration in all groups of cells with proneural 
BTICs being most susceptible 
Analyzing metformin's anti-proliferative effects showed that different groups of GBM cells 
exhibited different reaction patterns. This was also true when examining migration of GBM 
cells. In spheroid migration assays, photos were taken after 20 hs and 48 hs to assess the 
area covered in cells. Figures 10 and 11 compare the relative migratory rates normalized to 
0 hs and to the medium control of the four different groups of cells.  
  
  
Figure 10: Spheroid migration measured after 20 hs of treatment with different concentrations of 
metformin: Migration was normalized in two steps: Values of each time point were normalized to initial spheroid 
size, followed by normalization to the medium control. 
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Figure 11: Spheroid migration measured after 48 hs of treatment with different concentrations of 
metformin: Migration was normalized in two steps: Values of each time point were normalized to initial spheroid 
size, followed by normalization to the medium control. 
Looking at migration after 20 and after 48 hs, three trends were observed. Firstly, low doses 
of metformin were not able to reduce migratory rates significantly. Even migratory rates of 
proneural BTICs - which had been very responsive to low-dose metformin's anti-proliferative 
effects - were not significantly reduced by low doses. Secondly, intermediate doses of 
metformin consistently diminished migration in TCs but not in BTICs. Thirdly, high doses of 
metformin clearly reduced migration in all groups of cells. The effect size of 10 mM metformin 
varied across the four of groups.  
Proneural BTICs were most susceptible to 10 mM metformin's action with migration being 
reduced to 0.38 after 48 hs of treatment (p < 0.0001). 10 mM metformin exerted vast anti-
proliferative and anti-migratory effects on proneural BTICs. Mesenchymal BTICs on the other 
hand were less responsive to metformin's anti-migratory action. Migration was decreased by 
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20% to 0.80 (p < 0.0001), resulting in a significant difference in susceptibility when compared 
to proneural BTICs (p < 0.001). For proneural TCs, proliferation was reduced to 0.95 (non-
significant) while migration was reduced to 0.53 (p < 0.0001). Lastly, 10 mM metformin 
inhibited both proliferation and migration of mesenchymal TCs: Proliferation was reduced to 
0.24 (p < 0.0001), and migration was reduced to 0.61 (p < 0.0001). Table 18 sums up the 
differences of susceptibility to metformin regarding proliferation and migration highlighting 
that low doses of metformin significantly reduced proliferation of proneural BTICs and that 
high doses of metformin consistently decreased both, migration and proliferation of all GBM 
cells.  
Table 18: Review of the anti-proliferative and anti-migratory effects of different concentrations of 
metformin after 48 hs of treatment: The left column of each group (dark grey) shows how strongly proliferation 
was reduced. The right column shaded in light grey depicts contraction of migration at the 48 h time point. Only 
significant results are shown. Symbols indicate the following: - indicates that proliferation/migration was reduced 
by up to 25%, - - by 25-50%, - - -  by 50-75% and - - - - by more than 75%. 
 
Pro BTICs 
  Prolif.          Migra. 
Mes BTICs 
  Prolif.          Migra. 
Pro TCs 
  Prolif.          Migra. 
Mes TCs 
  Prolif.          Migra. 
0.01 mM -        
0.01 mM 3x - -        
0.1 mM - -         
1 mM - - -     -  - 
10 mM - - - - - - - - -  - - - - - - - - 
 
 
5.1.3 Unique cellular reaction patterns to metformin 
5.1.3.1 Detailed analysis of proliferation and migration of proneural BTICs RAV19 and 
RAV57 
As each group comprised two or three different cell lines, it was important to examine 
metformin’s effects on proliferation and migration on an individual level. The group of 
proneural BTICs consisted of RAV19 and RAV57. Experiments for each cell line were carried 
out twice, preferably with cells of comparable passage numbers to avoid changes in reaction 
patterns due to further passaging.  
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Figure 12: Brain-tumor initiating cells in culture flasks:  RAV19 (A) and RAV57 (B). 
Figure 13 shows the total number of cells per well as the sum of viable and dead cells.  
 
Figure 13: Total cell number per well obtained after treating RAV19 P25 and P26 with different 
concentrations of metformin for 48 hs: The numbers of viable cells are shown in grey. Accordingly, significant 
differences between proliferation in treated wells and proliferation in medium control wells are marked with grey 
stars. Absolute numbers of dead cells are shaded black. Significant differences between the fraction of dead cells 
in any treated well compared to those in the medium control are marked with a black star.  
In line with previous observations of proneural BTICs, RAV19 P25 and P26's proliferation 
was reduced by low-dose and high-dose metformin. 0.01 mM metformin decreased 
proliferation by 37% and 10 mM by 46% (p < 0.05 and p < 0.03). Additionally, the fraction of 
dead cells in wells treated with 10 mM metformin increased by 13% compared to the medium 
control (p < 0.02) so that 10 mM metformin proved to be a cytotoxic dose to RAV19 BTICs.  
RAV57 P16 and P18 grow adherently (see Figure 12). Therefore, cell counts and spheroid 
migration assays were performed as detailed in 4.2.2 and 4.2.4. Dead and viable cells were 
counted and results are outlined in the following figure. 
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Figure 14: Total cell number per well obtained after treating RAV57 P16 and P18 with different 
concentrations of metformin for 48 hs: The numbers of viable cells are shown in grey. Accordingly, significant 
differences between proliferation in treated wells and proliferation in medium control wells are marked with stars. 
Absolute numbers of dead cells are shaded black. Significant differences between the fraction of dead cells in any 
treated well compared to the fraction of dead cells in the medium control are marked with black stars. 
Proliferation data from RAV57 P16 and P18 coressponded well to the observations seen with 
RAV19 P25 and P26: Even low doses of metformin were effective to decrease proliferation. 
Interestingly, 0.01 mM metformin with triple re-treatment lowered proliferation by 43% 
(p < 0.006) while the single treatment reduced proliferation by 18% (non-significant). Thus, 
the effects of 3x 0.01 mM metformin were almost as pronounced as those of 1 mM 
metformin, which diminished proliferation by 52% (p < 0.008). Hence, both proneural BTICs 
examined were greatly susceptible to low-dose metformin. In addition, RAV57 P16 and P18 
were highly susceptible to high-dose metformin: 10 mM metformin decreased proliferation by 
71% (p < 0.0004). In summary, proliferation of both proneural cell lines, RAV19 and RAV57, 
was inhibited by low-dose and high-dose metformin.  
Spheroid migration assays with RAV19 P25 and P26 were carried out using laminin-coated 
U-bottom-wells to enable cell adhesion. As RAV57 P16 and P18 grow adherently, no laminin 
was required during spheroid migration assays. Figure 15 depicts relative migratory rates of 
both cell lines.  
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Figure 15: Relative increase of spheroid area of proneural BTICs RAV19 (A) and RAV57 (B) after 48h 
treatment with different concentrations of metformin: Spheroid sizes were measured after 20 and 48 hs. 
Migration was normalized in two steps: Values of each time point were normalized to initial spheroid size, followed 
by normalization to the medium control. 
Low doses of metformin were not able to inhibit migration of RAV19 and RAV57 spheroids. 
Yet, 10 mM proved to exert vast anti-migratory effects on both cell lines. RAV19's spheroid 
relative migratory rate was more than halved (p < 0.0001) and RAV57's was reduced to less 
than a third (p < 0.0001).  
Thus, individual examination of proneural BTICs RAV19 and 57 reveals that the effects of 
metformin within the group are homogeneous: Low and high doses of metformin decreased 
proliferation while high doses substantially decreased migration. 
 
5.1.3.2 Detailed analysis of proliferation and migration of mesenchymal BTICs 
RAV21, RAV24 and RAV27 
In the group of mesenchymal brain-tumor initiating cell lines, experiments were performed 
with RAV21 P19, RAV24 P12 and P14 as well as RAV27 P16 and P20. 
                 
Figure 16: Brain-tumor initiating cells in culture flasks: RAV21 (A), RAV24 (B) and RAV27 (C). 
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Figure 17: Total cell number per well obtained after treating RAV21 P19 (A), RAV24 P12 and P14 (B and C) 
and RAV27 P16 and P20 (D) with different concentrations of metformin: For (A), (B) and (D), the numbers of 
viable cells are shown in grey. Accordingly, significant differences between proliferation with treatment and at 
medium control conditions are marked with grey stars. Absolute numbers of dead cells are shaded black. 
Significant differences between the fraction of dead cells in any treated well compared to the fraction of dead cells 
at medium control conditions are marked with black stars. In (C), proliferation relative to the medium control from 
a crystal violet assay is shown. Here, the amount of viable cells was determined, only. 
Mesenchymal brain tumor initiating cell lines RAV21 and RAV27 responded to high-dose 
metformin. Proliferation decreased by 48% in RAV21 (p < 0.05) and by 49% in RAV27 
(p < 0.03) when cells were treated with 10 mM metformin for 48 hs. For RAV27, the fraction 
of dead cells in wells treated with 10 mM metformin was 27% higher than in the medium 
control (p < 0.05). Lower concentrations of metformin (0.01 mM) resulted in a 48% increase 
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in proliferation in RAV24 (p < 0.04). To validate cell-counting data, a crystal violet staining 
assay was exemplarily performed with RAV24. It also showed that metformin did not alter 
proliferation of RAV24 significantly. 
Proliferation and spheroid migration assays were preferably performed with mesenchymal 
cell lines of identical passage number to ensure comparability. Solely in the case of RAV21 
this was not possible, thus RAV21 P17 and P24 were investigated for migration assessment.  
 
 
 
Figure 18: Relative increase of spheroid area in mesenchymal BTICs RAV21 (A), RAV24 (B) and  RAV27 
(C) after 48h treatment with different concentrations of metformin:  Spheroid sizes were measured after 20 
and 48 hs. Migration was normalized in two steps: Values of each time point were normalized to initial spheroid 
size, followed by normalization to the medium control. 
Migratory rates of mesenchymal BTICs were influenced by metformin to a different extent. 
After 48 hs, migration of RAV21 P17 and P24 increased to 1.27 due to 0.01 mM metformin in 
triple re-treatment (p < 0.02); however, 10 mM metformin caused a decline to 0.83 (p < 0.02). 
Migratory rates of RAV24 P12 and P14 dropped to 0.58 with 10 mM metformin treatment 
(p < 0.0001) while those of RAV27 P16 and P20 remained unaffected by any concentration 
of metformin. RAV27 P16 and P20 showed aggressive migration. After 48 hs spheroid sizes 
were 55 times larger than initial spheroid sizes, regardless of any treatment (medium control 
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or 10 mM metformin). Spheroid sizes of RAV21 and RAV24 on the other hand quintupled, 
indicating a less aggressive migratory behavior. 
En masse, metformin exerted the following effects on mesenchymal BTICs: (i) 10 mM 
reduced proliferation and migration in RAV21, (ii) RAV24's proliferation remained unaffected 
while migratory rates declined, and (iii) RAV27's proliferation has halved, but its migratory 
rates did not change significantly.  
 
5.1.3.3 Detailed analysis of proliferation and migration of proneural TCs RAV19 and 
RAV57 
As illustrated in Figure 19, cells of RAV19 changed their morphology upon differentiation. 
While BTICs grew as spheres, RAV19 TCs grew adherently. Cells of RAV57 continued to 
grow adherently but changed morphology to a more spindle-like shape.  
           
Figure 19: Differentiated GBM cells in culture flasks:  RAV19 (A) and RAV57 (B). 
Due to the low proliferation rate of differentiated RAV 19 and 57, the usual 150,000 cells/well 
were not obtained. Therefore, 60,000 cells/well of RAV19 P23_6 were sowed out, 
70,000 cells/well of RAV57 P17_2 and 30,000 cells/well of RAV57 P20_3 were used.  
Consequently, the average number of cells per well obtained during cell counts decreased. 
Compared to an average of 100.000 to 200.000 cells/well counted for proneural BTICs, there 
was only an average of 20.000 to 40.000 cells/well to be determinded after differentiation.  
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Figure 20: Cell count with total number of cells per well after treatment of RAV19 P23_3 and P23_6 (A) and 
RAV57 P17_2 and P20_3 (B) with different concentrations of metformin and crystal violet staining assay 
of RAV57 P20_3 (C): For (A) and (B), the numbers of viable cells are shown in grey. Accordingly, significant 
differences between proliferation with treatment and at medium control conditions are marked with grey stars. 
Absolute numbers of dead cells are shaded black. Significant differences between the fraction of dead cells in any 
treated well compared to the fraction of dead cells at medium control conditions are marked with black stars. In 
(C), proliferation relative to the medium control from a crystal violet assay is shown. Here, the amount of viable 
cells was determined, only. 
During cell counts, neither RAV19 P23_3 and P23_6 nor RAV57 P17_2 and P20_3 showed 
significant changes in numbers of viable and dead cells after 48 hs of treatment with 
metformin. Alternative data obtained in a crystal violet staining assay performed with RAV57 
P20_3 showed that proliferation modestly decreased to 0.75 when treated with 10 mM 
metformin (p < 0.003).  
Spheroid migration assays were performed with proneural tumor cells of identical passage 
numbers as those used for cell counts.   
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Figure 21: Relative increase of spheroid area in proneural TCs RAV19 (A) and RAV57 (B) with additional 
data from a scratch migration assay performed with RAV57 P20_8 (C): For (A) and (B), spheroid sizes were 
measured after 20 and 48 hs. Migration was normalized in two steps: Values of each time point were normalized 
to initial spheroid size, followed by normalization to the medium control. For reasons of clarity, significances are 
only marked for the end point of 48 hs. For (C), gap areas were measured at 0, at 6 and at 8 hs. Values for 6 and 
8 hs were then divided by values obtained at 0 hs. In a second step, the gap area relative to initial gap size was 
divided by the average of relative gap area of the controls resulting in data showing gap area decrease relative to 
0 hs and to the medium control. 
As opposed to proliferation rates, migratory rates of proneural TCs were lowered by high-
dose metformin. After 48 hs, RAV19 TC spheroids had quintupled in size when 1 mM or 
10 mM metformin was present while spheroids in medium control wells had expanded to an 
average of 16 times their initial size (p < 0.003 in both cases). 10 mM metformin impaired 
RAV57 TC spheroids' expansion significantly but less pronounced: After 48 hours, it was 
11 times the initial size while spheroids in medium control wells had reached 15 times their 
initial size (p < 0.005). A scratch migration assay performed with RAV57 P20_8 supported 
these results. After 6 hours and after 8 hs, the cell free gaps in wells treated with 10 mM 
metformin were larger than those of the medium control wells measuring twice the size of 
control wells after 6 hs (p < 0.02) and four times the size after 8 hs (p < 0.002). Hence, 
metformin exerts anti-migratory effects on individual proneural TC lines. 
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5.1.3.4 Detailed analysis of proliferation and migration of mesenchymal TCs RAV21, 
RAV24 and RAV27 
All mesenchymal TCs grew adherently. Yet, in some cases, proliferation of mesenchymal 
TCs was slower than that of BTICs. Due to these diminished proliferation rates, less than the 
usual 150,000 cells/well were sowed out for RAV21 P24_10 (60,000 cells/ well), RAV24 
P10_5 (70,000 cells/well) and RAV24 P10_7 (100,000 cells/well).  
           
Figure 22: Differentiated GBM cells in culture flasks:  RAV24 (A) and RAV27 (B). 
Proliferation after treatment with metformin was assessed after 48 hs using cell counts and 
investigated exemplarily by crystal violet staining assays.  
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Figure 23: Cell counts with absolute number of cells and crystal violet stainings with proliferation 
normalized to control:  For cell counts of RAV21 P24_9 and P24_10 (A), RAV24 P10_5 and P10_7 (C) and of 
RAV27 P18_5 and P18_6 (E), the numbers of viable cells are shown in grey. Accordingly, significant differences 
between proliferation with treatment and at medium control conditions are marked with grey stars. Absolute 
numbers of dead cells are shaded black. Significant differences between the fraction of dead cells in any treated 
well compared to the fraction of dead cells at medium control conditions are marked with black stars. For crystal 
violet staining assays of RAV21 P24_9 (B) and RAV24 P10_7 (D), relative proliferation is shown.  
All three mesenchymal TC lines were very susceptible to high-dose metformin's anti-
proliferative action: RAV21 TC's proliferation rates decreased by 50% (p < 0.03), those of 
RAV24 TCs decreased by 89% (p < 0.0001) and those of RAV27 TCs by 90% (p < 0.0003). 
The anti-proliferative effects that 10 mM metformin exerted on RAV24 TCs and RAV27 TCs 
were cytotoxic in nature as the fraction of dead cells in metformin treated wells was 7 times 
higher than in control wells for RAV24 (p < 0.0007) and 3 times higher for RAV27 
(p < 0.0001). To support these findings, crystal violet staining assays were performed. There, 
the anti-proliferative effects of 10 mM metformin were less pronounced than in cell counts. 
10 mM metformin reduced proliferation to 86% in RAV21 TCs (p < 0.006) and to 69% in 
RAV24 TCs (p < 0.007). Each mesenchymal tumor cell line exhibited large proliferation 
decreases due to metformin confirming on an individual level the effects that had been 
characteristic for the entire group.  
Migratory rates of mesenchymal TCs RAV21, RAV24 and RAV27 were assessed in spheroid 
migration assays using cells of identical passage number as in proliferation assays. 
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Figure 24: Relative increase of spheroid area in mesenchymal TCs RAV21 (A), RAV24 (B) and RAV27 (C) 
after 48h treatment with different concentrations of metformin: Spheroid sizes were measured after 20 and 
48 hs. Migration was normalized in two steps: Values of each time point were normalized to initial spheroid size, 
followed by normalization to the medium control. For reasons of clarity, significances are only marked for the end 
point of 48 hs. 
Mesenchymal TCs RAV21, RAV24 and RAV27 migrated at different rates: After 48 hs, 
RAV21's average spheroid area was 10 times as large as the initial spheroid size, RAV24's 
average spheroid area expanded 7-fold and RAV27's was 63 times as large as initially. 
Migratory rates were significantly lowered by 10 mM metformin. RAV21 TCs' migration 
diminished to 0.73 (p < 0.02). RAV24 TCs' migratory rates were decreased to 0.56 
(p < 0.0002) by 1 mM metformin and to 0.30 (p < 0.0001) by 10 mM metformin. RAV27 TCs' 
migration, being very rapid in the first place, was diminished to 0.79 (p < 0.0001).  
Overall, differentiated mesenchymal GBM cell lines RAV21, RAV24 and RAV27 were highly 
susceptible to the anti-proliferative power of 10 mM metformin, while lower concentrations 
did not decrease proliferation significantly. Also, migration of RAV21, 24 and 27 TCs was 
noticeably lowered by 10 mM metformin and in case of RAV24 TCs, also by 1 mM 
metformin. 
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5.2 The functional effects of TGF-β2 on GBM cells 
TGF-β is described as a tumorigenic cytokine inducing proliferation, migration, invasion, 
angiogenesis and suppressing the immune response. Several studies have explored the 
effects of TGF-β on glioma proliferation and have found heterogeneous results. Apart, 
TGF-β₂ is described as a key inducer of migration in GBM. Hence, this study aimed to 
analyze the effects of TGF-β2 on glioma proliferation and migration to establish similarities 
and differences between BTICs, TCs, proneural and mesenchymal cells.   
Experiments to investigate the effects of TGF-β2 and SD-208 were performed analogous to 
those with different concentrations of metformin. There were 10 cell lines for cell counts and 
spheroid migration assays and each experiment was repeated once with the same cell line. 
During cell counts, triplicates were examined for each condition and during spheroid 
migration assays each condition had six replicates.  
5.2.1 TGF-β2's effects were anti-proliferative and anti-migratory 
 
Figure 25: Effects of TGF-β2 and its receptor antagonist, SD-208, on proliferation: The symbol # # indicates 
that the increase of proliferation caused by SD-208 was significant compared to the DMSO-control as SD-208 is 
dissolved in 1% DMSO.  
TGF-β2’s action on GBM cells was slightly but significantly anti-proliferative reducing 
proliferation by 15% compared to the medium control (p < 0.02). SD-208 increased 
proliferation by 20% compared to the DMSO-control (p < 0.005). Hence, on a grand scheme, 
TGF-β2 and SD-208 had opposite effects on proliferation.   
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Figure 26: Effects of TGF-β2 and its antagonist, SD-208, on migration: Migration was assessed after 20 hs 
(A) and 48 hs (B). Here, data is shown for all cell lines after two steps of normalization to initial spheroid size and 
then to relative increase in size of medium control spheroids.  
TGF-β2 reduced migration to 0.90 after 20 hs (p < 0.0002) and to 0.84 (p < 0.0001) after 
48 hs compared to the medium control. For SD-208, no significant effects were observed. 
Similarly, the combination of TGF-β2 and SD-208 did not influence migration significantly 
hinting that SD-208 might have nullified TGF-β2's anti-migratory effects.    
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5.2.2 Mesenchymal GBM cell lines were most susceptible to TGF-β2  
TGF-β2 and SD-208 affected different groups of cells to a different extent. The following 
section details differences in proliferation and migration after 20 and 48 hs.  
  
  
Figure 27: Cell counts after 48 hs of treatment: The absolute numbers of viable cells per well of any condition 
were divided by the average number of viable cells in the medium control wells.  
TGF-β2 decreased proliferation in all but proneural TCs. Firstly, in proneural BTICs, 
proliferation was reduced to 0.8 bordering significance (p = 0.054). Significant anti-
proliferative effects were observed in mesenchymal TCs where proliferation decreased to 
0.71 (p < 0.03). Compared to proliferation rates in DMSO-treated wells, SD-208 enhanced 
proliferation in differentiated cell lines: proneural TCs’ proliferation increased by 44% and that 
of mesenchymal TCs by 29%. Here, TGF-β₂ and SD-208 had antagonistic effects. TGF-β2 
was also able to inhibit proliferation in proneural BTICs where SD-208 did not show 
significant effects and SD-208 was able to increase proliferation in proneural TCs where 
TGF-β2 's effects were non-significant.  
Figures 28 and 29 illustrate whether these findings are in line with the migratory data.  
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Figure 28: Spheroid migration after 20 hs of treatment: Relative migratory rates were calculated by double 
normalization. Therefore, values for each 20 h time point were first divided by the corresponding value at 0 hs and 
secondly by the average of the medium control.  
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Figure 29: Spheroid migration after 48 hs of treatment: Relative migratory rates were calculated by double 
normalization. Therefore, values for each 20 h time point were first divided by the corresponding value at 0 hs and 
secondly by the average of the medium control.  
Regarding the role of TGF-β2 in migration, two trends could be distinguished: Proneural cell 
lines - whether stem-like or differentiated - only scarcely reacted to TGF-β2 with migration 
being reduced in proneural BTICs at the 20 h time point only (0.88 with p = 0.051). Apart, no 
significant effects were observed. Migratory rates of mesenchymal BTICs decreased to 0.79 
after 20 hs and to 0.65 after 48 hs of treatment (p < 0.0001 in both cases) making 
mesenchymal BTICs very responsive to TGF-β2's anti-migratory actions. Similarly, migratory 
rates of mesenchymal TCs were lowered to 0.89 after 20 hs (p < 0.02) and to 0.76 after 
48 hs (p < 0.0001). Hence, the anti-migratory power of TGF-β2 was more pronounced in 
mesenchymal cell lines than in proneural cell lines.    
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Figure 30: Comparing the effects of 10 ng/ml TGF-β2 on relative migratory rates of different groups of 
cells: Significances between different groups of cells are marked.  
Reviewing Figures 28 and 29, SD-208 exerted no effects on migration of proneural cell lines 
except on proneural BTICs after 20 hs. In mesenchymal cell lines, the effects were 
heterogeneous: Migration was impaired by SD-208 in mesenchymal BTICs (relative 
migratory rate was reduced by 22% with p < 0.005), but it was enhanced by 27% compared 
to the DMSO-control in mesenchymal TCs (p < 0.02).  
In summary, TGF-β2's effects were anti-proliferative and anti-migratory especially in 
mesenchymal cell lines. In mesenchymal TCs, TGF-β2 reduced both proliferation and 
migration while SD-208's effects were opposite. In all the other cell lines, the anti-proliferative 
and anti-migratory effects were only partially detectable: In proneural BTICs for example, 
TGF-β2 only reduced proliferation; in mesenchymal BTICs it only reduced migration. SD-208 
raised proliferation in proneural TCs but reduced migration in mesenchymal ones.  
Table 19: Overview over the effects of 10 ng/ml TGF-β2 and 1 µM SD-208 on proliferation and migration of 
different groups of GBM cells: The left column in dark grey shows how strongly proliferation is reduced after 48 
hs of treatment. The right column shaded in light grey depicts contraction of migration at the 48 h time point. Only 
significant results are shown. Symbols indicate the following: - indicates that proliferation/migration is reduced by 
up to 25%, - - by 25-50%, - - - by 50-75% and - - - - by more than 75%. If proliferation or migration are increased, 
+'s are used for indication. 
 
Pro BTICs 
  Prolif.          Migra. 
Mes BTICs 
  Prolif.          Migra. 
Pro TCs 
  Prolif.          Migra. 
Mes TCs 
  Prolif.          Migra. 
TGF-β2 10 ng/ml -   -    - - - 
SD-208 1 µM    - ++  ++ ++ 
 
Table 20: Overview over functional effects (48 h) of TGF-β2 and SD-208 on all GBM cell lines 
Effect after 48 h      TGF-β₂ SD-208 
Proliferation decrease       20%  20% 
Proliferation increase         0%    0% 
Migration decrease       60%  20% 
Migration increase       10%  30% 
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5.2.3 Unique cellular reaction patterns to TGF-β2 and SD-208 
5.2.3.1 Detailed analysis of proliferation and migration of proneural BTICs RAV19 and 
RAV57 
Figure 31 shows results for cell counts and spheroid migration assays of proneural BTICs 
RAV19 P25 and P26 as well as RAV57 P16 and P18. 
 
 
 
Figure 31: Cell count with total number of cells per well (A and B) and spheroid migration assays (C and 
D) after treatment with 10 ng/ml TGF-β2 or with 1 µM SD-208: In (A) and (B), absolute numbers of viable cells 
are colored grey. Accordingly, significant differences between relative proliferation in treated wells and the 
medium control wells are marked with grey stars. Absolute numbers of dead cells are shaded black. Significant 
differences between the fraction of dead cells in any treated well compared to the fraction of dead cells in the 
medium control are marked with black stars. To create line-plot diagrams (C) and (D), spheroid sizes were 
measured after 20 and 48 hs. Migration was normalized in two steps: Values of each time point were normalized 
to initial spheroid size, followed by normalization to the medium control. For reasons of clarity, significance is only 
marked for the end point of 48 hs. 
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The proliferation decrease after treatment with TGF-β2 was neither significant in RAV19 
BTICs nor in RAV57 BTICs. Yet, the fraction of dead cells of RAV57 BTICs increased by 
10% compared to the medium control in a suggestively significant manner (p = 0.0507) 
implying that TGF-β2 might be cytotoxic to RAV57 BTICs. Migration also remained mostly 
unaffected by TGF-β2 and SD-208. Solely the combination of TGF-β2 and SD-208 produced 
an increase in relative migratory rates of RAV57 BTICs. Proneural BTICs RAV19 and RAV57 
were mildly affected in their proliferation and migration after TGF-β2 or SD-208 treatment. 
5.2.3.2 Detailed analysis of proliferation and migration of mesenchymal BTICs 
RAV21, RAV24 and RAV27 
In proliferation assays, RAV21 P19, RAV24 P12 and P14 and RAV27 P16 and P20 were 
assessed 48 hs after treatment with 10 ng/ml TGF-β2 or 1 µM SD-208. To support data from 
cell counts, crystal violet staining assays were performed with RAV24 P12 and P14.   
 
 
Figure 32: Total cell number per well obtained after treating RAV21 P19 (A), RAV24 P12 and P14 (B and D) 
and RAV27 P16 and P20 (C) with 10 ng/ml TGF-β2 or with 1 µM SD-208: For (A), (B) and (C), the numbers of 
viable cells are shown in grey. Accordingly, significant differences between proliferation with treatmeant and at 
medium control conditions are marked with grey stars. Absolute numbers of dead cells are shaded black. 
Significant differences between the fraction of dead cells in any treated well compared to the fraction of dead cells 
at medium control conditions are marked with black stars. In (D), proliferation relative to the medium control from 
a crystal violet assay is shown. Here, the amount of viable cells was determined, only. 
0 
100000 
200000 
300000 
400000 
m
ed
iu
m
 
co
n
tr
o
l 
D
M
SO
 
co
n
tr
o
l 
SD
-2
0
8
 1
µ
M
 
TG
Fb
et
a2
 
1
0
n
g/
m
L 
N
u
m
b
e
r 
o
f 
ce
lls
 p
e
r 
w
e
ll 
Cell count: Total cell number of 
RAV21 BTICs  
dead cells 
viable cells 
0 
100000 
200000 
300000 
400000 
500000 
m
ed
iu
m
 
co
n
tr
o
l 
D
M
SO
 
co
n
tr
o
l 
SD
-2
0
8
 1
µ
M
 
TG
Fb
et
a2
 
1
0
n
g/
m
L 
N
u
m
b
e
r 
o
f 
ce
lls
 p
e
r 
w
e
ll 
Cell count: Total cell number of 
RAV24 BTICs  
dead cells 
viable cells 
0 
200000 
400000 
600000 
800000 
m
ed
iu
m
 
co
n
tr
o
l 
D
M
SO
 
co
n
tr
o
l 
SD
-2
0
8
 1
µ
M
 
TG
Fb
et
a2
 
1
0
n
g/
m
L 
N
u
m
b
e
r 
o
f 
ce
lls
 p
e
r 
w
e
ll 
Cell count: Total cell number of 
RAV27 BTICs  
dead cells 
viable cells 
0 
0,5 
1 
1,5 
medium 
control 
DMSO 
control 
SD-208 
1µM 
TGF-β₂ 
10ng/ml 
P
ro
le
fr
at
io
n
 n
o
rm
al
iz
e
d
 t
o
 c
o
n
tr
o
l 
Crystal violet staining: BTICs RAV24  
* 
* * 
A B 
C D 
RESULTS 
68 
 
In mesenchymal BTICs, TGF-β2 and SD-208 affected proliferation heterogeneously. As 
indicated in Figure 32 A, proliferation of RAV21 was lowered to 0.38 when 10 ng/ml TGF-β2 
was present (p < 0.03). RAV24 did not react to TGF-β2 and SD-208, in neither cell counts nor 
in crystal violet staining assays. Lastly, in RAV27, proliferation was not influenced by TGF-β2 
nor SD-208; however, the fraction of dead cells increased when TGF-β2 or DMSO were 
present, hinting that these substances are cytotoxic to RAV27 BTICs. Thus, SD-208 did not 
exert significant influences while TGF-β2’s action was either non-existent (RAV24), cytostatic 
(RAV21) or cytotoxic (RAV27).  
Migration was assessed using cells of identical passage numbers as proliferation. In case of 
RAV21, P17 and P24 were utilized.  
 
 
 
Figure 33: Relative increase of spheroid area for mesenchymal BTICs RAV21 P17 and 24 (A), RAV24 P12 
and P14 (B) and RAV27 P16 and P20 (C) after 48 hs of treatment with 10ng/ml TGF-β2 or with 1µM SD-208:  
Spheroid sizes were measured after 20 and 48 hs. Migration was normalized in two steps: Values of each time 
point were normalized to initial spheroid size, followed by normalization to the medium control. For reasons of 
clarity, significances are only marked for the end point of 48 hs. Preferably, values for SD-208 were compared to 
those of the DMSO control to determine significance (symbol: #); yet, where DMSO controls were missing, values 
for SD-208 were compared to the medium control (symbol: *).  
In all three mesenchymal BTIC lines, 10 ng/ml of TGF-β2 reduced migration. Spheroid 
migration of RAV21 was lowered to 0.83 after 48 hs (p < 0.01) by TGF-β2, but SD-208 
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exerted no significant effects. RAV24 BTICs’ migratory rates were decreased to 0.45 after 
48 hs (p < 0.0001) even though their proliferation rates had not been affected by TGF-β2 and 
SD-208. When TGF-β2 and SD-208 were combined, migratory rates were 25% lower than 
those of the DMSO control suggesting that in RAV24 BTICs, 1 µM SD-208 was not able to 
antagonize 10 ng/ml TGF-β2. In RAV27, TGF-β2's and SD-208’s abilities to reduce migration 
were comparable: TGF-β2 decreased it to 0.70 and SD-208 to 0.65 (p < 0.0001 in both 
cases). Combining TGF-β2 and SD-208 resulted in a 63% decrease of migration of RAV27 
BTICs. Overall, TGF-β2 lowered migration of all mesenchymal BTIC lines.  
5.2.3.3 Detailed analysis of proliferation and migration of proneural TCs RAV19 and 
RAV57 
Cell counts and spheroid migration assays were performed with RAV19 P23_3 and P23_6 
along with RAV57 P17_2 and P20_3.  
  
Figure 34: Cell counts with total number of cells per well after treatment with 10 ng/ml TGF-β2 or with 1 µM 
SD-208: RAV19 P23_3 and P23_6 (A) and RAV57 P17_2 and P20_3 (B) were used.The numbers of viable cells 
are shown in grey. Accordingly, significant differences between proliferation with treatment and at medium control 
conditions are marked with grey stars. Absolute numbers of dead cells are shaded black. Significant differences 
between the fraction of dead cells in any treated well compared to the fraction of dead cells at medium control 
conditions are marked with black stars 
RAV19 and RAV57 TCs proliferated slowly. Therefore, instead of the standard 
150,000 cells/well, 60,000 cells/well of RAV19 P23_6, 70,000 cells/well per well of RAV57 
P17_2 and 30,000 cells/well of RAV57 P20_3 were sowed out for cell counts. An increase in 
proliferation of RAV19 P23_3 and P23_6 by 78% was observed when 1 µM SD-208 was 
present (p < 0.04 compared to the DMSO control). TGF-β2 did not alter proliferation of 
RAV19 TCs. Neither SD-208 nor TGF-β2 had significant impact on the proliferation of RAV57 
TCs. Thus, proliferation of proneural TCs reactet scarcely to treatment with TGF-β2 and 
SD-208.  
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In addition to spheroid migration assays, which were performed with cells of identical 
passage number as proliferation assays, a scratch migration assay was performed for 
RAV57 P20_8 to support results from spheroid migration assays. 
 
 
 
Figure 35: Spheroid migration assays (A and B) and scratch migration assay (C) after treatment with 10 
ng/ml TGF-β2 or with 1 µM SD-208: For spheroid migration assays with RAV19 P23_3 and P23_6 (A) and with 
RAV57 P17_2 and 20_3 (B), spheroid sizes were measured after 20 and 48 hs. Migration was normalized in two 
steps: Values of each time point were normalized to initial spheroid size, followed by normalization to the medium 
control. For reasons of clarity, significances are only marked for the end point of 48 hs. In (C), results from a 
scratch migration assay with RAV57 P20_8 are shown. Gap area at 6 and at 8 hs were normalized to the 
corresponding 0 h values and afterwards normalized to the medium control. No DMSO control was used.  
Migration of RAV19 and RAV57 TCs was significantly altered by SD-208 and TGF-β2. 
Interestingly, migration of RAV19 P23_3 and 23_6 after 48 hs increased under TGF-β2 to 
1.41 (p<0.0001). SD-208 lowered migration by 45% compared to the DMSO-control 
(p < 0.008). RAV19 TCs was the only cell line in which TGF-β2 increased and SD-208 
decreased migration. For RAV57 TCs, TGF-β2 inhibited migration to 0.76 of the average 
medium control migration rates (48 hs; p < 0.0002) while SD-208 enhanced migration by 
32% compared to the DMSO control (p < 0.004). Scratch migration assays further 
demonstrated TGF-β2's ability to decrease migratory rates in RAV57 TCs. In TGF-β2 treated 
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wells, the cell free gap was almost twice the size of the medium control after 20 hs (p < 0.04) 
and approximately three times the size after 48 hs (p < 0.02).  
In summary, the effects of TGF-β2 and SD-208 on proneural TCs were heterogeneous. While 
SD-208 increased proliferation of RAV19 TCs, it decreased migration, and TGF-β2 increased 
migration. RAV57 TCs' proliferation rates were not affected by TGF-β2, but their migratory 
rates decreased after 48 hs. Thus, there is no homogenous group trend that could be 
postulated for proneural TCs. Hence, it is important to note that RAV19 TCs were the only 
cell line in which migration was increased by TGF-β2.  
 
5.2.3.4 Detailed analysis of proliferation and migration of mesenchymal TCs RAV21, 
RAV24 and RAV27 
Proliferation and migration were assessed using RAV21 P24_9 and P24_10, RAV24 P10_5 
and P10_7 as well as RAV27 P18_5 and P18_6. Proliferation was mostly assessed in cell 
counts and supported exemplarily by a crystal violet staining assay of RAV24 P10_7.  
 
 
Figure 36: Total cell number per well obtained after a 48 h treatment with 10 ng/ml TGF-β2 or with 1 µM 
SD-208: For cell counts of RAV24 P24_9 and P24_10 (A), of RAV24 P10_5 and P10_7 (B) and of RAV27 P18_5 
and P18_6 (C), the numbers of viable cells are shown in grey. Accordingly, significant differences between 
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proliferation with treatment and at medium control conditions are marked with grey stars. Absolute numbers of 
dead cells are shaded black. Significant differences between the fraction of dead cells in any treated well 
compared to the fraction of dead cells at medium control conditions are marked with black stars. In (D), 
proliferation relative to the medium control from a crystal violet assay is shown for RAV24 P10_7. Here, the 
amount of viable cells was determined, only. 
Compared to proneural TCs, mesenchymal TCs exhibited higher 48 h proliferation rates with 
an average number of 200.000 cells/well for RAV21 and RAV24 and approximately 400.000 
cells/well for RAV27. SD-208 did not influence proliferation significantly. TGF-β2, decreased 
proliferation of all mesenchymal TCs: In RAV21 TCs proliferation dropped to 0.40 
(p < 0.0001) and in a crystal violet staining performed with RAV24 P10_7 it decreased to 
0.85 (p < 0.02). The fraction of dead cells significantly increased in all mesenchymal TCs: 
For RAV21 TCs, it rose by 42% (p < 0.03), for RAV24 TCs by 23% (p < 0.0003) and for 
RAV27 TCs by 28% (p < 0.009). Thus, TGF-β2's effect on mesenchymal TCs's proliferation 
was cytotoxic.   
Migratory rates of mesenchymal TCs under treatment with 10 ng/ml TGF-β2 and 1 µM 
SD-208 were investigated in spheroid migration assays.  
 
 
 
Figure 37: Relative increase of spheroid area for mesenchymal TCs RAV21 P24_9 and P24_10 (A), RAV24 
P10_5 and P10_7 (B) and RAV27 P18_5 and P18_6 (C) after 48 hs of treatment with 10 ng/ml TGF-β2 or 
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with 1 µM SD-208:  Spheroid sizes were measured after 20 and 48 hs. Migration was normalized in two steps: 
Values of each time point were normalized to initial spheroid size, followed by normalization to the medium 
control. For reasons of clarity, significances are only marked for the end point of 48 hs. Preferably, values for SD-
208 were compared to those of the DMSO control to investigate significance (symbol: #); yet, where DMSO 
controls were missing, values for SD-208 were compared to the medium control (symbol: *). 
Migratory rates within the group of mesenchymal TCs varied. At 48 hs, a spheroid of RAV24 
TCs had an average of 7 times the initial size, a spheroid of RAV21 TCs was at 
approximately 10 times the initial size, and a spheroid of RAV27 TCs measured about 
60 times the initial size. SD-208 increased migration; yet, only the 36% increase of RAV24 
TCs' migration rate was significant. TGF-β2 decreased migration; RAV21 TCs' migratory 
rates were reduced by 30% (p < 0.0009), those of RAV24 TCs by 20% (non-significant) and 
those of RAV27 TCs by 23% (p < 0.0001). Combinations of 10 ng/ml TGF-β2 and 1 µM 
SD-208 resulted in migratory rates that were approximately equal to those of the DMSO 
control except in RAV27 TCs. Here, migration after individual SD-208 treatement was at 1.12 
(p < 0.0001) and after treatment with TGF-β2 + SD-208 it equaled 1.13 (p < 0.007).  
Thus, mesenchymal GBM cell lines RAV21, RAV24 and RAV27 formed a homogeneous 
group which was highly susceptible to the anti-proliferative and anti-migratory effects of 
TGF-β2.   
 
5.3 The functional effects of metformin and TGF-β2 on GBM cells 
Having examined the effects of low and high doses of metformin as well as of 10 ng/ml 
TGF-β2 individually, the third aim was to investigate if the effects of metformin and TGF-β2 
are functionally linked.  
5.3.1 Metformin and TGF-β2 were anti-proliferative and anti-migratory 
To determine the overall effects of metformin and TGF-β2 on proliferation and migration of 
GBM cells, relative proliferation rates from 20 experiments with 10 different cell lines were 
summed up. 
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Figure 38: Relative proliferation rates of all cell lines after 48 hs of treatment: After cell count of viable cells, 
each value was divided by the average of the medium control to normalize proliferation. 
Both, 10 mM metformin and 10 ng/ml TGF-β2, decreased proliferation. While 10 mM 
metformin reduced proliferation to 0.54 (p < 0.0001), TGF-β2 reduced it to 0.85 (p < 0.03). 
When GBM cells were treated with TGF-β2 and 0.01 mM metformin in triple treatment, 
proliferation equaled 0.79. The anti-proliferative effects of TGF-β2 + 0.01 mM metformin 
seemed largely due to the action of TGF-β2. The combination of TGF-β2 and 10 mM 
metformin reduced proliferation significantly more than both agents administered individually. 
Combined treatment reduced proliferation to 0.40 (p < 0.0001).  
The results for spheroid migration assays are summed up in Figure 39.  
  
Figure 39: Relative migratory rates for all cell lines after 20 and after 48 hs of treatment: Values for all cell 
lines were normalized to initial spheroid size and to relative migratory rates of the medium control.  
Firstly, 10 mM metformin inhibited migration which was at 0.76 after 20 hs (p < 0.0001) and 
at 0.60 after 48 hs (p < 0.0001). Also, TGF-β2 diminished spheroid migration to 0.90 at 20 hs 
(p < 0.0002) and to 0.84 after 48 hs (p < 0.0001). The combination of 10 mM metformin and 
10 ng/ml TGF-β2 decreased migration to 0.65 at 20 hs (p < 0.0001) and to 0.50 at 48 hs 
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(p < 0.0001). The anti-migratory effects of the combination were significantly more 
pronounced than 10 mM metformin’s and TGF-β2’s individual effects.  
Metformin and TGF-β2 reduced proliferation and migration of GBM cells. When combined, 
their anti-proliferative and anti-migratory effects were greater than those of the individual 
agents.  
 
5.3.2 The combination of 10 mM metformin and 10 ng/ml TGF-β2 reduced 
proliferation and migration especially in mesenchymal cell lines 
The anti-proliferative and anti-migratory effects of the combination of metformin and TGF-β2 
were different for each group of cells. The groups comprised proneural BTICs RAV19 and 
RAV57, mesenchymal BTICs RAV21, RAV24 and RAV27, proneural TCs RAV19 and 
RAV57 and mesenchymal TCs RAV21, RAV24 and RAV27.  
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Figure 40: Cell counts after a 48 h treatment: The absolute numbers of viable cells per well of any condition 
were divided by the average number of viable cells in medium control wells to calculate proliferation rates 
normalized to control. 
The combination of 10 mM metformin and 10 ng/ml TGF-β2 reliably reduced proliferation 
rates of GBM cells. In proneural BTICs, this effect was likely due to their high sensitivity to 
metformin. Both, 10 mM metformin and the combination of 10 mM metformin and TGF-β2 
reduced proliferation by 58% (p < 0.0001 in both cases). The anti-proliferative effects of 
TGF-β2 itself and in combination with 0.01 mM metformin in triple treatment were 
suggestively significant: Proliferation was decreased to 0.81 (p = 0.054) and 0.79 (p = 0.055) 
respectively. TGF-β2 did neither increase nor decrease the anti-proliferative effects of 
0.01 mM metformin in triple re-treatment. In proneural TCs, the addition of 10 ng/ml TGF-β2 
enhanced the effects of 10 mM metformin: 10 mM metformin did not reduce proliferation in 
proneural TCs, but the combination of 10 mM metformin and TGF-β2 decreased it to 0.71 
(p < 0.01).  
Mesenchymal BTICs and TCs resembled each other: In both, the anti-proliferative effects of 
10 mM metformin and TGF-β2 were more pronounced than those of the individual 
treatments. In mesenchymal BTICs, 10 mM metformin reduced proliferation by 31% 
(p < 0.002), TGF-β2 by 16% (non-significant) and their combination by 53% (p < 0.0001). 
Similarly, proliferation rates of mesenchymal TCs declined by 76% due to 10 mM metformin 
(p < 0.0001), by 29% for 10 ng/ml TGF-β2 (p < 0.03) and by 89 % when the two substances 
were combined (p < 0.0001).  
In summary, the effects of the combination treatment were different for each group. In 
proneural BTICs, the anti-proliferative effects of 10 mM metformin and the combination 
treatment were very similar, in proneural TCs, only the combination treatment decreased 
proliferation, and in mesenchymal BTICs and TCs, the anti-proliferative effects of 10 mM 
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metformin and TGF-β2 in combination were more pronounced than those of the individual 
agents.  
Having explored the reaction patterns of different groups of GBM cells regarding proliferation, 
the upcoming section will examine alterations in migration.  
 
 
 
  
  
Figure 41: Relative migratory rates after 20 hs of treatment: Values for all cell lines were normalized to initial 
spheroid size and to relative migratory rates of the medium control and finally summed up in the four groups.  
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Figure 42: Relative migratory rates after 48 hs of treatment: Values for all cell lines were normalized to initial 
spheroid size and to relative migratory rates of the medium control and finally summed up in the four groups. 
In proneural BTICs, 10 mM metformin but not TGF-β2 diminished migration. Consequently, 
combined treatment did not decrease migration to a significantly greater extent than 10 mM 
metformin (5% difference after 20 hs and 7% difference after 48 hs).  
For proneural TCs, TGF-β2 showed no significant influence on migration after 20 h or 48 hs. 
At 20 hs, there was no difference between the anti-migratory effects of 10 mM metformin or 
its combination with TGF-β2 (0.62 vs 0.61, p < 0.0001 in both cases). After 48 hs, 10 mM 
metformin reduced migration to 0.53 and the combination to 0.46 (p < 0.0001 in both cases), 
but the difference was not significant. Therefore, the effects seemed largely due to 
metformin's action.  
For mesenchymal BTICs, the combination treatment decreased migration significantly more 
than the individual treatments. After 20 hs, mesenchymal BTICs' migratory rate compared to 
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the medium control was at 0.89 under 10 mM metformin (p < 0.004), at 0.79 under TGF-β2 
(p < 0.0001), and at 0.62 under combined treatment (p < 0.0001). Similarly, after 48 hs, 
mesenchymal BTICs' migration was reduced to 0.80 under 10 mM metformin, to 0.65 under 
TGF-β2 and to 0.56 under combined treatment (p < 0.0001 in all cases).  
Mesenchymal TCs resembled their stem-like counterparts especially at the 20 h time point. 
After 20 hs, 10 mM metformin reduced migration to 0.70 (p < 0.0001), TGF-β2 to 0.89 
(p < 0.02) and their combination to 0.63 (p < 0.0001) compared to the medium control. The 
anti-migratory effects of the combination of 10 mM metformin and 10 ng/ml TGF-β2 were 
greater than those of the single treatments. After 48 hs, 10 mM metformin diminished 
migration to a similar extent compared to the combined treatment: 10 mM metformin yielded 
a decline to 0.60, TGF-β2 to 0.76 and in combination, they produced a decline to 0.52 
(p < 0.0001 in all cases).  
Table 21 gives an overview of the anti-proliferative and anti-migratory effects of metformin, 
TGF-β2 and their combinations.  
Table 21: Review of the anti-proliferative and anti-migratory effects of metformin, TGF-β2 and their 
combinations after 48 hs of treatment: The left column of each group (dark grey) shows how strongly 
proliferation was reduced. The right column shaded in light grey depicts contraction of migration at the 48 h time 
point. Blank spaces signify that there is not data for these conditions. Only significant results are shown. Symbols 
indicate the following: - indicates that proliferation/migration is reduced by up to 25%, - - by 25-50%, - - -  by 50-
75% and - - - - by more than 75%. 
 
Pro BTICs 
  Prolif.          Migra. 
Mes BTICs 
  Prolif.          Migra. 
Pro TCs 
  Prolif.          Migra. 
Mes TCs 
  Prolif.          Migra. 
0.01 mMx3 metf. - -        
10 mM metformin - - - - - - - - -  - - - - - - - - 
10 ng/ml TGF-β2    - -   - - - 
TGF-β2+0.01 mMx3   -    - -  
TGF-β2+10 mM - - - - - - - - - - - - - - - - - - - - - - 
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5.3.3 Unique cellular reaction patterns to the combination of TGF-β2 and 
metformin 
This section examines the effects of the combination of 10 mM metformin and TGF-β2 on an 
individual cell line level. Pictures of spheroid migration assays will be shown exemplarily 
together with close-up shots to investigate morphological changes after treatment.  
5.3.3.1 Detailed analysis of proneural BTICs RAV19 and RAV57 
Cell counts and spheroid migration assays were performed with RAV19 P25 and P26 and 
RAV57 P16 and P18. 
  
Figure 43: Total cell number per well obtained after 48 hs treatment: For cell counts of RAV19 P25 and P26 
(A) and of RAV57 P16 and P18 (B), the numbers of viable cells are shown in grey. Accordingly, significant 
differences between proliferation with treatment and at medium control conditions are marked with grey stars. 
Absolute numbers of dead cells are shaded black. Significant differences between the fraction of dead cells in any 
treated well compared to the fraction of dead cells at medium control conditions are marked with black stars. 
RAV19 BTICs' proliferation was reduced to 0.54 by 10 mM metformin (p < 0.03) and to 0.53 
by the combination of 10 mM metformin and TGF-β2. Thus, the anti-proliferative effect was 
likely due to metformin.  
Similar results were obtained for RAV57 BTICs. The proliferation reduction of 10 mM 
metformin to 0.29 (p < 0.0004) was virtually equal to that of the combination of 10 mM 
metformin and 10 ng/ml TGF-β2 (0.32; p < 0.0004). Thus, proneural BTICs were highly 
susceptible to metformin, but TGF-β2 left their proliferation largely unaffected.  
For spheroid migration, pictures of RAV57 BTICs are shown exemplarily.  
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Both, 10 mM metformin and its combination with TGF-β2 inhibited spheroid migration. Under 
TGF-β2, RAV57 BTICs migrated at approximately the same rate as in the medium control. 
Figure 45 outlines the results of spheroid migration assays.  
 
 
 
 
 
 
Figure 44: Spheroid migration of RAV57 BTICs: Pictures were taken 0, 20 and 48 hs after treatment with 
metformin, TGF-β2 and their combination at 5x magnification.  
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Figure 45: Relative increase of spheroid area of proneural BTICs RAV19 P25 and P26 (A) and RAV57 P16 
and P18 (B):  Spheroid sizes were measured after 20 and 48 hs. Migration was normalized in two steps: Values 
of each time point were normalized to initial spheroid size, followed by normalization to the medium control. For 
reasons of clarity, significances are only marked for the end point of 48 hs. 
Spheroid migration of RAV19 and of RAV57 remained mostly unaffected by TGF-β2. While 
48 h treatment with 10 mM metformin decreased migration to 0.43 in RAV19 (p < 0.0001) 
and to 0.33 in RAV57 (p < 0.0001), the effects of combined treatment differed. The 
combination reduced migration of RAV19 BTICs to 0.60 (p < 0.0002) and that of RAV57 
BTICs to to 0.29 (p < 0.0001).  
Finally, the effects of 10 mM metformin, TGF-β2 and the combination thereof on cell 
morphology are examined in Figure 46.  
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Figure 46: Spheroid photographs of RAV19 BTICs after 48 hs at 10x magnification: Medium control (A), 10 
mM metformin (B), 10 ng/ml TGF-β2 (C) and the combination of 10 mM metformin and 10 ng/ml TGF-β2 (D).  
When 10 mM metformin was present in a well (B), cell morphology changed as cells 
appeared to be more spherical compared to the medium control (A) where cells appeared 
spindle-shaped. Spindle-shaped cell morphology was also seen in TGF-β2 treated wells (C). 
When closely examining wells treated with the combination of 10 mM metformin and TGF-β2 
(D) it seems as if BTICs exhibit more protrusions than in metformin treated wells (B) hinting 
that possibly, the addition of TGF-β2 attenuated not only the effects of 10 mM metformin on 
migration but also on cell morphology.  
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5.3.3.2 Detailed analysis of mesenchymal BTICs RAV21, RAV24 and RAV27 
To investigate proliferation, cell counts were carried out with RAV21 P19, RAV24 P12 and 
P14 and RAV27 P16 and P20 and a crystal violet staining was performed with RAV24.  
  
  
Figure 47: Total cell number per well obtained after 48 hs treatment: For cell counts of RAV21 P19 (A), of 
RAV24 P12 and P14 (B) and of RAV27 P16 and P20 (C), the numbers of viable cells are shown in grey. 
Accordingly, significant differences between proliferation with treatment and at medium control conditions are 
marked with grey stars. Absolute numbers of dead cells are shaded black. Significant differences between the 
fraction of dead cells in any treated well compared to the fraction of dead cells at medium control conditions are 
marked with black stars. (D) depicts results of a crystal violet staining assay performed with RAV24 BTICs. 
Values were normalized to control.  
Among mesenchymal cell lines, reaction patterns to the combination of metformin and 
TGF-β2 were heterogeneous. Concerning RAV21 P19, the effects of combined metformin 
and TGF-β2 were more pronounced as proliferation was reduced to 0.84 by 0.01 mM 
metformin with triple re-treatment (non-significant), to 0.38 by TGF-β2 (p < 0.03) but to 0.14 
(p < 0.02) when both substances were present. Similarly, 10 mM metformin reduced 
proliferation to 0.53 (p < 0.05), and the combination with TGF-β2 decreased it to 0.08 
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(p < 0.02). Therefore, anti-proliferative effects on RAV21 P19 of combined treatment were 
greater than single applications' effects of low and high doses of metformin. TGF-β2 + 
0.01 mM metformin x3's fraction of dead cells was 1.66 times as large as the medium 
control's (p < 0.05) suggesting cytotoxicity. The combination treatment of TGF-β2 + 10 mM 
metformin decreased proliferation by 83% (p < 0.02), revealing cytostatic properties.  
RAV24, non-responsive to individual treatment with metformin or TGF-β2, reacted to the 
combination. It reduced migration to 0.63 (p < 0.003) in cell counts (B), a result which was 
supported by a crystal violet staining assay (D) in which proliferation was diminished to 0.80 
by combined metformin and TGF-β2 (p < 0.05).  
In RAV27, a rapidly proliferating mesenchymal cell line, two major trends were observed. 
Firstly, the fraction of dead cells compared to the medium control was 2.65 times larger 
under 10 mM metformin (p < 0.05), 1.76 times larger under 10 ng/ml TGF-β2 (p < 0.02) and 
2.59 times larger under combined treatment (p < 0.02). Hence, all three conditions appeared 
cytotoxic. Secondly, proliferation reduction was likely due to metformin, because both, 10 
mM metformin and combined treatment approximately halved proliferation (p < 0.003; 
p < 0.0007), but TGF-β2 by itself did not alter proliferation rates significantly.  
In summary, the anti-proliferative effects of combined metformin and TGF-β2 were more 
pronounced in RAV21; in RAV24, only their combination resulted in a proliferation decrease; 
and in RAV27, proliferation rate reduction was likely due to metformin.    
To investigate migration, spheroid migration assays were performed. Figure 48 depicts 
migration photographs of RAV24 BTICs exemplarily.  
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Judging from the photographs, 10 mM metformin, 10 ng/ml TGF-β2 and the combination 
thereof impaired migration of RAV24 BTICs to a similar extent. The following figure displays 
the results from quantitative assessment of migratory rates of RAV21, RAV24 and RAV27 
BTICs.  
 
 
 
 
 
Figure 48: Spheroid migration of RAV24 BTICs: Pictures were taken 0, 20 and 48 hs after treatment with 
metformin, TGF-β2 and their combination at 5x magnification. 
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Figure 49: Relative increase of spheroid area of mesenchymal BTICs RAV21 P17 and P24 (A), RAV24 P12 
and P14 (B) and RAV27 P16 and P20 (C):  Spheroid sizes were measured after 20 and 48 hs. Migration was 
normalized in two steps: Values of each time point were normalized to initial spheroid size, followed by 
normalization to the medium control. For reasons of clarity, significances are only marked for the end point of 48 
hs. 
After 48 hs, 10 mM metformin as well as TGF-β2 reduced migration of RAV21 BTICs to 0.83 
(p < 0.02, p < 0.009), and to 0.70 by their combination (p < 0.0001). The anti-migratory 
effects of the combination were more pronounced than those of the individual agents.  
The migratory rates of RAV24 BTICs after 48 hs were reduced to 0.58 by 10 mM metformin, 
to 0.45 by TGF-β2 and to 0.38 by their combination (p < 0.0001 in all cases) whereas 
proliferation was only influenced by the combined treatment.  
RAV27 BTICs' migration was not influenced by metformin while 10 ng/ml TGF-β2 decreased 
migration after 48 hs to 0.70 by itself (p < 0.0001) and to 0.64 when combined with 10 mM 
metformin (p < 0.0001).    
To conclude, RAV21 displayed vast sensitivity to anti-proliferative and anti-migratory effects 
of combined 10 mM metformin and 10 ng/ml TGF-β2. In RAV24, proliferation was only 
reduced by their combination, but migration was impaired under all three conditions. RAV27's 
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proliferation was diminished by metformin, but not by TGF-β2; yet, TGF-β2 lowered migration. 
Overall, the anti-proliferative and anti-migratory effects of the combination treatment were 
most pronounced.  
How the agents by themselves and in combination influenced cell morphology after 105 hs is 
exemplarily shown for RAV24 BTIC. 
  
  
Figure 50: Spheroid photographs of RAV24 BTICs after 105 hs at 10x magnification: Medium control (A), 10 
mM metformin (B), 10 ng/ml TGF-β2 (C) and the combination of 10mM metformin and 10ng/ml TGF-β2 (D). 
RAV24 BTICs changed to a more spherical shape under 10 mM metformin (B). TGF-β2 did 
not attenuate these effects (D). Thus, morphological changes align well with results from 
functional assays as the combination treatment produced the largest anti-proliferative, anti-
migratory and cell morphology changing effects.  
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5.3.3.3 Detailed analysis of proneural TCs RAV19 and RAV57 
Proliferation was assessed in cell counts with RAV19 P23_3 and P23_6 and RAV57 P17_2 
and P20_3. 
  
Figure 51: Total cell number per well obtained after 48 hs treatment: For cell counts of RAV19 P25 and P26 
(A) and of RAV57 P16 and P18 (B) the numbers of viable cells are shown in grey. Accordingly, significant 
differences between proliferation with treatment and at medium control conditions are marked with grey stars. 
Absolute numbers of dead cells are shaded black. Significant differences between the fraction of dead cells in any 
treated well compared to the fraction of dead cells at medium control conditions are marked with black stars. 
Neither RAV19 nor RAV57 TCs reacted much to any given substance. In RAV57, only 
10 ng/ml TGF-β2 + 10 mM metformin decreased proliferation to 0.55 (p < 0.002).  
Figure 52 illustrates migratory behavior of RAV19 TCs at 0, 20 and 48 hs.  
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Here, the anti-migratory effects of 10 mM metformin on RAV19 TCs become apparent. Even 
at 5x magnification, morphological changes can be detected which will be further illustrated 
by Figure 54. However, 10 ng/ml TGF-β2's effects were not anti-migratory which will be 
further assessed in Figure 53.   
 
 
 
 
 
Figure 52: Spheroid migration of RAV19 TCs: Pictures were taken 0, 20 and 48 hs after treatment with 
metformin, TGF-β2 and their combination at 5x magnification. 
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Figure 53: Relative increase of spheroid area of proneural TCs RAV19 P23_3 and P23_6 (A) and RAV57 
P17_2 and P20_3:  Spheroid sizes were measured after 20 and 48 hs. Migration was normalized in two steps: 
Values of each time point were normalized to initial spheroid size, followed by normalization to the medium 
control. For reasons of clarity, significances are only marked for the end point of 48 hs. 
As Figure 52 suggested, anti-migratory effects were observed in RAV19 BTICs under 10 mM 
metformin treatment. After 48 hs, migration was reduced to 0.32 by 10 mM metformin 
(p < 0.0001) and to 0.36 in combination with 10 ng/ml TGF-β2 (p < 0.0001), even though 
10 ng/ml TGF-β2 increased migration to 1.41 (p < 0.0001). Thus, the anti-migratory effects 
obtained by the combined treatment were likely due to metformin.  
After 48 hs, migration of RAV57 was lowered to 0.73 by 10 mM metformin (p < 0.0002), to 
0.76 by 10 ng/ml TGF-β2 (p < 0.0002) and to 0.56 by their combination (p < 0.0001). In this 
case, the anti-migratory effects of metformin and TGF-β2 were greater than for single agents.  
Figure 54 displays morphological changes in RAV19 TCs induced by 120 hs of treatment 
with high dose metformin. 
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Figure 54: Spheroid photographs of RAV19 TCs after 120 hs at 10x magnification: Medium control (A), 10 
mM metformin (B), 10 ng/ml TGF-β2 (C) and the combination of 10 mM metformin and 10 ng/ml TGF-β2 (D). 
Compared to tumor cells rich in protrusions as seen in medium control wells (A) and TGF-β2 
treated wells (C), tumor cells in metformin treated wells 10 mM metformin (B and D) lost 
almost all of their protrusions and adopted a spherical shape. Morphological changes are 
thus in line with results from functional assays.  
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5.3.3.4 Detailed analysis of mesenchymal TCs RAV21, RAV24 and RAV27 
In proliferation assays, RAV21 P24_9 and P24_10 were used along with RAV24 P10_5 and 
P10_7 as well as RAV27 P18_5 and P18_6.  
 
 
Figure 55: Total cell number per well obtained after 48 hs treatment: For cell counts of RAV21 P24_9 and 
24_10 (A), of RAV24 P10_5 and P10_7 (B) and of RAV27 P18_5 and P18_6 (C), the numbers of viable cells are 
shown in grey. Accordingly, significant differences between proliferation with treatment and at medium control 
conditions are marked with grey stars. Absolute numbers of dead cells are shaded black. Significant differences 
between the fraction of dead cells in any treated well compared to the fraction of dead cells at medium control 
conditions are marked with black stars. (D) depicts proliferation normalized to non-treated controls.  
Mesenchymal TCs reacted to metformin and to TGF-β2. RAV21's proliferation rates 
decreased to 0.51 under 10 mM metformin (p < 0.03), to 0.4 under 10 ng/ml TGF-β2, to 0.38 
under TGF-β2 + 0.01 mM metformin with triple re-treatment and to 0.14 under the combined 
treatment of 10 mM metformin and 10 ng/ml TGF-β2 (p < 0.0001 in the latter three 
instances). Thereby, the effects of combined treatment were suggestively significant when 
comparing effects of 10 ng/ml TGF-β2 + 10 mM metformin to those of 10 mM metformin 
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p < 0.002 and to those of TGF-β2 p = 0.069). Also, TGF-β2 increased the fraction of dead 
cells 2.35-fold compared to the medium control (p < 0.03).  
RAV24's proliferation was diminished by 90% through 10 mM metformin and by 92% through 
combined treatment (p < 0.001 in both cases). These effects appeared cytotoxic as the 
fraction of dead cells multiplied times 7 in both cases (p < 0.001). The effects of TGF-β2 by 
itself and in combination with 0.01 mM metformin triple treatment were also cytotoxic with the 
fraction of dead cells approximately tripling (p < 0.0003 in both cases); yet their ability to 
reduce proliferation was not significant. A crystal violet staining assay underlined these 
trends. Here, proliferation was reduced to 0.77 by 10 mM metformin (p < 0.004), to 0.90 by 
TGF-β2 (p < 0.05), to 0.69 by TGF-β2 + 0.01 mM metformin x3 (p < 0.003) and to 0.49 by 
TGF-β2 + 10 mM metformin (p < 0.0001). Thus, the effects of the combination of metformin 
and TGF-β2 were more pronounced than those of single agents for low and high doses.  
Proliferation of RAV27 was reduced by high-dose metformin and its combination with 
TGF-β2. It was decreased by 90% by 10 mM metformin (p < 0.0003), by 34% through TGF-β2 
(non significant), by 54% through TGF-β2 + 0.01 mM x3 (p < 0.002) and by 92% by TGF-β2 + 
10 mM metformin (p < 0.0003). Under all of these conditions the fraction of dead cells was 
significantly larger than in the medium control. It tripled for 10 mM metformin or TGF-β2 + 10 
mM metformin treatment (p < 0.0003 in both cases) and it doubled under treatment with 
TGF-β2 or TGF-β2 + 0.01 mM metformin x3 (p < 0.009 in both cases).  
Concluding, TGF-β2's effects were cytotoxic to mesenchymal TCs RAV21, RAV24 and 
RAV27. The combination of TGF-β2 and 10 mM metformin consistently decreased 
proliferation.  
To compare these findings to spheroid migration, Figures 56 and 57 give an overview.  
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From photographs presented in Figure 56, it seems that migration of RAV27 TCs was 
inhibited mostly by the combination of 10 mM metformin and TGF-β2. Quantitative results are 
outlined in Figure 57.  
 
 
 
 
 
 
Figure 56: Spheroid migration of RAV27 TCs: Pictures were taken 0, 20 and 48 hs after treatment with 
metformin, TGF-β2 and their combination at 5x magnification. 
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Figure 57: Relative increase of spheroid area of mesenchymal TCs RAV21 P24_9 an P24_10 (A), RAV24 
P10_5 and P10_7 (B) and RAV27 P18_5 and P18_6 (C):  Spheroid sizes were measured after 20 and 48 hs. 
Migration was normalized in two steps: Values of each time point were normalized to initial spheroid size, followed 
by normalization to the medium control. For reasons of clarity, significances are only marked for the end point of 
48 hs. 
Migration of RAV21 after 48 hs was lowered by metformin, TGF-β2 and combinations thereof 
and the effects were comparable (A). 10 mM metformin lowered migration to 0.73 (p < 0.02), 
TGF-β2 to 0.71 (p < 0.0009) and their combination to 0.69 (p < 0.0005).  
Migratory rate reduction in RAV24 after 48 hs was likely due to 10 mM metformin. Migration 
was decreased to 0.3 by 10 mM metformin (p < 0.0001), to 0.8 by 10 ng/ml TGF-β2 (non-
significant) and to 0.32 by their combination.  
TGF-β2 reduced migration of RAV27 TCs to 0.77 (p < 0.0001), 10 mM metformin reduced 
migration to 0.79 (p < 0.0001).  
Hence, the combination of TGF-β2 and 10 mM metformin consistently decreased migration. 
Reaction patterns ranged from equal anti-migratory power of TGF-β2
 and metformin in 
RAV21 TCs, over no significant effect of TGF-β2 but vast decrease through 10 mM metformin 
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in RAV24 TCs to pronounced anti-migratory effects in RAV27 TCs. These three 
mesenchymal TC lines showed heterogeneous reaction patterns.  
Pictures taken of RAV21 TCs serve as an example to show how metformin and TGF-β2 
influenced cell morphology.  
  
  
Figure 58: Spheroid photographs of RAV21 TCs after 48 hs at 10-fold magnification: Medium control (A), 10 
mM metformin (B), 10 ng/ml TGF-β2 (C) and the combination of 10 mM metformin and 10 ng/ml TGF-β2 (D). 
As outlined in Figure 58, 10 mM metformin (B) resulted in discrete cell swelling. The 
presence of TGF-β2 led to cell free areas immediately next to the initial spheroid into which 
only few cells migrated.  
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5.4 Synopsis of the functional effects of metformin, TGF-β2 and SD-208 
Table 22 summarizes all significant changes in proliferation and migration of all cell lines and 
for all conditions at the 48 h time point.  
Table 22: Summary of all treatment conditions and their effects on proliferation and migration of all cell 
lines after 48 h: Proliferation (dark grey) and migration (light grey) are depitcted after 48 h. Blank spaces signify 
that there is not data for these conditions. Only significant results are shown. Symbols indicate the following: - 
indicates that proliferation/migration is reduced by up to 25%, - - by 25-50%, - - -  by 50-75% and - - - - by more 
than 75%. Accordingly, + indicates a proliferation / migration increase by up to 25% and ++ by up to 50%. 
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Apart from effects on proliferation and migration, changes in morphology were also 
observed. They were exemplarily shown for RAV19 BTICs, RAV24 BTICs, RAV19 TCs and 
RAV 21 TCs as they best exemplified group trends and had the best picture quality. Changes 
in morphology can be summed up as follows: 
 10 mM metformin:  
o spherical, non-spindle like, smaller: RAV19 BTICs, RAV24 BTIC  
o small, irregular, no protrusions: RAV19 TCs  
o bigger, less spindle-like: RAV21 TCs. 
 10 ng/ml TGF-β2:  
o unaltered compared to control: RAV19 BTICs, RAV19 TCs,  
o less spindle-like: RAV24 BTICs  
o lower density and cell free areas: RAV21 TCs.  
 10 mM metformin + 10 ng/ml TGF-β2:  
o effects cancel out RAV19 BTICs 
o more spherical and smaller than after 10 mM metformin: RAV24 BTICs 
o equal morphology compared to metformin-treated cells: RAV19 TCs  
o bigger, less spindle-like and cell free areas: RAV21 TCs. 
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6 DISCUSSION 
 
Proliferation and migration are two of the main tumor characteristics of GBM. Both are 
influenced by TGF-β2, which has been described as a tumor suppressor and tumor promotor 
in glioma, and by metformin, a potential anti-glioma drug. While previous data on TGF-β2's 
effects on glioma is heterogenous showing increased, decreased and steady proliferation 
rates (see Table 23) and possibly reduced migratory rates, data concerning metformin (see 
Table 2) more consistently indicates that overall, metformin reduces proliferation and 
migration of GBM in vitro. This study aimed to investigate functional effects of the two agents 
on primary tumor cells obtained in brain surgery at the University Hospital Regensburg and 
uncovering possible links.   
 
6.1 The role of metformin in GBM 
Several researchers have explored metformin's effects on GBM's proliferation and migration. 
Mostly, doses of 10 mM and higher were used, because Würth et al. (2013) calculated the 
IC50 for metformin at approximately 10 mM. Lower doses often failed to produce an effect 
(see Table 2). However, doses as high as 10 mM seem hardly achievable in the human 
brain, so this study explored whether 10 mM consistently reduces proliferation and migration 
and whether lower doses are effective in some GBM cell lines as well.  
In this study, 10 mM metformin decreased proliferation by 46% or, on an individual level, in 
7 / 10 cases. Looking at proliferation inhibition in detail, cytostatic and cytotoxic effects were 
identified. High-dose metformin (10 mM) was cytostatic in 3 / 7 cases and revealed its 
cytotoxic properties in 4 / 7 cases, meaning that the amount of dead cells in metformin 
treated wells significantly exceeded the amount of dead cells in control wells. No effects on 
proliferation were observed in 3 / 10 cases. These results align with pertinent literature. 
Würth et al. (2013), Gao et al. (2013), Liu et al. (2014) and Sesen et al. (2015) observed 
proliferation reduction after treatment with 10 mM metformin. Ferla et al. (2012) observed a 
dose-dependent proliferation reduction between 2 and 16 mM metformin treatment. Sesen et 
al. (2015) established a timeline of cytotoxicity. After 12 hs, the earliest cell cycle arrests 
could be detected, and after 48 hs consistent cell death can be found. Thus, 48 hs generally 
seems to be acceptable to investigate alterations in proliferation. Liu et al. (2014) also 
observed cytostatic effects in the three cell lines examined while Isakovic et al. (2007) and 
Sesen et al. (2015) describe apoptosis and autophagy.  
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Cytotoxic effects of metformin were described only for doses higher than 10 mM  (Würth et 
al. 2013). However, in this study, cytotoxic effects were observed at 10 mM metformin, 
suggesting that glioma cell lines considerably differ in their sensitivity to metformin. Two of 
the cases in which cytotoxic effects were observed, were in mesenchymal TC lines. Here, 
results from cell counts differed from a crystal violet assay. The observed difference between 
the amount of proliferation reduction in cell counts versus crystal violet staining could be due 
to different procedures. Cell counts involved several steps of scraping the cells off the well 
with a sterile cell scraper, washing them with PBS multiple times and pipetting them up and 
down to avoid the formation of lumps which would have distorted cell count results. These 
procedures were carried out identically for each cell line, but metformin may have weakened 
RAV24 and RAV27 TCs in a way that cell count procedures, especially pipetting, led to cell 
death. Figure 55 shows that the total amount of dead and viable cells was only slightly or 
moderately lower than that of the control wells after 10 mM metformin treatment supporting 
that RAV24 and RAV27 became fragile after metformin treatment and died during cell count 
procedures. In this case, the magnitude of proliferation decrease may be more accurately 
reflected by the crystal violet staining assay, as the procedures of staining and washing were 
more gentle. Determining whether 10 mM metformin was cytotoxic in mesenchymal TCs or 
whether effects were actually cytostatic but distorted by cell count procedures, remains 
difficult. Certainly, the amount of dead cells in mesenchymal TC cell counts impressively 
proves that metformin weakens GBM cells which might be why metformin increases 
sensitivity to irradiation treatment (Sesen et al. 2015).     
In 3 / 10 cases, cell lines did not respond to 10 mM metformin at all. One of the cell lines was 
RAV24 BTIC, a cell line which in general did not respond to metformin treatment neither in 
cell counts nor in a crystal violet staining assay. This leads to the assumption that either, 
doses were too low for an effect, treatment time was too short, or RAV24 BTIC simply resists 
metformin's action. The other two cell lines which did not respond to high-dose metformin 
treatment were RAV19 TC and RAV57 TC. As outlined in section 5.3.3.3, proneural TCs 
proliferation rates were 10-times slower than the average proliferation rate, making gauging 
alterations in proliferation after 48 hs difficult. Sesen et al. (2015) propose that some glioma 
cells, namely those with PTEN mutations, respond only after treatment times of 96 hs. Würth 
et al. (2010) observed maximum anti-proliferative effects after 72 h. Most likely, longer 
treatment duration is needed to accurately investigate metformin's anti-proliferative effects on 
slowly proliferating cell lines.  
Low doses of metformin yielded anti-proliferative results in only proneural BTICs. They 
reacted to doses as low as 0.01 mM metformin in triple re-treatment and the effect of 
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0.01 mM metformin in triple re-treatment was significantly more pronounced than that of 
0.01 mM metformin alone.  
Some caution is advisable regarding the results for RAV19 BTIC (see Figures 12 and 13). 
Their responsiveness to low dose metformin could have been because they grew in spheres, 
and in cell counts, spheres may distort results. The aggregation of cells leads to 
unrealistically high numbers in one count and unrealistically low numbers in another. To 
disintegrate spheres, RAV19 BTICs were pipetted up and down more extensively than other 
cell lines. The results for all conditions are in a similar range, as each condition had a total of 
six replicates. As standard deviation is small, the results are probably accurate despite 
RAV19 BTIC's spherical growth. This is especially interesting as spherical growth may 
impede metformin reaching cells located at the center of a sphere. Metformin's ability to 
decrease proliferation of a cell line growing spherically underlines its anti-glioma potential. 
Very low doses of metformin may exert anti-proliferative effects in certain glioma cell lines, 
while re-treatment may increase metformin's power. 
Metformin in a concentration of 0.01 mM (= 10 µM) may actually be reached in the brain of a 
human diabetic. Given that a concentration of 44 µM can be reached in rat brain tissue after 
3 weeks of 300 mg/kg metformin administered orally per day (Łabuzek et al. 2010) and that 
12 µM were measured in a mouse brain after oral administration of 50 mg/kg metformin 
(Wilcock and Bailey 1994), the metformin concentration in the brain of a 70 kg patient with an 
oral intake of 3000 mg metformin (which equals around 43 mg/kg) could be 10 µM. 
Therefore, if rat data is applicable to humans, 0.01 mM metformin may actually be achieved 
in human diabetics.  
Another way of calculating metformin concentrations in human brains considers plasma to 
brain ratios of metformin. In mice models, metformin concentration in the brain is about 10% 
of the plasma concentration (Kim et al. 2016). Studies of human patients show that the 
plasma concentration of metformin is commonly found between 8 and 31 µM (Menendez et 
al. 2014). Therefore, levels between 0.8 and 3.1 µM could be attained in human brain tissue. 
Now, the maximum daily intake of 3000 mg metformin was established as a safe dose for 
long-term diabetic treatment (Pollak 2013). Hence, clinical trials exploring maximum tolerable 
doses of metformin for cancer patients and using alternative administration routes (e.g. 
intraperitoneal administration) should be conducted (Menendez et al. 2014, Pollak et al. 
2013). The first study to explore tolerable doses is a phase I trial investigating doses of 
metformin and chloroquine in IDH1/2-mutant gliomas (NCT02496741). Alternatively, the use 
of phenformin, another biguanide exerting strong anti-neoplastic effects on BTICs, should be 
considered (Pollak et al. 2013, Jiang et al. 2016). As lactic acidosis was observed more often 
in phenformin treatment than in metformin treatment, phenformin is not used to treat diabetes 
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anymore (Jiang et al. 2016). However, Jiang et al. 2016 argue that only very low doses of 
phenformin are needed to treat GBM bearing mice rendering side effects less probable. In 
summary, the effects of low-dose metformin on proneural BTICs observed in this study set 
the rationale to explore more aggressive dosing of metformin or alternative application of 
phenformin.      
Looking at pooled data from all cell lines, migration was reliably reduced. After 20 hs, 10 mM 
metformin reduced migration by 34% and after 48 h by 40%. Looking at individual cell lines, 
migration was lowered in 9 / 10 cases. Overall, 1 mM metformin also reduced migration 
significantly after 20 h and after 48 h (10% and 20% respectively); yet individual analysis 
shows that this was true for only 2 / 10 cell lines. These results correspond well with other 
researchers' findings who report migration inhibition at different dosages: 0.3 - 3 mM (Gao et 
al. 2013), 2 - 16 mM metformin (Ferla et al. 2012) and 5 - 50 mM metformin (Würth et al. 
2013). However, Kim et al. (2016) found no migration reduction with 5 mM or 15 mM 
metformin. Of note, they did not examine proneural cell lines, but classic, mesenchymal and 
neural cell lines. Hence, susceptibility to metformin's anti-migratory effects seems to vary 
considerably among GBM.  
For any concentration of metformin given, proneural BTICs were more sensitive to 
metformin's anti-proliferative power than mesenchymal BTICs. Several factors may account 
for these differences. Firstly, proliferation rate and confluence levels influence the 
effectiveness of metformin. Isakovic et al. (2007) noted that 4 mM metformin induces cell 
cycle arrest in non-confluent cells but induces apoptosis in confluent cells. Thus, cells 
proliferating at a high rate, reaching confluence while being treated with metformin, may be 
affected more severely. The reverse was observed in proneural TCs proliferating 10-times 
slower than the rest and not responding to metformin.  
Secondly, the mutational background plays an important role as it affects the expression of 
regulatory and metabolic genes. Among proneural cells' characteristic mutations are idh-
mutations and PDGFRA alterations; p53 mutations are also found frequently (Verhaak et al. 
2010). According to Viollet et al. (2012) and Buzzai et al. (2007), colon cells with p53 
mutations are at a selective disadvantage when being treated with metformin, because 
metformin depletes energy levels leading to a metabolic shift that p53 (-/-) cells are unable to 
perform. Thus, proneural glioma cells carrying p53 mutations might be more responsive to 
metformin, because they are unable to react to metformin-induced energy depletion. Another 
predictor may be pten mutational status. Sesen et al. (2015) observed that GBM cells 
carrying pten wild-type are more sensitive to metformin, because 10 mM metformin reduces 
proliferation within 48 hs. PTEN mutated GBM cells' proliferation, on the other hand, is 
affected only after 96 hs. They explain that in PTEN wild type cells, Akt is not constitutively 
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active and may be inhibited by metformin whereas cells with pten mutations exhibit 
constitutive Akt activity which is not influenced by metformin treatment (Sesen et al. 2015). 
Thus, proneural cell lines' sensitivity to metformin may be due to their p53 (-/-) and/ or pten 
wt mutational status which would need to be confirmed for the cell lines used in this study.  
Thirdly, metabolic reactions reflected in oxygen consumption vary. Earlier this year, we were 
able to show that proneural BTICs RAV57 heavily rely on oxidative phosphorylation, while 
mesenchymal BTICs RAV27 did not to such an extent. Oxygen consumption of RAV57 was 
therefore reduced by 1 mM metformin and drastically impaired by 10 mM metformin while 
RAV27's respiration did not change after treatment with 1mM metformin (Seliger and Meyer 
et al. 2016). Correspondingly, mesenchymal cells rely more heavily on glycolysis than 
proneural cells (Mao et al. 2013). Overall, p53 and PTEN mutational status and also 
proneural subtype and reliance on oxidative phosphorylation (OXPHOS) may present 
valuable markers to predict GBM's sensitivity to metformin. The finding that proneural cells 
seem more sensitive to metformin is important, because Verhaak et al. (2010) noted that the 
proneural subtype does not respond to aggressive chemotherapy treatment whereas the 
mesenchymal subtype does. Additionally, Patel et al. (2014) found that proneural subsets of 
cells are present in all tumors of investigation regardless of their overall classification. Thus, 
metformin may present a drug to specifically target omnipresent chemotherapy-resistant 
proneural tumor cells.    
Proneural TCs were less sensitive to metformin than mesenchymal TCs. This result again 
might have been due to very slow proliferation of proneural TCs, making gauging 
proliferation after 48 hs nearly impossible. In a crystal violet staining assay, exemplarily 
performed for RAV57 TC, 10 mM metformin decreased proliferation suggesting that longer 
observation periods would help detect anti-proliferative effects in proneural TCs as well.  
Proneural TCs were also less sensitive to metformin's anti-proliferative effects than proneural 
BTICs. Another reason might be that the stem-cell like subset of tumor cells called BTICs 
relies on oxidative phosphorylation more than their differentiated counterparts (Janiszewska 
et al. 2012). As metformin targets oxidative phosphorylation by (partially) blocking complex I 
of the mitochondrial respiratory chain, this might explain why metformin selectively affects 
BTICs (Kim et al. 2016). Gritti et al. (2014) explain that the difference in sensitivity to 
metformin is due to differentiated expression of the ion channel CLIC1. The chloride ion 
channel is normally stored in the cytosol and is inserted into the plasma membrane during 
G1 phase preceding transition into S phase. The expression of CLIC1 is higher in BTICs than 
in TCs. Metformin specifically blocks CLIC1 in its open state, which traps GBM cells in their 
G1 phase, leading to apoptosis and reduced proliferation rates. Aldea et al. (2015) confirm 
metformin's selective cytotoxicity for cancer stem cells but not for differentiated cells. Würth 
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et al. (2013) ascribe BTICs' sensitivity to metformin to the fact that Akt inhibition is possible in 
these cells. On the contrary, Akt is continuously active in TCs thus rendering them resistant 
to metformin. In summary, BTICs seem more susceptible to metformin due to their reliance 
on OXPHOS, their high expression of CLIC1 and discontinuous Akt activation.  
Strikingly, differentiation of BTICs to TCs through the use of a different medium (DMEM + 
10% FCS instead of RHB-A + EGF + FGF) changed sensitivity to metformin. While proneural 
cells became less sensitive to 10 mM metformin after being differentiated in DMEM and FCS, 
mesenchymal cells became markedly more sensitive to 10 mM metformin. The seeming 
resistance to metformin of slowly proliferating proneural TCs was most likely due to a short 
observation interval.  
Concerning mesenchymal cell lines, glucose content of different media might account for the 
increase in sensitivity towards metformin upon differentiation. Analysis of glucose content of 
RHB-A in the lab group revealed that it contains 30 mM glucose while DMEM contains 
5.6 mM. Sato et al. (2012) found that the sensitivity to metformin depends on the availability 
of glucose. In their experiments they showed that lower concentrations of glucose (17.5 mM 
instead of 26 mM) help metformin activate AMPK and FOXO3 more effectively. Thus, 
metformin's anti-proliferative effects may have been stronger in mesenchymal TCs, because 
they were kept in 5.6 mM glucose instead of 30 mM. Except for Würth et al. (2013), all 
researchers examining the effects of metformin on glioma used DMEM supplemented with 
5-10% FCS as media (see Table 2). According to our laboratory standards, DMEM and 10% 
FCS is used as differentiating media, while serum-free and growth factor supplemented 
RHB-A is used to maintain stem cell properties. Therefore, only the results of Würth at al. 
(2013) describe metformin's effects on BTICs, while all other results would be describing 
effects on TCs. Examening media and cell lines when comparing results is important, 
because as shown for our cell lines, media may considerably change responses to different 
treatments. This is also true for tumor environment in vivo. As the tumor environment plays a 
very important role, cell media should imitate these conditions as realistically as possible. For 
future experiments with metformin or any other drug influencing tumor metabolism, careful 
attention should be paid to the selection of cell media, their glucose contents and 
supplements. Identical glucose concentrations should be used for BTICs and TCs to attain 
comparable results. Preferably, these concentrations should be low to better reflect in vivo 
conditions where glucose levels are at 0-3 mM in tumor tissue and 2-5 mM in healthy brain 
tissue (Markus et al. 2010). To maintain consistently low glucose concentrations without 
glucose depletion, a Nutrostat setup may be advisable (Birsoy et al. 2014). Fresh media with 
respective glucose concentration is added at the same rate as old media is removed without 
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cell loss (Birsoy et al. 2014). Nutrient concentrations in removed media may be measured to 
determine, among others, the rate of conversion of glucose into lactate (Birsoy et al. 2014).  
This study shows for the first time that low doses of metformin are able to lower proliferation 
of proneural BTICs. These concentrations may actually be achievable in brain tissues of 
GBM patients. Potential markers to predict susceptibility to metformin treatment may be p53 
and pten mutational status and proneural subtype. This study confirms the anti-proliferative 
and anti-migratory effects of 10 mM metformin on almost all GBM cell lines examined and 
shows that differences in reaction patterns may be predicted based on subtype. Proneural 
BTICs examined in this study appear sensitive to metformin while mesenchymal cells and 
TCs might be less sensitive. Investigation of further cell lines is needed to prove whether 
proneural subtype is a valid predictor for GBM's sensitivity to metformin. Then, metformin 
may present a drug to specifically target chemotherapy-resistant proneural cells as well as a 
drug that specifically targets BTICs, the cell subpopulation responsible for rapid tumor 
recurrence of GBM. However, further characterization of protein expression (CLIC1), 
signaling pathways (constitutive Akt activity), mutational background (p53, pten) and 
metabolic properties (reliance on oxidative phosphorylation) in used cell lines is needed to 
link functional results to molecular characteristics and identify reliable markers for sensitivity 
to metformin in patient treatment.    
 
6.2 The role of TGF-β2 in GBM 
The cytokine TGF-β2 has been found to exert multiple effects on GBM, namely induction of 
proliferation, migration and invasion, angiogenesis and immunosuppression (Platten et al. 
2001, Hau et al. 2006, Joseph et al. 2014). As TGF-β2 may act as a tumor promoter or 
inhibitor depending on tissue context, previous findings related to proliferation have been 
ambiguous (see Table 23) indicating an increase in proliferation in 22%, a decrease in 37% 
and no effects in 41% of the cases. Thus, the effects of TGF-β2 on proliferation seem difficult 
to predict. This study aimed at elucidating GBM's migratory and proliferative response to 
TGF-β2. TGF-β2 was used as it seems to be the most important isoform in glioma (Bruna et 
al. 2007, Aigner and Bogdahn 2008, Hau et al. 2011, Frei et al. 2015). More specifically, 
TGF-β2 and SD-208, a TGFR-I inhibitor, were used according to prior laboratory experience 
and pertinent literature (Uhl et al. 2004, Seliger and Meyer et al. 2016). As SD-208 was 
dissolved in DMSO, respective DMSO controls were used to calculate significance.  
Summarizing all data, TGF-β2 decreased proliferation by 15% (p < 0.02) compared to 
medium controls and SD-208 increased proliferation by 20% compared to DMSO controls 
(p < 0.005). TGF-β2 also decreased migration by 10% after 20 hs and by 16% after 48 hs 
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(p < 0.0002), but SD-208 treatment yielded no effect. Examined in more detail, TGF-β2 
inhibited proliferation in 2 / 10 cases. It reduced migration in 6 / 10 cases, in all three 
mesenchymal BTIC lines, in two mesenchymal TC lines and in one proneural TC line. Lastly, 
TGF-β2 increased migration in 1 / 10 cases, RAV19 TC. Its antagonist SD-208 increased 
proliferation in 2 / 10 cases, one proneural and one mesenchymal TC line, and migration in 
3 / 10 cases, one proneural and two mesenchymal TC lines, while it reduced migration in 
2 / 10 cases, one mesenchymal BTIC line and one proneural TC line. Of the seven cases 
where SD-208 showed an effect, four showed an opposite effect to TGF-β2, two cases 
exhibited no TGF-β2 effect and in one case the combination of SD-208 and TGF-β2 yielded 
the strongest migration inhibition (RAV27 BTIC).  
Comparing these results to pertinent literature reveals that they match only to a certain 
extent. Table 23 summarizes research on TGF-β2's effects on GBM cell proliferation. 
Table 23: The effects of TGF-β on proliferation of different glioma cells 
Study Human glioma cell 
lines 
Medium &      
Treatment 
Prol. ↑  Prol. ↓ Prol. = 
Rich et 
al. 1999 
U87, T98G, U373, 
D54, U251, D259, 
D270, D409, D423, 
D538, D566, D645 
Improved zinc option 
medium + 10% FCS 
TGF-β1 + TGF-β2 
2 / 12 6 / 12 4 / 12 
Piek et al. 
1999 
U-178 MG, U-343 MG, 
U-343 MGa 31L, U-
343 MGa 35L, U-251 
MGAgCl1, U-1242 MG 
DMEM + 5 % FCS +  
5% NCS 
TGF-β1 
2 / 6 2 / 6 2 / 6 
Bruna et 
al. 2007 
U87MG, U373MG, 
A172, T98G, hs683, 
U251, C3, C4, C52 
DMEM + 10% FCS 
TGF-β 
4 / 10 2 / 10 4 / 10 
Beier et 
al. 2012 
R8, 11, 18, 28, 44, 49, 
53, 54, 58; GS01, 04, 
05, 07 
DMEM-F12 + 
20 ng/mL EGF + 
bFGF + LIF + B27  
TGF-β1 + TGF-β2 
1 / 13 5 / 13 7 / 13 
Abbreviations: Prol. = proliferation; FCS = fetal calf serum; TGF-β = transforming growth factor beta; DMEM = 
Dulbecco’s modified Eagle’s medium; NCS = newborn calf serum; EGF = epidermal growth factor; bFGF = basic 
fibroblast growth factor; LIF = leukemia inhibitory factor  
Firstly, prior research has shown that proliferation increases in 20% of the cases, but in this 
study, no single case showed increased proliferation after treatment with TGF-β2. While a 
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proliferation decrease was observed in 20% of the cases in this study, it was reported in 37% 
of all cases in pertinent literature. With only 10 cell lines examined in this study and 41 in the 
literature reviewed, data on GBM's proliferative response to TGF-β2 is still scarce, 
challenging the significance of a 17% deviation. However, this study noted no proliferation 
increase due to TGF-β2 at all, which challenges that TGF-β2 acts as a tumor promoter by 
increasing proliferation.  
Secondly, migration data seems to deviate as well. In this study, a migration decrease was 
seen in 60% of the cases and an increase in 10%, while pertinent literature mostly elaborates 
on TGF-β2's pro-invasive stimuli (Wild-Bode et al. 2001, Baumann and Leukel et al. 2009, 
Seliger et al. 2013, Joseph et al. 2014, Iwadate 2016, Iwadate et al. 2016). Thus, TGF-β2's 
effects remain heterogeneous. This study shows that if TGF-β2 has an effect at all, it is more 
likely to be anti-proliferative and anti-migratory. Bruna et al. (2007) argue that TGF-β induces 
proliferation in glioma cells with an unmethylated pdfg-b gene. Consequent gene expression 
increases proliferation. Here, further investigating pdfg-b methylation status to determine 
whether used GBM cell lines only exhibited methylated pdfg-b genes and whether the 
hypothesis of Bruna et al. (2007) is applicable would be worthwhile.     
Generally, mesenchymal cell lines were more sensitive to TGF-β2's influence because all cell 
lines in which proliferation was inhibited and 5 / 6 of the cases of migration inhibition 
concerned mesenchymal cell lines. Interestingly, endogenous TGF-β2 levels in mesenchymal 
BTICs were already between 2.5 and 40 times higher than in proneural BTICs (see Table 8). 
TGF-β2 signaling seems to be more important in mesenchymal cells than in proneural cells. 
Additionally, differences in susceptibility to TGF-β2 may be due to different receptor setups in 
proneural and mesenchymal cell lines. On the one hand, Beier et al. (2012) showed that 
proneural cells possess deficient TGF-β receptors type II. As TGF-β2 normally binds to the 
TGFR-II before it can associate with TGFR-I and activate the Smad-signaling cascade 
(Aigner and Bogdahn 2008), TGF-β2 signaling is impaired in proneural cells. Conversely, Jun 
et al. (2016) report that TGF-β signaling is enhanced in mesenchymal cell lines. 
Mesenchymal cells are characterized by high CD44 expression. In these cells, epithelial 
membrane protein 3 (EMP3) interacts with the TGF-β receptor type II and thus enhances 
TGF-β2 signaling. Differences in sensitivity may be caused by higher endogenous TGF-β2 
levels, and enhanced EMP3-mediated TGF-β signaling in mesenchymal cell lines as well as 
TGFR-II deficiency of proneural cell lines. 
However, TGFR-II deficiency does not mean that proneural GBM cells do not use TGF-β as 
a tumor promoter. Proneural cells profit from TGF-β as an immunosuppressor. In vivo, 
proneural tumor sites exhibit less immune infiltration through CD8+ T- and NK-cells than 
mesenchymal tumor sites (Beier et al. 2012). Apparently, proneural cells inhibit NK2D 
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expression on CD8+ T- and NK-cells through TGF-β signaling thus escaping immune 
surveillance even more effectively than mesenchymal cells (Beier et al. 2012). Because of 
this, the results of this study should be viewed with caution. Even though TGF-β₂ exhibited 
far less tumorigenic characteristics than expected, it is by no means a general tumor 
suppressor in GBM. TGF-β's abilities to suppress the immune response and induce 
angiogenesis remain important hallmarks in vivo.   
In the majority of cases, TGF-β2 and SD-208 exerted independent or opposite effects. In 
4 / 20 cases, TGF-β2 exerted an anti-migratory effect, but these effects were no longer 
observed when TGF-β2 and SD-208 treatments were combined. In 2 / 20 cases, only SD-208 
exerted an effect, and in migration assays, this was not present for combined treatment. In 
4 / 20 cases, one case regarding proliferation and 3 cases regarding migration, effects were 
observed for both agents. The effects on migration of combined treatment canceled out in 
1 / 3 cases, or the effects of SD-208 remained in 2 / 3 cases. In RAV27 BTIC, both TGF-β2 
and SD-208, reduced migration and the effect became more pronounced for combined 
treatment (see Table 22). TGF-β2 and SD-208 acted as functional antagonists as described 
by Uhl et al. (2004), but in two cases the effects of SD-208 remained more pronounced when 
treatment was combined, and in RAV27 BTIC, effects of both agents were anti-migratory. As 
the experiments with RAV27 BTIC were the first performed for this study, the role of DMSO 
was not clear and no DMSO controls were performed for migration assays. Consequently, 
migration under SD-208 was compared to medium controls. Possibly, the anti-migratory 
effect observed under SD-208 treatment was due to an anti-migratory influence of DMSO. In 
conclusion, the results obtained for RAV27 BTIC's migration should be viewed with caution.  
Apart from RAV27's data, the data obtained for RAV19 TCs seems contradictory. It was the 
only cell line in which migration was increased by TGF-β2 and fittingly, SD-208 decreased 
migration. However, SD-208 also seemingly increased proliferation. Here, the results from 
the proliferation assay should be interpreted with extreme caution. Unfortunately, only three 
instead of the standard six replicates were carried out for DMSO controls, and they all 
showed a strong proliferation decrease. The values obtained for SD-208 in six replicates 
showed great deviations (values between 0.76 and 2.55). While migration data seems 
reliable due to many replicates (12) and small standard deviations (view Figure 35), 
proliferation data might not be reliable, because RAV19 TC proliferated slowly and data 
obtained in cell counts might not sufficiently support any statement about their proliferation 
behavior under TGF-β₂ stimulation. A longer observation period is needed to evaluate slow 
proliferating cell lines' responses to treatment. As migration data seems reliable, however, 
the question remains why RAV19 TC was the only cell line in which TGF-β2 increased 
migration. pdfg-b methylation status would be of interest to define whether this marker could 
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reliably predict proliferation increase caused by TGF-β2. In most cases the effects of TGF-β2 
and SD-208 were the opposite of expected. Cases of contradictory data with an insufficient 
number of DMSO controls performed further underline the need to pay attention to media 
and components that might lead to bias. Lastly, the example of migration increase in RAV19 
TC indicates that responses to TGF-β2 remain heterogeneous and not fully predictable.  
With the exception of RAV27 BTIC, all effects of SD-208 were observed in TCs, not in 
BTICs. This might have been due to different media used for BTICs and TCs. TGF-β2 
ELISAs performed in the laboratory group revealed that RHB-A contains 0.02 ng/ml TGF-β2 
while DMEM + 10% FCS contains 0.23 ng/ml. Different concentrations of TGF-β2 in the 
media may affect how TGF-β2 and SD-208 influence proliferation and migration. When media 
contain high levels of TGF-β2, adding more might be cytotoxic or SD-208 might exert vast 
effects. TCs cultured in DMEM +10 % FCS were exposed to TGF-β2 concentrations 10 times 
higher than those for BTICs in RHB-A. This could explain why SD-208 exerted vast effects 
on TCs but not on BTICs and why TGF-β2 had cytotoxic effects on all mesenchymal TCs 
when effects on mesenchymal BTICs were mainly anti-migratory. Another hypothesis would 
be that mesenchymal TCs were more fragile, because 10 mM metformin was also cytotoxic 
for them.  
Evidence suggesting that RHB-A media might enhance TGF-β2 signaling comes from that 
EGF concentrations and glucose content of media may influence TGF-β2 signaling. RHB-A 
media were supplemented with 20 ng/ml EGF. As Aigner and Bogdahn (2008) point out, 
EGF-signaling converges on Smad-signaling via MAPK. Maybe, Smad-signaling was 
activated by EGF independently of TGFR interactions. As SD-208 acts on TGFR-I but not on 
Smad-signaling, it may have been unable to counteract this TGFR-independent activation. 
This might account for the fact that in 9 / 10 cases, SD-208 treatment did not change 
proliferation nor migration of BTICs. However, RHB-A contained six times more glucose than 
DMEM. Gu et al. (2014) describe a linear correlation between media glucose content and 
TGF-β production by renal epithelial cells: the higher the glucose content the higher the TGF-
β levels. If GBM followed the same pattern, then RHB-A would have led to increased 
autocrine TGF-β₂ production. Yet, as TGF-β2 concentrations of serum-containing DMEM 
were already 10 times higher than those of RHB-A, a possible increase of autocrine TGF-β2 
production of BTICs was probably less pronounced and not influencing results as much as 
different TGF-β2 contents of the culture media. Therefore, future experiments need to be 
conducted with identical media for both BTICs and TCs to exclude bias due to different 
TGF-β2 levels in culture media, bias due to TGFR-independent Smad-activation through EGF 
and bias due to different glucose contents. 
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Recapitulating the findings of this study, TGF-β2's effects were far more anti-proliferative and 
anti-migratory than previously expected (8 / 9 cases in which an effect was observed). 
Fittingly, in many cases, SD-208 proved to induce proliferation and migration especially in 
TCs (5 / 7 cases). Interestingly, mesenchymal cell lines were more sensitive to TGF-β2 while 
proneural cell lines were almost resistant. This might be attributed to TGFR-II deficiency in 
proneural cell lines and the expression of EMP3 in mesenchymal cell lines. Overall, the role 
of TGF-β₂ remains ambiguous. On the one hand, TGF-β₂ levels in brain tumors seem lower 
than expected and are subject to a high degree of inter-individual variation (Riemenschneider 
et al. 2015). On the other hand, this in vitro study only examined two GBM properties 
influenced by TGF-β₂, proliferation and migration. In vivo, TGF-β₂ also induces angiogenesis 
and suppresses the immune response (Friese et al. 2004, Hau et al. 2006, Aigner and 
Bogdahn 2008, Crane et al. 2010, Beier et al. 2012). Therefore, TGF-β2 should not be 
considered a tumor suppressor in GBM. However, TGF-β2 seems to promote proliferation 
and migration of GBM cells to a lesser extent than previously expected. 
 
6.3 Possible links between metformin and TGF-β2 in GBM 
Previous research has described TGF-β2's ability to increase proliferation and migration of 
GBM cells (Rich et al. 1999, Piek et al. 1999, Wild-Bode et al. 2001, Bruna et al. 2007, 
Baumann et al. 2009, Beier et al. 2012, Seliger et al. 2013, Iwadate 2016) and it has been 
suggested that metformin lowers both (Beckner et al. 2005, Isakovic et al. 2007, Sato et al. 
2012, Ferla et al. 2012, Würth et al. 2013, Gao et al. 2013, Liu et al. 2014, Sesen et al. 2015, 
Kim et al. 2016). This study addressed the question of whether metformin exerts opposite 
effects compared to TGF-β2 and whether TGF-β2's effects can be attenuated through 
metformin use. To determine whether the effects of two or more treatments are synergistic, 
additive or antagonistic, a combination index (CI) needs to be calculated according to the 
method of Chou-Talalay (Chou 2010). The Chou-Talalay combination index is calculated with 
a formula based on the mass-action law principle. However, results of equimolar 
concentrations of the drugs themselves and their combination are needed (Chou 2010). 
Unfortunately, respective data did not exist for this study. Chou (2010) explains, that neither 
the arithmetic sum nor P values may accurately define synergistic, additive or antagonistic 
effects. Hence, this study avoids these terms.  
Overall, relationships between TGF-β and metformin may be functional, but signaling 
pathways may also be interconnected. As mentioned in chapter 3.4., possible links between 
TGF-β and metformin include:  
1. functionally opposed effects such as proliferation increase or decrease 
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2. metformin directly influencing core signaling pathways of TGF-β, especially Smad- 
signaling 
3. TGF-β directly influencing core signaling pathways of metformin, namely inhibition of 
complex I of the mitochondrial respiratory chain and subsequent AMPK activation and 
mTOR inhibition or Akt activation and mTOR inhibition 
4. metformin changing the tumor environment in a way that TGF-β signaling is impacted 
5. metformin and TGF-β converging on the same signaling pathways. 
As this study examined the functional effects of metformin and TGF-β2, the first possible link 
will be addressed in detail before literature on the latter four possible links will be discussed 
to give an outlook for future experiments.   
The combination of 10 mM metformin and 10 ng/ml TGF-β2 reduced proliferation in 9 / 10 
cases and migration in 10 / 10 cases. Compared to treatment with single agents, the 
following scenarios were observed: 
1. the combined treatment reduced proliferation to a greater extent than each of the 
single agents: 5 / 10  
2. the combined treatment reduced migration to a greater extent than the single agents: 
3 / 10  
3. the combined treatment reduced migration to a lesser extent than the single agents: 
1 / 10  
4. the combined treatment had no greater influence on proliferation than metformin by 
itself: 4 / 10 
5. the combined treatment had no greater influence on migration than metformin by 
itself: 4 / 10  
6. the combined treatment had no greater influence on proliferation than TGF-β2 by 
itself: 1 / 10. 
Hence, metformin and TGF-β2 exerted similar effects on GBM cells or did not influence their 
respective effects.  
Scenarios 1-3 describe situations in which the combination treatment exerted greater effects 
than the single agents. Reviewing scenario 1, in three cases, TGF-β2 did not influence 
proliferation by itself but it augmented metformin's anti-proliferative action, demonstrating its 
anti-proliferative potential. In the other two cases, TGF-β2 had already proven its anti-
proliferative power as a single agent, but combined treatment with metformin increased the 
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effect. In all cases of scenario 2, TGF-β2 had already demonstrated its anti-migratory power 
as a single agent, but combined with metformin the effect increased. In only one case 
(scenario 3) did TGF-β2 attenuate metformin's anti-migratory capacity: for RAV19 BTIC. 
Therefore, the first three scenarios show that with only one exception, metformin's and TGF-
β2's effects were not only consistently anti-migratory and anti-proliferative, but also increased 
when both agents were combined.  
Scenarios 4-6 describe those 9 / 20 cases in which proliferation and migration were not 
altered by combined treatment. In most cases, these effects were due to metformin and did 
not change when treatment was combined with TGF-β2. However, in one case, the anti-
migratory effects were more likely due to TGF-β2 (scenario 6). Thus, approximately half of 
the cases in which treatments of metformin and TGF-β2 were combined, displayed uniform 
and enhanced effects of the two agents and the other half exhibited no mutual influence on 
existing anti-proliferative and anti-migratory actions.  
Mesenchymal cells were more susceptible to TGF-β2, which is why the combination was 
more effective in lowering proliferation or migration than metformin itself mostly in 
mesenchymal cells. Contrarily, proneural BTICs and TCs showed virtually no response to 
TGF-β2 treatment with the exception of proliferation of RAV57 TC which was reduced by only 
the combination of metformin and TGF-β2.  
The effects of the combination of 0.01 mM metformin in triple re-treatment and 10 ng/ml 
TGF-β2 were only investigated concerning proliferation due to technical reasons. It reduced 
proliferation in 3 / 10 cases. Compared to treatment with single agents, the following two 
scenarios were observed: 
1. the combined treatment reduced proliferation to a greater extent than each of the 
single agents: 2 / 10  
2. the combined treatment had no greater influence on proliferation than TGF-β2 by 
itself: 1 / 10. 
Interestingly, this combination affected only mesenchymal cells. Moreover, 0.01 mM 
metformin in triple re-treatment exerted no effect on any of the three cell lines when given as 
a single agent. In one case (scenario 2), the anti-proliferative effect was most probably due 
to TGF-β2's action. Regarding scenario 1, the cell lines affected were RAV21 BTIC and TC. 
In one case, TGF-β2 by itself had already shown an anti-proliferative effect and it was 
enhanced by the addition of 0.01 mM metformin in triple re-treatment. Yet, in another case, 
neither of the agents had shown any effect individually, but the combination clearly reduced 
proliferation. As discussed before, low dose metformin did not affect mesenchymal cells 
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when given by itself. Interestingly, it was still able to increase TGF-β2's anti-proliferative 
effects on RAV21 cells. Apparently, these cells were weakened by TGF-β2 to an extent that 
the addition of even low dose metformin could further inhibit their multiplication. 
Although there were instances in which the combined treatment of TGF-β2 and either 10 mM 
or 0.01 mM x3 metformin reduced proliferation and migration of GBM cells to a greater extent 
than metformin by itself, TGF-β2 and metformin treatment should not be combined to treat 
GBM patients. TGF-β2 weakenes the immune response and may induce angiogenesis 
(Friese et al. 2004, Hau et al. 2006, Aigner and Bogdahn 2008, Crane et al. 2010, Beier et al. 
2012) and thus enhance tumor growth. Unless when treating GBM with oncolytic viruses 
(Han et al. 2015), the immuno-suppressive effect of TGF-β in GBM remains undesired in 
treatment of GBM.    
As TGF-β2 neither produced pro-proliferative / pro-migratory stimuli by itself nor attenuated 
metformin's anti-proliferative / anti-migratory effects, the hypothesis that metformin might 
counteract TGF-β2's impact on proliferation and migration of GBM is disproved. As a recent 
publication from our laboratory group (Seliger and Meyer et al. 2016) is the only existing 
literature on possible links between TGF-β2 and metformin in GBM, putting this study into 
scientific context is difficult. Direct functional interactions of metformin and TGF-β have only 
been described for EMT and mammosphere formation in breast cancer tissue (Cufí et al. 
2010, Vazquez-Martin et al. 2010, Oliveras-Ferraros et al. 2011) and TGF-β-induced EMT in 
renal epithelial cells (Lee et al. 2013) all of which have found metformin to directly antagonize 
TGF-β's functional effects. However, results obtained from tissues other than GBM and from 
the investigation of functional effects other than proliferation and migration seem very difficult 
to compare to the results of this study, because (as this study demonstrates) TGF-β's effects 
are highly dependent on context and cell lines. To further explore functional connections 
between TGF-β2 and metformin, data should be obtained in a manner that allows for 
calculations of CI according to Chou-Talalay. This requires at least five data points: two 
different concentrations of metformin, two different concentrations of TGF-β2 and one of the 
combination (Chou 2010). Preferably, more data points should be employed, e.g. using 
concentrations below and above the EC50 (Chou 2010). Thus, the effects of metformin and 
TGF-β2 could be accurately described as synergistic or antagonistic.    
Apart from effects on proliferation and migration, changes in morphology were also observed 
(see section 5.4). Metformin, TGF-β2 and the two combined changed morphology, and some 
of the changes reflect the results obtained in functional assays. Firstly, RAV19 BTIC is an 
example of how the effects of metformin and TGF-β2 may be opposed: While metformin 
treatment caused changes towards a smaller spherical morphology characteristic of 
apoptosis (Elmore 2007), TGF-β2 did not change morphology (see Figure 46). The 
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combination treatment led to a varied picture with more protrusions than after 10 mM 
metformin treatment but less than in control wells. The effects seem to attenuate each other. 
This serves as an example of the opposite effects of metformin and TGF-β2 emphasizing 
again that other functional characteristics investigated in this study were consistent. RAV24 
BTICs demonstrate the opposite: combined treatment enhanced apoptotic effects of 
metformin and TGF-β2 as indicated by very small spherical cells (Elmore 2007) (see Figure 
50). This was very much in line with results of cell counts where only combined treatment 
lowered proliferation (see Figure 47). Judging from the images of RAV19 TCs taken after 120 
hs (see Figure 54), metformin and metformin + TGF-β2 could lower proliferation, an effect not 
observed in cell counts due to the relatively short 48-h observation period. Morphological 
changes after metformin treatment indicated cytostatic and cytotoxic effects leading to 
apoptosis while TGF-β2 did not alter morphology. The latter underlines that proneural cells 
seem virtually resistant to TGF-β2 treatment. Mesenchymal cell lines such as RAV21 TCs, on 
the contrary, were sensitive to TGF-β2. Metformin treatment rendered RAV21 TCs fragile and 
the proliferation decrease caused by all three, metformin and TGF-β2 individually and their 
combination, can be made out (see Figure 58). Cell swelling as observed in RAV21 TCs is a 
sign of necrosis or "oncotic cell death" (Elmore 2007) and could indicate that metformin's and 
TGF-β2's effects were cytotoxic. In cell counts, the fraction of dead cells in wells treated with 
single 10 mM metformin +/- 10 ng/ml TGF-β2 was not quite significant (p = 0.09), but after 
TGF-β2 treatment, a significant amount of cells died (p = 0.024) underlining the impression of 
cell images. Cell-free areas were observed in some images of TGF-β2 treated RAV21 TCs. 
Their significance remained unknown. Overall, morphological changes were mostly 
consistent with results from cell counts concerning cytotoxicity and may represent an 
alternative to assessing cytostatic and cytotoxic effects. Results from this study align with 
pertinent literature: Isakovic et al. (2007) also describe morphological changes induced by 
4 mM metformin either to a more spindle-like shape or to a granular shape. Taking into 
account that Sato et al. (2012) found that 1 mM reduces sphere formation and induces 
differentiation, more spindle-like shapes might represent differentiation while granular shapes 
represent either apoptosis (smaller cell size) or oncotic cell death (larger cell size) (Elmore 
2007). Hence, morphological changes in GBM cells already point to important cell events 
such as differentiation, apoptosis or oncotic cell death; yet, verifying these events using 
appropriate differentiation or apoptosis markers is helpful.  
Apart from functional effects on proliferation, migration and cell morphology, metformin and 
TGF-β2 may also influence each other's signaling pathways or lead to indirect effects which 
can alter signaling. To understand signaling interactions of metformin and TGF-β2 in glioma, 
metformin signaling in GBM has to be scrutinized. Table 24 summarizes current research on 
metformin's molecular mechanisms on glioma:  
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Table 24: Proposed mechanisms for metformin's effects on GBM 
Study Cell lines Proposed mechanisms of metformin 
Isakovic 
et al. 
2007 
C6 (rat)*; U251       AMPK activation and downstream JNK activation 
(member of the MAPK family) 
 in confluent glioma cell cultures: AMPK activation --> 
permanent mitochondrial depolarization and ROS 
production --> caspase-dependent apoptosis 
 in low-density glioma cell cultures: AMPK activation --> 
temporary mitochondrial depolarization and absence of 
ROS production --> cell cycle arrest  
 ROS does not cause mitochondrial depolarization, but 
might be its consequence. 
 Pan-caspase inhibitors prevent apoptosis in confluent 
glioma cell cultures hinting that caspases play a crucial 
role in apoptosis of glioma cells.  
Ferla et 
al. 2012 
LN18, LN229  AMPK activation --> STAT3 downregulation and Akt 
inhibition 
Sato et 
al. 2012 
dnf.  Normally, Akt and ERK phosphorylate FOXO3, thus 
keeping it inactive. Hence, Akt inhibition results in 
FOXO3 activation.  
 AMPK activation --> FOXO3 activation (transcription 
factor) --> increased gene expression of p21 --> 
proliferation reduction  
 FOXO3 activation --> differentiation of BTICs (reduced 
stem-cell marker expression of Nestin, Musashi and 
Bmi1 and increased differentiation marker expression of 
neural βIII-tubulin and astrocyte GFAP) 
 FOXO3 activation --> reduction of BTICs' tumorigenic 
potential after transplantation 
 lower glucose levels in the culture medium (17.5 mM 
instead of 26 mM) --> more effective AMPK and FOXO3 
activation --> enhanced differentiation of BTICs 
Würth et 
al. 2013 
GBM1-4  in BTICs: prevention of EGF-induced activation of Akt --> 
net inhibition of Akt --> mTOR inhibition --> decreased 
proliferation 
 in differentiated cells: continuous activation of Akt --> no 
mTOR inhibition --> no effect of metformin 
 No AMPK-activation is observed after treatment with 
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metformin, demonstrating that mTOR inhibition results 
from Akt inhibition and not from AMPK activation, both of 
which would be possible pathways to mediate mTOR 
signaling.  
Gao et al. 
2013 
U251   downregulation of fibulin-3 --> downregulation of MMP2 -
-> lowered migration 
Gritti and 
Würth et 
al. 2014 
3 GBM cell lines  GBM cells express CLIC1, a chloride ion channel, which 
is normally stored in the cytosol and inserted into the 
plasma membrane during G1 phase preceding transition 
into S phase  
 CLIC1 expression: higher in BTICs than in TCs 
 specific CLIC1 blockage in its open state when located 
within the plasma membrane --> GBM cells trapped in 
G1 phase --> lowered proliferation 
 dose- and time-dependency --> high-dose and long-term 
applications of metformin favorable 
Liu et al. 
2014 
T98G, A172, 
U87 
 neither ATP-depletion nor AMPK signaling are 
necessary for metformin's anti-proliferative action 
 metformin increases PRAS40's association with 
RAPTOR --> mTOR inhibition --> proliferation reduction 
Sesen et 
al. 2015 
U87, U251, 
LN18, SF767 
 partial block of complex I of the respiratory chain (12-
31%) 
 AMPK activation or Redd1 / DDIT4 activation --> mTOR 
inhibition 
 in pten wt cells: Akt inhibition  
 in pten mutated cells: Akt is not affected by metformin   
 --> AMPK-dependent and AMPK-independent effects 
Yu et al. 
2015 
U87, U251  Akt inhibition 
 AMPK activation --> mTOR inhibition 
Kim et al. 
2016 
TS13-20, TS15-
88, TS09-03, 
GSC11, U87 
 no AMPK activation nor mTOR inhibition  
 
 
* If not otherwise stated, cell lines were derived from humans. Abbreviations: AMPK = AMP-activated kinase; 
JNK = c-Jun N-terminal kinase; MAPK = Mitogen-activated protein kinase; ROS = Reactive oxygen species; 
STAT3 = Signal transducer and activator of transcription 3; Akt = refers to a mouse named "Ak", expressing 
spontaneous lymphomas and "t" thymoma, also Akt = PKB = protein kinase B; ERK = Extracellular signal-
regulated kinase = nowadays known as MAPK; FOXO3 = Forkhead box protein O3; p21 = Protein 21; Bmi1 = 
Polycomb complex protein; BTICs = Brain tumor initiating cells; GFAP = Glial fibrillary acidic protein; EGF = 
Epidermal growth factor; mTOR = mammalian Target of rapamycin; MMP2 = Matrix metalloproteinase 2;      
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TCs = Tumor cells (differentiated); CLIC1 = Chloride intracellular channel1; G1 phase = gap phase one; S 
phase = synthesis phase; ATP = Adenosine triphosphate; PRAS40 = Proline-rich Akt substrate of 40 kDa; 
RAPTOR = Regulatory-associated protein of mTOR; Redd1 = Regulated in development and DNA damage 
responses 1; DDIT4 = DNA damage-inducible transcript 4 protein; PTEN = Phosphatase and tensin homolog.  
As outlined in Table 24, metformin has a multitude of molecular mechanisms. One of the 
main axes seems to be via AMPK activation and subsequent mTOR inhibition. In our study 
(Seliger and Meyer et al. 2016), we showed that TGF-β2 does not activate AMPK nor inhibit 
mTOR. Therefore, we could demonstrate that TGF-β2 does not act on metformin's main 
signaling axis. However, a multitude of other pathways such as Akt, JNK, FOXO3, RAPTOR 
and CLIC1 remain to be explored to confirm that metformin signaling is not influenced by 
TGF-β2.  
The question is whether metformin could alter TGF-β2's main signaling axis which is Smad-
mediated. We revealed that metformin neither increases levels of TGF-β2 mRNA nor protein 
levels, nor does it alter Smad2-signaling (Seliger and Meyer et al. 2016). Thus, no direct 
influence of metformin on Smad signaling was observed in two GBM cell lines. Also, indirect 
effects such as an increase in lactate levels due to metformin treatment and a subsequent 
activation of TGF-β2 could play a role (Seliger and Leukel et al. 2013). These were not 
observed in the two cell lines utilized in our study (Seliger and Meyer et al. 2016). Yet, further 
research is needed to validate these results for a greater number of cell lines.   
Lastly, metformin and TGF-β are part of complex signaling networks which overlap at certain 
points. Metformin and TGF-β signaling converge on FOXO signaling exerting similar effects: 
TGF-β-activates Smad signaling and several other factors including FoxO that are able to 
activate p21 transcription and thus inhibit proliferation (Moustakas 2005). In GBM, metformin 
activates AMPK which activates FOXO3 which increases gene expression of p21 and thus 
reduces proliferation (Sato et al. 2012). Hence, FOXO mediated p21 induction may represent 
a common pathway for TGF-β and metformin. Also, TGF-β and metformin resemble each 
other in their ability to induce apoptosis mediated by either JNK- or Akt. Both converge on 
JNK, a member of the MAPK family. TGF-β-induced JNK activation can either activate 
Smad3 signaling or inhibit Smad2 signaling and ultimately lead to apoptosis (Moustakas and 
Heldin 2005). Metformin, correspondingly, activates JNK in GBM which leads to apoptosis 
(Isakovic et al. 2007). Similar effects are described for Akt: Moustakas and Heldin (2005) 
state that TGF-β inhibits Akt in a Smad-dependent way, which leads to apoptosis. Metformin 
also inhibits Akt and induces apoptosis in GBM (Sato et al. 2012), so that TGF-β and 
metformin show similar capabilities to induce apoptosis. Contrary effects of TGF-β and 
metformin are observed concerning Sox expression. TGF-β alters transcription of sex 
determining region Y-box 4 (Sox4) in the nucleus of GBM cells which increases expression 
of Sox2 and helps BTICs retain their stemness and their self-renewing capacities (Ikushima 
et al. 2009). Metformin, however, may upregulate microRNA30a in prostate cancer cells, 
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which decreases Sox4 and thus inhibits proliferation and EMT (Zhang et al. 2014). In GBM, a 
combination of 2-desoxy-glucose and metformin consistently reduces Sox2 expression (Kim 
et al. 2016), showing that TGF-β and metformin act as direct signaling antagonists on Sox2 
expression. The pathways outlined above indicate possible intersections of metformin and 
TGF-β signaling. However, most results regarding the molecular mechanisms of TGF-β do 
not originate from the examination of GBM tissue. As the effects of TGF-β are highly context- 
and cell line-dependent and as cancerous tissues exhibit great heterogeneity concerning 
genetic and metabolic characteristics, these possible intersections of metformin's and 
TGF-β2's signaling networks need to be investigated for GBM to allow for legitimate 
conclusions.   
 
6.4 Outlook 
Culture media are in vitro imitations of the tumor environment. Methodically, this study 
showed that culture media have to be chosen very carefully. As the tumor environment 
strongly influences GBM's metabolism and its hallmarks of cancer, the culture media need to 
realistically reflect conditions from tumor environment in vivo or at least be controlled for any 
substance influencing results. Thus, for studies investigating metformin and TGF-β2, glucose 
content, lactate content, pH, TGF-β2 content, autocrine TGF-β2 secretion, EGF levels, or any 
other substance influencing metabolisms or TGF-β2 signaling need to be identical to make 
results of different cell lines comparable and also need to be as realistic as possible to reflect 
in vivo conditions. Also, any future study investigating the effects of two substances in terms 
of possible synergism or antagonism should be planned to yield data sets applicable for the 
Chou-Talalay method to calculate the CI. Any study further exploring the interactions of 
metformin and TGF-β2 on a molecular level should use signaling networks established in 
other tumor models as an example to test for interactions in GBM. Hence, exploration of 
signaling pathways of Akt and JNK, FOXO3 and p21 expression, RAPTOR, and Sox2 
expression could prove valuable.  
To establish ties between fundamental research and clinical applications of metformin in 
cancer treatment, several steps are needed. Firstly, the functional results obtained in this 
study should be linked to molecular and genetic properties of GBM cells. To further 
understand the exact mechanisms of metformin's and TGF-β2's action, results from other 
laboratory groups should be validated including but not limited to differential investigation of 
respiratory chain inhibition, apoptosis markers, CLIC1 expression, Redd1 / DDIT4 
expression, to determine if certain mechanisms apply to certain subgroups of cells and may 
eventually be used as markers for susceptibility. Also, proposed susceptibility markers for 
metformin such as reliance on OXPHOS, or p53 and pten mutations need to be linked to 
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functional results of this study. Similarly, markers of susceptibility to TGF-β2, such as TGFR-II 
deficiency of proneural cells and EMP3 expression of mesenchymal cells, should be tested. 
The establishment of reliable markers will help to stratify GBM patients according to their 
potential benefit from metformin treatment. Also, reliable markers set the rationale for more 
aggressive metformin administration in patients with susceptible GBM subtypes. This more 
aggressive treatment may use higher oral doses of metformin, alternative application routes 
(e.g. intraperitoneal), alternative medication such as phenformin, combinations such as 
metformin and 2DG or even different approaches yet to be discovered. Thus, further 
fundamental and clinical research is needed to improve treatment of GBM patients and 
improve their progression-free and overall survival. 
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8 APPENDIX 
8.1 Table of Abbreviations  
°C   Degree Celcius 
α   Alpha 
αVβ3   an Integrin 
β   Beta 
µ   Micro 
µl   Microlitre 
µM   Micromolar 
 
2DG   2-desoxy-glucose 
4E-BP1   EIf4e Binding Protein 
 
ACC   Acetyl-CoA Carboxylase 
Acetyl-CoA  Acetyl-Coenzyme A 
ADP   Adenosine Diphoshate 
Akt     Refers to a mouse named "Ak", expressing spontaneous lymphomas 
   and "t"  thymoma, also Akt  PKB  protein kinase B  
AMP    Adenosine Monophosphate 
AMPK    AMP-activated Protein Kinase 
Atg13    Autophy-related Protein 13 
ATP     Adenosine Triphosphate 
 
bFGF     Basic Fibroblast Growth Factor  
Bmi1     Polycomb Complex Protein 
BMP   Bone Morphogenic Protein 
BTICs    Brain Tumor Initiating Cells  
 
CD   Cluster of Differentiation 
CHI3LI    Chitinase 3 like Protein  
CI   Combination Index 
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C-Jun    p39 
CLIC1    Chloride Intracellular Channel1 
cm   Centimeter 
CNS   Central Nervous System 
CO2   Carbon Dioxide 
CREB1  CAMP Responsive Element Binding Protein 1 
CTLA-4   Cytotoxic T Lymphocyte Antigen 
 
DDIT4    DNA Damage-Inducible Transcript 4 Protein 
DEPTOR    DEP Domain-Containing mTOR-Interacting Protein 
df   Dilution Factor 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DMSO   Dimethylsulfoxide 
DNA     Deoxyribonucleic Acid  
 
e.g.   exempli gratia 
EDTA   Ethylenediaminetetraacetic Acid 
EGF     Epidermal Growth Factor 
EGFR    Epidermal Growth Factor Receptor 
EGFRvIII  Epidermal Growth Factor Receptor Variant III 
EIF4e    Eukaryotic Translation Initiation Factor 4E 
ELISA   Enzyme-linked Immunosorbent Assay 
EMP3   Epithelial Membrane Protein 3 
EMT   Epithelial - Mesenchymal Transition 
ERK     Extracellular Signal-Regulated Kinase  nowadays known as MAPK 
et al.    et alii / et aliae  
 
f   Female 
FCS     Fetal Calf Serum 
FET-PET     O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography 
FGF   Fibroblast Growth Factor 
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FOXO3    Forkhead Box Protein O3 
 
G1 Phase    Gap Phase 1 
GBM     Glioblastoma  
GFAP    Glial Fibrillary Acidic Protein (an Astrocyte Marker)  
GFR   Glomerular Filtration Rate 
Glc.   Glucose 
GβL    G Protein Beta Subunit-Like 
 
h   H(s) 
 
I.p.     Intraperitoneal Administration 
IC50   Half Maximal Inhibitory Concentration 
IDH     Isocitrate Dehydrogenase 
IFN-gamma    Interferon Gamma 
IGF   Insulin-like Growth Factor 
IgG1   Immunoglobulin G1 
IL-8   Interleukin 8 
 
JAK1     Janus Kinase 1 
JNK     c-Jun N-Terminal Kinase 
 
kg   Kilogram 
 
LDH   Lactate Dehydrogenase 
LIF     Leukemia Inhibitory Factor 
LKB1    Liver Kinase 1 
LOH   Loss of Heterozygosity 
 
m   Milli / Male / Meter 
MAPK    Mitogen-Activated Kinase also known as Ras-Raf-MEK-ERK Pathway  
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MEK     Raf/Mitogen Activated And Extracellular Signal-Regulated Kinase 
   Kinase 
MEM     Minimal Essential Media 
MERTK    C-Mer Proto-Oncogene Tyrosine Kinase  
Mes.    Mesenchymal 
MET     HGFR Hepatic Growth Factor Receptor; CD44  Cluster of  
   Differentiation 44  
metf.   Metformin 
meth.   Methylated 
mg   Milligram 
mgmt   O6-Methylguanine-DNA-Methyltransferase 
Migra.   Migration 
ml   Milliliter 
mm   Millimeter 
mM   Millimolar 
MMP2    Matrix Metalloproteinase 2 
MRI   Magnetic Resonance Imaging 
mTOR    Mammalian Target of Rapamycin 
mTORC1   Mammalian Target of Rapamycin Complex 1 
mut.   Mutated 
 
n.d.   Not Determined 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate 
NCS     Newborn Calf Serum 
neAA   Non Essential Amino Acids 
neg.    Negative 
NF1     Neuro Fibromatosis 1 
NF-kappa B    Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cell 
ng   Nanogramm 
NK   Natural Killer Cells 
NKG2D  Natural Killer Group 2D 
nM   Nanomolar 
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OCT   Organic Cation Transporter 
Olig2   Oligodendrocyte Transcription Factor 2 
OS   Overall Survival 
OXPHOS  Oxidative Phosphorylation 
 
P   Passage Number 
p   Phosphorylated 
P160rock    A Serine/Threonine Protein Kinase 
P21     Protein 21 
P53    Protein 53 
p70s6k   Ribosomal Protein S6 Kinase 
PBS   Phosphate Buffer Saline 
PD-1   Programmed Cell Death 1 
PDGF-B   Platelet Derived Growth Factor B  
PDGFRA    Platelet Derived Growth Factor Receptor A 
PDL-1   Programmed Cell Death 1 Ligand 
PI3K     Phosphoinositide 3-Kinase 
PI3KCA    Phosphoinositide 3 Kinase Catalytic Subunit Alpha 
PI3KR1   Phosphoinositide 3 Kinase Receptor 1 
PIP2   Phosphatidylinositol-4,5-Bisphosphate 
PIP3   Phosphatidylinositol-3,4,5-Triphosphate 
PKC     Protein Kinase C 
PLC     Phospholipase C 
pos.    Positive 
PP2A     Protein Phosphatase 2 
PRAS40    Proline-rich Akt Substrate of 40 kda 
prim.   Primary 
Pro.   Proneural 
Prol.     Proliferation 
PTEN    Phosphatase and Tensin Homolog  
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Ra     Rat Sarcoma 
RAF    Rapidly Accelerated Fibrosarcoma 
RAG GTPase  Ras-related GTPase 
RAPTOR    Regulatory-associated Protein of mTOR 
Ras     Rat arcoma 
RAV   Regensburg Arabel Vollmann 
REDD1    Regulated in Development and DNA Damage Responses 1  
RELB    V-Rel Avian Reticulo-Endotheliosis Viral Oncogene Homolog B 
Rho     Small GTPases of the Ras Superfamily 
ROS     Reactive Oxygen Species 
rpm   Rotations per Minute 
RPMI1640   Cell Media developed at the Roswell Park Memorial Institute (USA) 
R-Smad    Regulatory Small Body Size Mother of Decapentaplegic 
 
S phase    Synthesis Phase 
S6K     Ribosomal Protein S6 Kinase 
SD-208  2-(5-Chloro-2-Fluorophenyl)-4-[(4-Pyridyl)Amino]Pteridine 
Sec.   Secondary 
Sox2   Sex Determining Region of Y 
STAT1    Signal Transducer and Activator of Transcription 1 
STAT3    Signal Transducer and Activator of Transcription 3 
 
T2D   Type 2 Diabetes 
TAK1     TGF-β Activated Kinase 1 
TCs     Tumor Cells (differentiated);  
TGF-β    Transforming Growth Factor Beta 
THBS-1  Thrombospondin 1 
TIC     Tumor Initiating Cell 
TIMP-1  Tissue Inhibitor of Metalloproteinase 1 
TMZ     Temozolomide 
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TNFRSF1A    Tumor Necrosis Factor Receptor Superfamily Member 1A 
TNF-α   Tumor Necrosis Factor Alpha 
TP53    Tumor Protein 53  
TRADD    Gene Encoding for Tumor Necrosis Factor Receptor Type 1- 
   associated DEATH Domain Protein 
TSC2    Tuberous Sclerosis Complex Protein 2 
TTF   Tumor Treatment Field 
 
UKR   University Hospital Regensburg 
unmeth.  Unmethylated 
 
V   Volume 
VEGF    Vascular Endothelial Growth Factor 
VEGFR    VEGR Receptor 
 
WHO   World Health Organization 
wt   Wild-Type 
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